ONKOLOŠKI INŠTITUT LJUBLJANA
INSTITUTE OF ONCOLOGY LJUBLJANA

EPIDEMIOLOGIJA IN REGISTER RAKA
EPIDEMIOLOGY AND CANCER REGISTRY

Rak v Sloveniji 2011

Cancer in Slovenia

Rak v Sloveniji 2011

Cancer in Slovenia

Naslov / Title
Rak v Sloveniji 2011 / Cancer in Slovenia 2011

Uredniški odbor / Editorial Board
Maja Primic Žakelj, glavna urednica / editor-in-chief
Matej Bračko, Marko Hočevar, Katja Jarm,
Vera Pompe-Kirn, Primož Strojan, Vesna Zadnik,
Branko Zakotnik in Tina Žagar

Računalniška obdelava / EDP analysis
Katja Jarm in Tina Žagar

Oblikovanje in priprava za tisk / Design & Typesetting
Studio N, studio za oblikovanje in grafično pripravo

Tisk / Printing
Littera picta d.o.o., Ljubljana

Izdajatelj / Published by
Onkološki inštitut Ljubljana / Insitute of Oncology Ljubljana, Slovenia
Epidemiologija in register raka / Epidemiology and Cancer Registry
Register raka Republike Slovenije / Cancer Registry of Republic of Slovenia

Naklada / Published in
500 izvodov / 500 copies

Nasvet za citiranje / Recommended reference
Rak v Sloveniji 2011. Ljubljana: Onkološki inštitut Ljubljana, Epidemiologija in register raka, Register raka Republike Slovenije, 2015.
Cancer in Slovenia 2011. Ljubljana: Institute of Oncology Ljubljana, Epidemiology and Cancer Registry, Cancer Registry of Republic of Slovenia, 2015.

Osebje Registra raka Republike Slovenije / Staff of the Cancer Registry of Republic of Slovenia

Maja Primic Žakelj, vodja / head
Barbara Babuder, Andrej Kirn, Andrej Krašovec, Gaber Plavc, Polona Škulj, Darja Strle, Fani Škrlec, Nataša Šturm in Tina Žagar

Naslov / Correspondence to

Register raka Republike Slovenije / Cancer Registry of Republic of Slovenia
Onkološki inštitut Ljubljana / Institute of Oncology Ljubljana
Zaloška c. 2, 1001 Ljubljana, p.p. 2217, Slovenija
Telefon / Phone: + 386 1 5879 450
E-pošta / E-mail: register@onko-i.si
Spletna stran / Web site:
http://www.onko-i.si/rrs/ http://www.slora.si/
http://www.onko-i.si/crs/ http://www.slora.si/en/

Vsebina

Contents

Slike / Figures

Podatki v tabelah / Data in tables

Uvod

Register raka Republike Slovenije (RRRS) je eden najstarejših populacijskih registrov raka v Evropi. Leta 1950 ga je na Onkološkem inštitutu Ljubljana (OI) ustanovila in do leta 1975 vodila pokojna profesorica dr. Božena Ravnihar. Njeno delo je prevzela profesorica dr. Vera Pompe Kirn, ki je do upokojitve leta 2003 skrbela za nadaljnje uveljavljanje RRRS v domačem in mednarodnem merilu. Od leta 2003 je RRRS z Enoto za epidemiologijo posebna služba OI, ki se imenuje Epidemiologija in register raka. V njej delujejo še *bolnišnični register OI*, ki omogoča podrobnejši pregled nad bolniki, zdravljenimi na OI (ne glede na to, kje imajo stalno prebivališče), in RRRS oskrbuje z velikim delom podatkov, *državni register za vodenje in spremljanje organiziranega presejalnega programa za raka maternicnega vratu* (Register ZORA) in od leta 2007 *informacijski sistem za vabljenje žensk in epidemiološko spremljanje organiziranega presejalnega programa za raka dojk* (Register DORA).

Podatki o novih primerih raka, incidenci, preživetju in prevalenci, ki se zbirajo v RRRS, so skupaj s podatki o umrljivosti, ki jih zbira in obdeluje Nacionalni inštitut za javno zdravje RS, osnova za ocenjevanje bremena rakavih bolezni v državi. Pomembni so za načrtovanje in ocenjevanje onkološkega varstva na področju primarne in sekundarne preventive, diagnostike, zdravljenja in rehabilitacije, za načrtovanje zmogljivosti in sredstev, ki so potrebni za obvladovanje rakavih bolezni (osebje, medicinska oprema, posteljne zmogljivosti); dragoceni so tudi za klinične in epidemiološke raziskave v Sloveniji in v širših mednarodnih raziskavah ter za vrednotenje učinkovitosti presejalnih programov.

Redna letna poročila RRRS so namenjena neposrednemu seznanjanju strokovne javnosti in drugih zainteresiranih z obdelanimi podatki RRRS. Ker nas omejuje tehnologija zbiranja podatkov, saj je njihovih virov več, je za dokončanje letne zbirke podatkov, njihovo analizo in objavo rezultatov potreben čas, ki je pri nas in v drugih državah podoben, običajno 2 leti do 3. V poročilih pa zadnja leta objavimo tudi pričakovano incidenco raka v letu, ko je poročilo izdano (v tokratnem poročilu za leto 2013); izračunana je s posebno statistično metodo za napovedovanje incidence raka.

RRRS je prva letna poročila izdal v letih 1953-1957 za leta 1951-1955. Prva analiza podatkov za leto 1950 je bila objavljena v *Zdravstvenem vestniku leta 1951*. Podatki za leta 1957-1971 so bili objavljeni v periodičnih publikacijah Svetovne zdravstvene organizacije *Epidemiological and Vital Statistics* in v *World Health Statistics Report*. Od leta 1965 so bili podatki spet redno objavljani v posebnih letnih poročilih z naslovom *Rak v Sloveniji* (1965-1977) in *Incidenca raka v Sloveniji* (1978-2006), in sicer v slovenskem in angleškem jeziku. Poleg letnih poročil so objavljene tudi 4 monografije: *Zemljevidi incidence raka v Sloveniji 1978-1987*, *Preživetje bolnikov z rakom v Sloveniji 1963-1990*, *Preživetje bolnikov z rakom v Sloveniji 1983-1997* in *Preživetje bolnikov z rakom, zbolelih v letih 1991–2005 v Sloveniji*. Seznam drugih pomembnejših del, objavljenih v zadnjih petih letih, je v dodatku na koncu poročila.

Podatki RRRS so vključeni v številne mednarodne podatkovne zbirke in projekte. Objavljeni so v vseh devetih zvezkih in v deseti elektronski verziji knjige *Rak na petih kontinentih (Cancer Incidence in Five Continents),* ki jo izdaja Mednarodna agencija za raziskovanje raka, in v podatkovnih zbirkah *ECO*, *GLOBOCAN* in *ACCIS*. Preživetje slovenskih bolnikov je obdelano v mednarodnih raziskavah *EUROCARE-2, EUROCARE-3, EUROCARE-4, EUROCARE-5, EUROCARE-6, RARECARE* in *EUNICE*.

Leta 2010 smo v celoti prenovili računalniško bazo in posodobili obdelavo podatkov v RRRS. Od takrat deluje tudi *interaktivni spletni portal*, ki smo ga poimenovali *SLORA* po začetnih črkah besed »Slovenija in rak«. Dostopen je na elektronskem naslovu www.slora.si. Omogoča preprost in hiter dostop do večine podatkov o raku v Sloveniji, ki jih zbirata RRRS do zaključenega leta obdelave, trenutno 2011 (incidenca, prevalenca in preživetje), in Nacionalni inštitut za javno zdravje RS (umrljivost) ter do evropskih in svetovnih podatkovnih zbirk o raku. S hitrim dostopom do tujih baz tako omogoča tudi primerjavo bremena raka z drugimi državami v Evropski uniji in v svetu. Dodane so tudi obširne strokovne razlage, ki pojasnjujejo podatke in seznanjajo uporabnike z nevarnostnimi dejavniki raka, možnostmi zgodnjega odkrivanja in uspešnostjo zdravljenja raka.

Viri in nabor podatkov

Prijavljanje raka je v Republiki Sloveniji obvezno in zakonsko predpisano že od ustanovitve RRRS (Ur. l. SRS št. 10/50, št. 29/50, št. 14/65, št. 1/80, št. 45/82, št. 42/85; Ur. l. RS št. 9/92 in št. 65/00). Osnovni vir podatkov so *prijavnice rakave bolezni*. Registru jih pošiljajo iz vseh bolnišnic in diagnostičnih centrov v Sloveniji, iz ordinacij osnovnega zdravstvenega varstva pa le izjemoma, če bolnik ni napoten na nadaljnje preiskave in/ali zdravljenje.

S prijavnicami zbiramo osebne podatke, podatke o vrsti bolezni (anatomsko mesto raka, histološka oz. citološka diagnoza, stadij po TNM ali drugi klinični klasifikaciji) in o vrsti zdravljenja. Dodatni vir podatkov so zdravniška poročila o vzroku smrti, ki nam jih pošilja Nacionalni inštitut za javno zdravje RS. Veliko časa porabimo za poizvedbe o bolnikih, za katere nimamo popolnih podatkov ali pa dobimo o njih prvo informacijo šele ob smrti.

Za izračun preživetja bolnikov potrebujemo podatek, ki se imenuje *vitalno stanje* (ali je oseba živa, mrtva ali izgubljena iz registra prebivalstva). Podatek dobimo iz Centralnega registra prebivalstva (CRP), in sicer za vse osebe iz RRRS. Od leta 2010 smo po prenovi računalniške baze s posebej varovano spletno tehnologijo neposredno povezani s CRP, zato ta podatek dobimo dnevno. Pri izgubljenih osebah upoštevamo kot datum izgube datum zadnje prijave oz. datum izgube, kot velja v CRP, odvisno od tega, kateri datum je kasnejši. Od leta 1985, odkar RRRS prejema od CRP enotno matično številko občana (EMŠO), je v RRRS odstotni delež izgubljenih manjši od 1 %; pri bolnikih, registriranih v zadnjem desetletju, je znašal le 0,1 %.

Pri analizi prostorske razporeditve raka upoštevamo Uredbo o standardni klasifikaciji teritorialnih enot – SKTE (2000), ki predpisuje delitev slovenskega ozemlja na 11 ravneh. Točno opredeljevanje stalnih naslovov bolnikov z rakom nam omogoča redna povezava z Registrom prostorskih enot Geodetske uprave RS. V Tabeli 6 smo do Letnega poročila 2002 prikazovali podatke po 9 zdravstvenih regijah, v skladu z omenjeno uredbo pa smo potem prešli na raven SKTE-3, na 12 statističnih regij.

Slovenske statistične regije

Priprava podatkov za računalniško obdelavo

Podatke, prispele v RRRS na prijavnicah, posebej usposobljene medicinske sestre najprej kodirajo v skladu z mednarodnimi in v RRRS dogovorjenimi pravili.

Za razvrščanje neoplazem po primarni lokaciji je od leta 1997 v veljavi deseta revizija Mednarodne klasifikacije bolezni in sorodnih zdravstvenih problemov za statistične namene (MKB-10), pred tem pa smo uporabljali osmo.

Pri uvrščanju med maligne bolezni je treba opozoriti še na klasifikacijo morfologije neoplazem, za katero uporabljamo morfološki del Mednarodne klasifikacije bolezni za onkologijo, od poročila za leto 2001 njeno tretjo izdajo. V tej izdaji je nekaj novosti, med drugimi navedba, katere histološke vrste sodijo med maligne, in nekaj novih histoloških vrst, ki do tedaj niso bile obravnavane posebej. Tako npr. gastrointestinalne stromalne tumorje (GIST) uvrščamo med posebne histološke vrste šele od leta 2001. Po tretji reviziji so med maligne uvrščene kronične mieloproliferativne bolezni in mielodisplastični sindromi (sedaj v topografski šifri C96.7) in policitemije, ki jih od 2001 uvrščamo v skupino C94. V skladu z novimi pravili mejno malignih tumorjev jajčnikov ne uvrščamo več v kategorijo C56, pač pa v D39.1.

V letošnjem poročilu ponovno razvrščamo neoplazme limfatičnega in krvotvornega tkiva tudi v skladu z verzijo 2010 desete revizije Mednarodne klasifikacije bolezni in sorodnih zdravstvenih problemov za statistične namene (MKB-10). Ta verzija ima bolezni limfatičnega in krvotvornega tkiva razvrščene na drug način kot tista iz leta 1995 in tako bolj odgovarja klinični obravnavi teh bolnikov.

Od leta 1993 je obvezno prijavljanje sprememb materničnega vratu, označenih kot CIN III (šifra 219 po 8. reviziji MKB), dotlej pa so se registrirale le spremembe, označene s šifro 234.0 (carcinoma in situ). Primerjava s podatki za obdobje 1961-1992 tako ni možna. Po 10. reviziji MKB so vse intraepitelijske spremembe materničnega vratu uvrščene v šifro D06. Od leta 1987 registriramo tudi prijavljene intraepitelijske karcinome dojke (šifra D05), od leta 1995 pa intraepitelijske karcinome mehurja (šifra D09.0) in kožne melanome Clark I (šifra D03).

Za prikaz porazdelitve bolezni po stadiju ob diagnozi v letnih poročilih uporabljamo poenostavljeno razvrščanje v eno od treh skupin: omejena bolezen, regionalno razširjena bolezen in oddaljeno razširjena bolezen. Primer opredelimo na osnovi ugotovitev katere koli zapisane preiskave – od popisa operacije do obdukcije, če bolnik poprej ni bil zdravljen. Poenostavljena opredelitev stadijev pri solidnih tumorjih praviloma sledi klasifikaciji TNM. V omejeni stadij je tako praviloma uvrščen primer bolezni, pri katerem je tumor označen s T1 ali T2. Pri dojki, kožnem melanomu in ščitnici so v omejeni stadij vključeni tudi tumorji T3; pri materničnem vratu, materničnem telesu in sarkomih, ter pri jajčniku, jajcevodu in trofoblastnih tumorjih v omejeni stadij sodijo le tumorji T1. Pri omejeni bolezni seveda niso prizadete področne bezgavke in ni zasevkov v oddaljenih organih (N0, M0). V stadiju regionalne razširitve je primer, pri katerem je tumor opredeljen kot T3 in T4 (razen v omenjenih izjemah) in/ali so prizadete tudi področne bezgavke (N1), zasevkov v oddaljenih bezgavkah in organih pa ni (M0). V skupino oddaljeno razširjene bolezni pa uvrščamo primere, pri katerih je zapisano, da so bili zasevki že

v oddaljenih bezgavkah ali organih (M1). V bazi RRRS hranimo tudi podatek o stadiju bolezni po klasifikaciji TNM ali drugih klasifikacijah, če je bil tako opredeljen na prijavnici oz. je bilo na njej vsaj dovolj podatkov za njegovo naknadno opredelitev. Maligni limfomi so opredeljeni po klasifikaciji Ann-Arbor.

Kakovost podatkov RRRS in popolnost registracije

Kakovost podatkov registrov raka opredeljujejo naslednji kazalniki: odstotni delež mikroskopsko (histološko ali citološko) potrjenih primerov in odstotni delež primerov, registriranih samo iz zdravniških poročil o vzroku smrti. Vrednosti teh kazalcev so prikazane v Tabeli 3.

Popolnost registracije kaže delež vseh novih primerov raka na področju, ki ga pokriva register in ki so vključeni v podatkovno zbirko registra. Neposredno jo je mogoče meriti samo s posebnimi raziskavami, namenjenimi oceni popolnosti, npr. s ponovnim pregledom odpustnih diagnoz in popisov bolezni v bolnišnicah ali ambulantah na določenem območju. V Sloveniji takih raziskav zaenkrat še nismo delali, veliko pa nam k popolnosti zajema pomagajo kolegi kliniki, ki jih zanima, kakšno je preživetje bolnikov, zdravljenih pri njih; ko nam pošljejo podatke o svojih skupinah bolnikov, v njih velikokrat najdemo take, ki jih v podatkovni zbirki RRRS še ni.

Na splošno velja, da je popolnost podatkov večja tam, kjer ima register dostop do zdravniških poročil o vzroku smrti. Za tiste, ki so umrli za rakom, pa (še) niso zapisani v registru, RRRS tako išče dodatne podatke. Na ta način se izboljša popolnost registracije rakov s slabo napovedjo izida, ne pa manj usodnih. Domnevamo, da je v Sloveniji – in tudi v drugih evropskih populacijskih registrih raka – manj popolna registracija nemelanomskega kožnega raka in tistih malignomov, ki se zdravijo samo ambulantno.

Incidenca in umrljivost

Incidenca in *umrljivost* pomenita absolutno število vseh na novo ugotovljenih primerov kake bolezni oz. število vseh umrlih za to boleznijo v točno določeni populaciji v enem koledarskem letu. V incidenco raka ne štejemo novih primarnih rakov parnega organa iste lokacije, če je bila histološka vrsta obeh rakov, npr. leve in desne dojke, enaka. Prav tako v incidenco ne štejemo novega pojava raka iste histološke vrste na istem organu, npr. multiple lezije v debelem črevesu. V incidenco so vključeni primeri bolezni bolnikov s stalnim bivališčem na območju Republike Slovenije ne glede na to, kje so bili bolniki zdravljeni.

Za *oceno incidence* v letu 2014 (prikazano v Tabeli 1) je uporabljena metoda po Dybi in Hakulinenu, ki je primerna za napoved incidence v krajšem časovnem obdobju, saj upošteva samo obdobje diagnoze in starost; pri dolgoročnejših napovedih je treba upoštevati tudi vpliv rojstne kohorte.

Grobe in starostno specifične stopnje

Groba incidenčna stopnja je število novih primerov bolezni, preračunano na 100.000 oseb opazovane populacije, *groba umrljivostna stopnja* pa število vseh umrlih na 100.000 oseb opazovane populacije. Natančneje sta stopnji definirani kot število novih primerov bolezni (oz. število umrlih) v določenem časovnem obdobju, praviloma enem letu (= incidenca oz. umrljivost), deljeno s številom oseb, ki so na začetku tega obdobja izpostavljene tveganju, da zbolijo oz. umrejo zaradi določene bolezni; izražamo jo na 100.000 oseb-let. *Starostno specifična stopnja* pove to relativno število (incidenčno oz. umrljivostno stopnjo) v posamezni petletni starostni skupini.

Starostno standardizirane stopnje

Če analiziramo incidenco (ali umrljivost) v daljšem časovnem obdobju, v katerem se lahko starostna struktura prebivalstva v času spreminja, ali če primerjamo incidenco (ali umrljivost) med populacijami z različno starostno strukturo, je treba uporabiti eno od metod starostne standardizacije. Starostno standardizirana stopnja je teoretična incidenčna (oz. umrljivostna) stopnja, pri kateri predpostavimo, da je starostna struktura opazovane populacije taka kot v standardni populaciji. V Tabeli 2 prikazujemo poleg grobe incidenčne stopnje rakavih bolezni v Sloveniji še starostno standardizirane stopnje na svetovno, evropsko in slovensko standardno populacijo z metodo *neposredne standardizacije*. Starostno standardizirane umrljivostne stopnje so dostopne na spletišču SLORA. V Tabeli 6b je za primerjavo incidenčnih stopenj med slovenskimi statističnimi regijami uporabljen slovenski standard, starostna struktura prebivalcev Slovenije ob popisu leta 2002. Uporabljena standardna populacija je vedno enaka za oba spola, kar v posameznih primerih lahko privede do nepričakovanih rezultatov, ko so standardizirane stopnje pri enem spolu (ponavadi pri moških, ki so v povprečju mlajši) večje od grobih stopenj, pri drugem spolu pa manjše.

Kumulativne stopnje in kumulativno tveganje

Kumulativna incidenčna (ali umrljivostna) stopnja (KS) (prikazana v zadnjem stolpiču Tabele 5) je petkratna vsota starostno specifičnih incidenčnih (ali umrljivostnih) stopenj po petletnih starostnih skupinah do 74. leta starosti, preračunana na 100 prebivalcev. Je poseben primer neposredne starostne standardizacije, kjer je standardna populacija v vseh starostnih skupinah enaka in zato vrednost ni odvisna od izbora standarda. Kumulativno stopnjo smo uporabili za prikaz časovnega trenda incidence in umrljivosti v spodnjem delu Slike 4.

Kumulativno tveganje (KT) je verjetnost posameznika, da zboli za rakom v izbranem starostnem obdobju, npr. do 74. leta starosti, če ne umre prej zaradi drugih vzrokov. Kumulativno tveganje izražamo v odstotkih. Če je KS manjša kot 10/100, jo lahko uporabimo za približek kumulativnemu tveganju. Pri večjih kumulativnih stopnjah pa kumulativno tveganje izračunamo iz kumulativne stopnje po obrazcu: $KT = 100\ (1 - e^{-KS/100})$.

Kumulativno incidenčno stopnjo raka dojk pri ženskah 7,0/100 tako lahko uporabimo za oceno kumulativnega tveganja raka dojk, ki je v tem primeru 7,0-odstotno. To pomeni, da bo 7,0 % deklic, rojenih leta 2010 (ali približno ena od 14), do 74. leta starosti verjetno zbolelo za rakom dojk.

Prevalenca

Prevalenca je število vseh bolnikov z rakom, ki so bili živi na izbrani datum, ne glede na to, kdaj so zboleli. Celotna prevalenca obsega vse bolnike, ne glede na to, kako dolgo pred datumom izračuna so zboleli, medtem ko delna prevalenca šteje samo bolnike, ki so zboleli v določenem obdobju, npr. 1, 5 ali 10 let pred datumom, na katerega to mero računamo. Pri raku so ta obdobja še zlasti pomembna, saj odsevajo število bolnikov v različnih fazah poteka bolezni, npr. enoletna vključuje bolnike v času prvega zdravljenja, triletna bolnike v obdobju rednih kontrolnih kliničnih pregledov, petletna in zlasti še desetletna pa vključuje bolnike, za katere vsaj pri večini rakavih bolezni menimo, da so ozdravljeni.

Nekateri bolniki zbolijo za več kot eno rakavo boleznijo, zato je vsota prevalenc bolnikov po posameznih vrstah raka večja kot skupna prevalenca, pri kateri štejemo samo bolnike ne glede na število posameznih rakavih bolezni.

Relativno preživetje

Relativno preživetje je približek preživetja bolnikov v primeru, da bi kot vzrok smrti upoštevali samo izbranega raka. Izračuna se kot razmerje med opazovanim preživetjem proučevane skupine bolnikov in preživetjem, ki ga glede na spol in starost v določenem obdobju pričakujemo v celotni populaciji, iz katere prihajajo bolniki. Pričakovano preživetje se izračuna na podlagi podatkov o splošni umrljivosti, ki se v obliki tablic umrljivosti za posamezno državo rutinsko objavljajo v okviru demografske statistike; za naše izračune so uporabljene slovenske letne popolne momentne tablice umrljivosti. Izračunano je s knjižnjico *relsurv* v programskem paketu R.

Opozarjamo še, da metoda, uporabljena za izračun relativnega preživetja, prikazanega v tem poročilu, ni enaka tisti, s katero je mogoče prikazati relativno preživetje na spletnem portalu SLORA. Za izračun relativnega preživetja na spletišču SLORA je uporabljena t.i. Hakulinenova ali popolna metoda izračuna relativnega preživetja. Po tej metodi prispevajo bolniki, ki jim zaradi predhodnega zaključka opazovanja ne sledimo polni čas, k relativnemu preživetju samo leta, za katera so dejanski podatki na voljo. Tako skupina zbolelih tri leta pred zaključkom opazovanja prispeva k eno- in triletnemu relativnemu preživetju, k petletnemu pa ne.

Prebivalstvo Slovenije

Podatki o številu prebivalcev in o starostni strukturi so pomembni pri izračunavanju in interpretiranju večine kazalnikov bremena raka. Za Slovenijo je točno število in starostna struktura prebivalcev na voljo za popisna leta že ves čas registracije raka. Nacionalni popis prebivalstva je bil napravljen približno na vsakih deset let. Podatkov za vmesna obdobja do leta 1985 ni, zato smo pri izračunu kazalnikov predpostavili, da je bila med dvema popisnima letoma struktura enaka. Od sredine osemdesetih let, odkar število prebivalstva v Sloveniji spremlja Centralni register prebivalstva, je mogoče dobiti ažuren podatek o številu in starostni strukturi prebivalcev. V letnih poročilih uporabljamo podatek o prebivalcih na datum 30. junij posameznega leta, kot ga dobimo na podatkovnem portalu SI-STAT Statističnega urada RS. Podatki o prebivalstvu po spolu in petletnih starostnih skupinah za celotno Slovenijo za leto 2011 so v spodnji tabeli.

Prebivalci Slovenije po starosti in spolu na dan 30. 6. 2011.

Starostna skupina	Skupaj	Moški	Ženske
0–4	107.935	55.491	52.444
5–9	91.415	47.042	44.373
10–14	92.798	47.798	45.000
15–19	100.877	51.885	48.992
20–24	125.692	65.167	60.525
25–29	143.004	74.903	68.101
30–34	157.765	82.888	74.877
35–39	152.403	79.603	72.800
40–44	148.795	76.473	72.322
45–49	157.195	80.166	77.029
50–54	153.172	77.810	75.362
55–59	152.273	77.547	74.726
60–64	127.980	63.256	64.724
65–69	93.306	43.361	49.945
70–74	88.038	38.782	49.256
75–79	72.685	28.147	44.538
80+	87.163	25.111	62.052
Skupaj	**2.052.496**	**1.015.430**	**1.037.066**

Pri razporeditvi prebivalcev v posamezne statistične regije (spodnja tabela) je uporabljen le podatek o stalnem naslovu oseb in ne tudi začasnem, kot je upoštevan v pripravi števila prebivalcev po klasični »statistični« definiciji.

Prebivalci Slovenije po statističnih regijah in spolu na dan 30. 6. 2011.

Statistična regija	Skupaj	Moški	Ženske
Pomurska	119.146	58.097	61.049
Podravska	322.843	159.269	163.574
Koroška	72.521	36.433	36.088
Savinjska	260.093	129.680	130.413
Zasavska	44.106	21.619	22.487
Spodnjeposavska	70.686	35.429	35.257
JV Slovenija	141.954	71.486	70.468
Osrednjeslovenska	534.807	261.420	273.387
Gorenjska	203.703	100.637	103.066
Notranjsko-Kraška	52.419	26.443	25.976
Goriška	119.163	59.544	59.619
Obalno-Kraška	111.055	55.373	55.682
Slovenija	**2.052.496**	**1.015.430**	**1.037.066**

Leta 2011 je v Sloveniji za rakom zbolelo 12.922 ljudi, 7.162 moških in 5.760 žensk. (*Slika 1*), umrlo pa 5.864 ljudi, 3.266 moških in 2.598 žensk. Od rojenih leta 2011 bosta do 75. leta starosti predvidoma za rakom zbolela eden od dveh moških in ena od treh žensk (*Tabela 5*).

Konec decembra 2011 je živelo 85.504 ljudi (37.020 moških in 48.484 žensk), ki so kadar koli od ustanovitve RRRS zboleli za rakom (*Slika 1*). Ocenjujemo, da je leta 2014 za rakom zbolelo približno 14.300 prebivalcev Slovenije, približno 8.000 moških in 6.300 žensk. Ocene incidence za posamezne lokacije raka so prikazane v *Tabeli 1* skupaj s povprečnimi petletnimi vrednostmi za zadnje 10-letno obdobje.

Ogroženost z rakom se zmerno veča in je največja v starejših letih; od vseh bolnikov z rakom je leta 2011 kar 58 % moških in 57 % žensk zbolelo po 65. letu starosti. Pri otrocih in mladostnikih (do 20. leta) obsegajo rakave bolezni manj kot 1 % vseh primerov raka *(Slika 2)*. Ker se slovensko prebivalstvo stara, je samo zaradi vedno večjega deleža starejših pričakovati, da se bo število novih primerov raka še večalo.

Ker na incidenco raka najbolj vpliva starostna struktura prebivalstva, so za verodostojnejšo primerjavo z drugimi državami z različno starostno strukturo v *Tabeli 2* poleg grobih stopenj izračunane tudi starostno standardizirane. Glede na to, da so v uporabi različni standardi, smo uporabili tri standardne populacije, svetovno, evropsko in slovensko.

Pet najpogostejših vrst raka pri nas – kožni (razen melanoma), rak debelega črevesa in danke, prostate, pljuč in dojke – obsega 59 % vseh novih primerov rakavih bolezni *(Slika 3)*. Raki teh organov so povezani z nezdravim življenjskim slogom, čezmernim sončenjem, nepravilno prehrano, kajenjem in čezmernim pitjem alkoholnih pijač, zato je ogroženost z njimi treba zmanjšati z ukrepi primarne preventive. Pri moških je bil z 21,5 % vseh novih primerov na prvem mestu rak prostate. Pri ženskah je bil na prvem mestu rak dojk, ki je predstavljal slabo petino primerov vseh rakov pri ženskah (19,8 %) *(Slika 3)*.

Od leta 1950 se je groba incidenčna stopnja raka v Sloveniji zvečala za 589 % pri moških in za 346 % pri ženskah; v zadnjih 10 letih se je pri moških večala povprečno za 3,3 % letno, pri ženskah pa za 1,9 %. Groba umrljivostna stopnja se je v zadnjih 10-ih letih večala pri moških povprečno za 1,6 % letno, pri ženskah pa za 2,1 % (*Slika 4*). Več kot polovica zvečanja incidence gre na račun staranja prebivalstva. Kumulativna incidenčna stopnja se je v zadnjih 10-ih letih pri moških večala v povprečju le za 1,7 % letno, pri ženskah pa za 0,4 %. Kumulativna umrljivostna stopnja se od leta 1985 pri obeh spolih manjša *(Slika 4)*, pri moških za 1,6 % letno, pri ženskah pa za 0,1 %. Manjšanje verjetnosti smrti za rakom ob večanju incidence kaže, da je zdravljenje uspešnejše in da vse več bolnikov ozdravi in/ali živi z rakom, medtem ko jih je prej več umrlo zaradi rakave bolezni.

Časovni trend pogostejših rakov pri moških kaže, da se je incidenčna stopnja pljučnega raka večala vse do začetka devetdesetih let prejšnjega stoletja, ko se je ustalila pri vrednosti okoli 85/100.000, v zadnjih desetih letih se postopno manjša (za 0,8 % povprečno letno), strmo pa pljučnega raka prehitevata rak prostate (povečanje za 8,3 % povprečno letno) ter rak debelega črevesa in danke (povečanje

za 5 % povprečno letno). Izjemno povečanje incidence raka prostate v zadnjem desetletju ni posledica kakega novega nevarnostnega dejavnika, pač pa predvsem vse širše rabe testa za določanje za prostato specifičnega antigena (PSA) pri zdravih moških in odkrivanja velikega števila primerov, ki bi drugače ostali vse življenje prikriti. V zadnjem desetletju se skoraj ne spreminja incidenčna stopnja raka glave in vratu. Pri ženskah se večajo incidenčne stopnje raka dojk, pljučnega raka in raka materničnega telesa, medtem ko se incidenčna stopnja raka materničnega vratu od leta 2003 počasi manjša. Pri obeh spolih se veča pogostost raka debelega črevesa in danke, malignega melanoma in drugih kožnih rakov, podobno kot drugod v svetu pa je želodčnega raka pri obeh spolih vse manj; povprečne letne odstotne spremembe so prikazane pri krivuljah na *Sliki 5*.

Slika 6 prikazuje petletno relativno preživetje bolnikov z vsemi (razen kožnega) in izbranimi raki, zbolelih v letih 2007-2011 po spolu in za oba spola skupaj. Za primerjavo je prikazano tudi relativno preživetje bolnikov, zbolelih v predhodnem petletnem obdobju (2002-2006). Pri moških se je skupno preživetje povečalo za 7 odstotnih točk, predvsem zaradi večjega odkrivanja in boljšega prijavljanja raka prostate nižjih stadijev, ki so povezani z boljšo prognozo, saj je preživetje bolnikov, zbolelih v zadnjem obdobju, večje kar za 8 odstotnih točk. Ker se 95 % intervala zaupanja ne prekrivata, lahko zaključimo, da je razlika statistično značilna. Preživetje bolnic, zbolelih v obeh petletnih obdobjih, je skoraj enako (59 %); statistično značilno se je povečalo preživetje bolnic z rakom danke (za 10,8 odstotnih točk), večje preživetje pa so imele tudi bolnice z rakom ščitnice, s kožnim melanomom ter s kostnim in pljučnim rakom.

Konec novembra 2014 so bili objavljeni izsledki raziskave CONCORD–2, ki obravnava preživetje 25,7 milijonov bolnikov z rakom, starejših od 15 let in 75.000 otrok, zbolelih v letih 1995–2009, ki so jim sledili najmanj do 31. decembra 2009. Podatke je poslalo 279 populacijskih registrov raka iz 67 držav vsega sveta. Pri izračunu preživetja so uporabili novejšo metodo čistega preživetja. Za prikaz na *Sliki 7* smo izbrali petletno starostno standardizirano čisto preživetje odraslih bolnic in bolnikov z raki, ki jih iščemo v organiziranih presejalnih programih: žensk z rakom dojk in materničnega vratu ter bolnikov z rakom debelega črevesa in danke iz vseh držav in regij, ki so poslale izbrane podatke. V članku, objavljenem v okviru raziskave CONCORD–2, je prikazano še preživetje odraslih bolnic in bolnikov z želodčnim, jetrnim in pljučnim rakom ter rakom jajčnikov, prostate in levkemijo; pri otrocih je prikazano samo preživetje bolnikov z levkemijo. Preživetje je izračunano za tri zaporedna petletna obdobja, 1995–1999, 2000–2004 in 2005–2009; na sliki je prikazana primerjava med državami le za zadnje obdobje 2005–2009. Petletno preživetje bolnic in bolnikov z rakom debelega črevesa in danke ter bolnic z rakom dojk se postopno veča v večini držav razvitega sveta. Pri bolnicah in bolnikih, ki so zboleli za rakom debelega črevesa in danke v letih 2005–2009, je preživetje doseglo 60 % ali več v 22 državah sveta; v Sloveniji je bilo 56,0 % (debelo črevo) in 55,2 % (danka). Petletno preživetje bolnic z rakom dojk je bilo 85 % ali več v 17 državah; v Sloveniji je bilo 80,2 %. Pri raku materničnega vratu so precejšnje razlike, preživetje je v razponu od manj kot 50 % do več kot 70 %; razlike med obdobji 1995–1999 do 2005–2009 so zelo majhne. Take mednarodne primerjave preživetja bolnikov z rakom in trendov preživetja so pomembne zato, da opozorijo strokovno in laično javnost ter politike na velike razlike, ki so posledica neenakosti v zgodnji diagnostiki

in zdravljenju bolnikov. Hkrati pa poudarjajo vlogo registrov raka pri ocenjevanju bremena raka ter pomen kakovostno zbranih podatkov (iz objavljenega je namreč razvidno, katere ocene preživetja so manj zanesljive).

Najpogostejši raki so v raznih življenjskih obdobjih različni. Pri otrocih in mladostnikih do 20. leta je rak zelo redka bolezen, v zadnjih letih (2007–2011) je v povprečju letno zbolelo 34 dečkov in 32 deklic. Najpogostejše pri dečkih so bile levkemije (26,0 %), sledili so jim tumorji centralnega in avtonomnega živčnega sistema (16,6 %) in Hodgkinova bolezen (11,8 %), pri deklicah pa so bili na prvih dveh mestih tudi levkemije (25,6 %) in tumorji centralnega in avtonomnega živčnega sistema (14,4 %), na tretjem pa Hodgkinova bolezen (11,3 %). Mlajših odraslih moških (starih 20–34 let) je zbolelo v povprečju 126 letno; med njimi je skoraj polovica primerov raka mod (41,3 %), sledi kožni melanom (9,9 %), za nemelanomskim kožnim rakom (8,7 %) pa tumorji centralnega in avtonomnega živčnega sistema (6 %). Pri mlajših ženskah (v povprečju je letno 146 novih primerov) pa je bil na prvem mestu kožni melanom (16,0 %), sledili so rak dojk (15,8 %) in rak ščitnice (13,8 %) (*Slika 8*).

Pri večini bolnikov je diagnoza bolezni potrjena mikroskopsko. Iz *Tabele 3* je razvidno, da je bila leta 2011 pri 93,9 % od 12.922 na novo registriranih primerov raka diagnoza potrjena mikroskopsko (histološko ali citološko), pri 5,8 % z drugimi preiskavami, le 0,3 % primerov pa je bilo v RRRS vpisanih samo na osnovi zdravniškega poročila o vzroku smrti. Ta zadnja odstotna vrednost, ki je že več let podobna, odseva število bolnikov, ki verjetno zaradi starosti ali napredovale bolezni niso bili zdravljeni v bolnišnici. Iz *Tabele 3* je poleg načina postavitve diagnoze razvidno tudi število vseh novih primerov po posameznih mestih raka, v *Tabeli 4* je prikazano razporejanje teh primerov po 5-letnih starostnih skupinah, v *Tabeli 5* pa so te vrednosti preračunane v starostno specifične stopnje na 100.000 prebivalcev.

V *Tabeli 6a* je število novih primerov vseh in izbranih rakov prikazano po statističnih regijah. Ta števila so pomembna za načrtovanje zdravstvenih zmogljivosti, starostno standardizirane vrednosti v *Tabeli 6b* pa kažejo razlike v ogroženosti z rakom v posameznih regijah, saj te niso posledica razlik v starostni strukturi prebivalcev.

Kakšna je bila morfološka slika malignomov pri 12.138 primerih, pri katerih je bila diagnoza potrjena mikroskopsko, kaže *Tabela 7*. V njej so posebej prikazani primeri, ki so potrjeni histološko (95 %), in tisti, ki so bili potrjeni samo citološko (5 %).

Tabela 8 prikazuje porazdelitev bolnikov po stadiju, v katerem je bila bolezen odkrita. Uporabljena je poenostavljena opredelitev stadijev, ki upošteva vse preiskovalne metode, vključno operacijo in tudi obdukcijo, če bolnik ni bil poprej zdravljen.

Tabela 9 kaže starostno porazdelitev ekstranodalnih in nodalnih lokacij ne-Hodgkinovih malignih limfomov. Ker je število ekstranodalnih lokacij majhno, so prikazane le absolutne številke.

V *Tabeli 10* je prikazana starostna porazdelitev neoplazem limfatičnega in krvotvornega tkiva v skladu z verzijo 2010 desete revizije Mednarodne klasifikacije bolezni in sorodnih zdravstvenih problemov za statistične namene (MKB-10).

Tabela 11 prikazuje osnovne podatke o zdravljenju bolnikov. Ker je veliko bolnikov zdravljenih na več načinov, je vsota bolnikov po vrsti zdravljenja večja od števila novih primerov. Iz *Tabele 11a* je razvidno, kako so bili bolniki zdravljeni, v *Tabelah 11b* in *11c* pa, v katerih zdravstvenih ustanovah so bili bolniki v okviru prvega zdravljenja operirani in/ali zdravljeni s sistemskimi zdravili; z obsevanjem se z redkimi izjemami (tujina) zdravijo samo na Onkološkem inštitutu Ljubljana.

Tabela 12 prikazuje prevalenco vseh in pogostejših rakov na dan 31. 12. 2011. Poleg celotne prikazujemo tudi delno, to je 1-, 3-, 5- in 10-letno prevalenco.

V *Tabeli 13* so uradni podatki o umrljivosti za rakom v letu 2011; zbira jih Nacionalni inštitut za javno zdravje RS.

Zahvala

Zdravniki, medicinske sestre in administrativno osebje iz slovenskih bolnišnic in drugih zdravstvenih ustanov so RRRS dokaj vestno pošiljali prijavnice s podatki o novih primerih raka, o poteku bolezni in usodi bolnikov. Dopolnili so nam tudi morebitne pomanjkljive prijave. Podatke, ki so za RRRS nujni, a jih ni bilo mogoče najti v bolnišnicah, so nam z zavzetim delom priskrbeli družinski in splošni zdravniki.

Vsaj polovico podatkov, obdelanih v tem poročilu, sta prispevali sodelavki Bolnišničnega registra Onkološkega inštituta v Ljubljani Ana Dotzauer in Maruška Ferjančič. Patologinja dr. Gorana Gašljević nam je pomagala pravilno opredeliti histološke izvide.

Poročila bi skorajda ne mogli napraviti, njegovi podatki pa bi bili bistveno manj verodostojni, ko bi ne imeli naklonjenega sodelovanja Centralnega registra prebivalstva RS, Nacionalnega inštituta za javno zdravje RS in Statističnega urada RS.

Vsem imenovanim in tudi drugim, ki so kakorkoli prispevali k temu poročilu, se najlepše zahvaljujemo.

Uredniški odbor

Introduction

Cancer Registry of the Republic of Slovenia (CRRS) is one of the oldest population based cancer registries in Europe. It was founded at the Institute of Oncology Ljubljana (IO) in 1950 by the late Professor Božena Ravnihar, who headed it till 1975. She was succeeded by Professor Vera Pompe-Kirn, who contributed a lot to the further development of the CRRS as well as its recognition at the national and international level all until her retirement in 2003. Since 2003, the CRRS has been merged with the Unit of Epidemiology into a single Epidemiology and Cancer Registry service. Besides the CRRS, the new service also comprises the *hospital-based Cancer Registry* of the IO, which contributes a considerable part of information to the CRRS and facilitates a more detailed overview of patients treated at the IO, irrespective of their permanent residence. In the last decade, a new *national registry in charge of coordinating and monitoring the organised cervical cancer screening programme* (Registry ZORA) has been established, while an *information system to support organized breast screening program* has been established in 2007 (Registry DORA).

The data on cancer collected by the CRRS, incidence, survival and prevalence, serve together with mortality data collected by the Institute of Public Health of RS as the basis for assessing the cancer burden in the country. They are important for planning and evaluation of all levels of cancer control, primary prevention, diagnosis, treatment and rehabilitation, for planning facilities and funding needed for cancer control (personnel, equipment and hospital capacities) as well as for clinical and epidemiological research in Slovenia and in international multicentre studies and for evaluation of effectiveness of cancer screening programs.

The Annual Reports of the CRRS are one of the regular ways of disseminating information on cancer among professionals and other interested groups. As we are limited by the technology of data collection from a variety of sources, data collection, their linking and publication is rather time consuming (with us and elsewhere) and usually takes two to three years. Over the last few years the estimated numbers and rates for the expected incidence in the year the Annual Report is published (in this report for the year 2014) are presented; they are calculated by a special statistical method.

The first annual reports of the CRRS for the period 1951-1955 were issued during the years 1953-1957. The first data analysis for the year 1950 was published in *Zdravstveni vestnik* in 1951. The data for the period 1957-1971 were appearing in the periodicals *Epidemiological and Vital Statistics Report* and *World Health Statistics Report*, both edited by the World Health Organization. From 1965 onwards, the data have been appearing regularly in special bi-lingual (Slovene-English) annual reports, first entitled *Cancer in Slovenia* (1965-1977), and then *Cancer Incidence in Slovenia* (1978-2006). Besides Annual Reports, four special publications have been published: *Atlas of Cancer Incidence in Slovenia 1978-1987*, *Cancer Patients' Survival in Slovenia 1963-1990*, *Cancer Patients' Survival in Slovenia 1983-1997* and *Survival of Cancer Patients, diagnosed in 1991–2005 in Slovenia*. The list of other relevant publications in last five years is at the end of this report.

Data of the CRRS are included in several international databases and projects. They have been published in all nine volumes and the tenth electronic version of the *Cancer Incidence in Five Continents* issued by the International Agency for Research

on Cancer. The data are included in international databases *ECO*, *GLOBOCAN* and *ACCIS*. The survival of Slovenian cancer patients is analysed in the international studies *EUROCARE-2*, *EUROCARE-3*, *EUROCARE-4*, *EUROCARE-5*, *EUROCARE-6*, *RARECARE* and *EUNICE*.

In 2010, the CRRS's database has been upgraded and data processing modernized. At the same time an interactive web portal named SLORA was launched as well. The name comes from the first letters of the sentence in Slovenian language: "SLOvenia and RAk/cancer". It is available at www.slora.si. It enables a simple access to data on cancer in Slovenia collected by the CRRS (incidence, prevalence and survival; currently till 2011) and the National Institute of Public Health of Republic of Slovenia (RS) (mortality) and comparison with other countries in the European Union and in the world. It describes the data and offers its users professional explanations of cancer risk factors, screening and early detection and treatment outcomes.

Data sources and the list of data collected

Notification of cancer has been compulsory in Slovenia since the foundation of the CRRS and prescribed by law (Official Gazette of SRS, No 10/50, 29/50, 14/65, 1/80, 45/82 and 42/85; Official Gazette of RS, No 9/92 and 65/00). The main sources of data are *notifications of cancer,* gathered from all hospitals and diagnostic centres in Slovenia, exceptionally also from primary health care centres in case the patient has not been referred for further diagnostic investigations and/or treatment.

The data gathered with notifications are identification data, data on the cancer disease (anatomic cancer site, histological or cytological diagnosis and stage by TNM or other clinical classification) and basic data on treatment. Additional sources of information are death certificates that we get from National Institute of Public Health of RS. Where patients' data are incomplete or the only information about their disease is acquired from the death certificate, time consuming queries about patients must be performed by the CRRS's staff.

Calculation of patient survival requires the patient's *vital status* (a person may be alive, dead or lost to follow-up). This data is obtained from the Central Population Registry for all persons registered in the CRRS data base as alive. Since 2010, together with the upgrade of CRRS's database, an on-line connection with the Central Population Registry has been established using a specially secured web technology. This enables an on-line connection and up-to-date vital status of all registered patients. In persons lost to follow-up the date of last notification or the date of loss obtained from the Central Population Registry, whichever first, is considered as the date of loss to follow-up. From 1985, since the uniform personal ID number has been used in Slovenia, the percentage of the lost to follow-up in CRRS is below 1%, furthermore, in patients registered in the last decade being only 0.1%.

When analysing the spatial distribution of cancer, the Decree on the standard classification of territorial units from the year 2000 that introduced the system of division of Slovenian territory at eleven levels is followed. Our regular connection with the Registry of Spatial Units of the Surveying and Mapping Authority enables us to perform the exact mapping of patients' permanent address. Till the Annual Report 2002 the data have been presented by 9 health regions in Table 6 and in accordance with aforementioned decree 12 statistical regions are used to present the data since then.

Statistical regions of Slovenia

Preparation of data for computer processing

In CRRS specially trained nurses code the data retrieved from notifications of cancer in accordance with the international and internal CRRS guidelines.

Since 1997, cancer sites are coded according to the 10th revision of the International Statistical Classification of Diseases and Related Health Problems (ICD-10); before, the 8th revision was used (ICD-8). When classifying tumours as malignant, the behaviour digit of the morphology code of the third edition of International Classification of Diseases for Oncology has been used since the report for 2001. In this edition some changes were introduced in terms of morphology and behaviour code and some new morphology codes were added for tumours that till 2001 have not been coded separately. Gastrointestinal stromal tumours (GIST) are a distinct entity since 2001. According to this classification, chronic myeloproliferative disorders and myelodisplastic syndromes as well as policytaemia are classified as malignant, the former two being assigned C96.7 and the latter the topography code C94. According to the new rules, ovarian tumours of borderline malignancy are currently coded as D39.1 (and not C56).

In this report, malignant neoplasms, stated or presumed to be primary, of lymphoid, haematopoietic and related tissue are also coded according to Version for 2010 of 10th revision of the International Statistical Classification of Diseases and Related Health Problems. In this Version, the classification of lymphoid and haematopoietic malignant neoplasms is different from the one in Version 1995 corresponding better with the clinical management of these patients.

In 1993, compulsory registration of all cervical intraepithelial dysplasia classified as CIN III was introduced (code 219 according to ICD-8). Till then, only carcinoma in situ (code 234.0) was registered. Thus, the comparison with the data for the period 1961-1992 is not possible. According to ICD-10, all cervical intraepithelial neoplasms (in situ and CIN III) are coded as D06. Since 1987, the number of all reported intraepithelial carcinomas of breast (D05) and since 1995, all reported intraepithelial carcinomas of the bladder (D09.0) and all malignant melanomas Clark I (D03) have been registered as well.

For stage description, a simplified definition of stages at diagnosis is used, classifying them into localized, regional and remote stage of disease. The simplified definition is based on all investigation methods, including surgery. In case the patient was not treated before death, the autopsy record is considered as well. In solid tumors, the simplified stage definition generally follows the TNM classification. Localized stage includes all cancers where the tumor has been classified as T1 and T2. In breast cancer, skin melanoma and thyroid cancer T3 tumor is also included in localized stage. In uterine cervix, corpus and sarcomas, ovarian cancer, tube and trophoblastic tumors only T1 tumor is included in localized stage. In all of these cases neither regional lymph node involvement nor distant metastases are found (N0, M0). The regional stage includes tumors classified as T3 and T4 (with aforementioned exceptions) and/or regional lymph node metastases (N1), without presence of metastases in distant lymph nodes or organs (M0). The disease with metastases in distant lymph nodes or organs is classified as the remote stage (M1).

Stage according to TNM or any other appropriate classification is also stored in the CRRS database, if available. Malignant lymphomas are classified according to Ann-Arbor System.

Data quality and completeness of registration

The quality of information can be assessed by the following parameters: the percentage of microscopically (histologically or cytologically) confirmed cases and the percentage of cancer cases registered on the basis of death certificates only. The values of these parameters are presented in Table 3.

The completeness of registration shows the proportion of all new cancer cases in the region covered by the registry that are included in the registry's data base. It can be measured directly only by means of special surveys for the evaluation of completeness, e.g. by reviewing patients' records in the hospitals or outpatient clinics in a particular region. In Slovenia, no such surveys have been carried out so far. However, a considerable contribution towards the completeness of registration is made by our colleagues – clinicians, who send us the data on their groups of patients in order to provide us with information about their vital status and among them we often find cases that have not been entered into the CRRS database yet.

In general, the registration is more complete where the registries have access to death certificates. This enables the registry to send out additional inquiries where disease for the deceased has not been entered into the database yet. This improves the completeness of registration of cancers with poor prognosis, but not also of less fatal ones. It is presumed that in Slovenia – as well as in other European population based cancer registries – registration is less complete in non-melanoma skin cancer and in malignomas that are treated on the out-patient basis only.

Incidence and mortality

Incidence and mortality are absolute numbers of all newly diagnosed cases of any disease or number of deceased from this disease in a defined population in one calendar year. New primary cancers of the same histology in paired organs, e. g. in the left and right breast, are not comprised in the incidence figures, neither are any new cancers of the same histology appearing in the same organ, e.g. multiple lesions of the colon. The incidence registered by CRRS includes only the data on patients with permanent residence in Slovenia, regardless of the country where they have been treated.

The method by Dyba and Hakulinen was used for estimation of incidence in 2010 (presented in Table 1). This method is suitable for predictions in shorter time period, taking into account the period of diagnosis and age structure of population. For long-term predictions the cohort effect should be included also.

Crude and age specific rates

Crude incidence rate is the number of new cases per 100,000 population, while crude mortality rate is the number of deaths per 100,000 population. More precisely it is defined as number of new cases (or number of deaths) in a specified time interval, usually one calendar year (=incidence or mortality), divided by the number of persons at risk of disease (or death) at the beginning of time interval; it is expressed per 100,000 person-years. The *age specific rate* expresses incidence or mortality rate in an individual five-year age group.

Age standardized rates

When analysing the incidence (or mortality) rate within longer time period (if the age structure of population changes) or comparing the incidence (or mortality) between populations with different age structure, age standardization is needed to adjust the rate for the effect of age. The age-standardized rate is a theoretical incidence (or mortality) rate assuming that the age structure in the observed population is the same as in the standard population. In Table 2, besides crude cancer incidence rates, age standardized rates by direct method are presented, using World, European and Slovenian standard population. Age standardized mortality rates are also available at SLORA web-portal. In Table 6b the incidence rates in different statistical regions in Slovenia are compared using the Slovenian standard, which is the age structure of Slovenian 2002 census population. Because the standard population is always the same for both sexes, there are some situations where standardized rate is bigger than crude rate in one sex, usually in males who are on average younger, and smaller in the other.

Cumulative incidence rate and cumulative risk

The cumulative incidence (or mortality) rate (cumulative incidence rate is presented in the last column of Table 5) is five times the sum of the age-specific incidence (or mortality) rates over five-year age groups up to the age of 74 years, calculated per 100 population. The cumulative rate can be interpreted as a form of direct age-standardization with the same standard population size in each age group. Thus, it avoids the arbitrary choice of standard population. The cumulative incidence rate was also used to present the incidence time trend in the lower part of the Figure 4.

The cumulative risk (CR) is the risk an individual would have of developing the disease in question during a certain age period, e.g. up to the age of 74, if no other causes of death were in operation. The cumulative risk is expressed per 100 (per cent). If cumulative rate is lower than 10/100, its value is practically equal to that of the cumulative risk. When cumulative rate is greater than 10/100, it should be calculated from cumulative risk according to the following formula: $CR = 100\ (1 - e^{-CR/100})$.

Cumulative incidence rate of breast cancer in females 7.0/100 can be used to estimate cumulative risk of breast cancer that is in this case 7.0%. This means that 7.0% of women born in 2010 (approximately each 14^{th} woman) are expected to develop breast cancer by their age of 75 in the absence of any other cause of death.

Prevalence

Prevalence is the number of all cancer patients that are alive on a given date, regardless of when they were diagnosed with cancer. Lifetime cancer prevalence is defined as all persons living and ever diagnosed with cancer, while partial prevalence counts only those patients, diagnosed with cancer within a defined period of time e. g. 1, 5 or 10 years before the date on which prevalence is calculated. In cancer these periods are important, as they reflect the number of cancer cases in different course of disease, e. g. the one-year prevalence includes patients during their primary treatment, 1–4 years prevalence those requiring regular follow-up, while 5–9 and especially 10 and more years prevalence includes predominantly those considered cured from cancer.

Some patients have more than one cancer, hence the sum of prevalence of cancer patients by individual cancer site is bigger than the prevalence of all cancer patients, as patients are counted only once regardless of the number of cancer diseases.

Relative survival

Relative survival is an approximation of patients' survival in the case where the observed cancer would be considered as the only cause of death. Relative survival is a ratio between the observed and the expected survival, i.e. the survival expected with respect to gender and age in certain time period in the whole population the patients come from. The expected survival is calculated from general mortality data published routinely in the form of mortality tables for an individual country within the framework of its vital statistics. The relative survival for the needs of this report was calculated using the Slovenian annual complete yearly life tables using package *relsurv* in statistical software R.

It should be noted that the method used for survival calculation in this report is different from the one used to present survival at web-portal SLORA where the relative survival is computed by complete or Hakulinen's method. In this method the patients followed up for a shorter period of time are considered in the calculation only for the time when they were actually followed. Thus, a group diagnosed three years before the completion of study contributes to one- and three-year complete relative survival but not also to five-year survival.

Population of Slovenia

Population data, especially the number and age structure, are important for calculation and interpretation of most indicators of cancer burden. Census population data are available for the whole time period since the beginning of cancer registration. Census has been performed nearly every 10 years, but till 1985 no data were available for intermediate years, so for this time period it was assumed that the population structure between two censuses was the same. Since the middle of the eighties, the population data are available for any particular date from the Central Population Registry. In CRRS Annual Reports the population data on June 30 of a particular year are used, which are obtained from Statistical Office of Republic of Slovenia. In the following table, numbers of inhabitants of Slovenia in 2009 by age and by sex are presented.

Population of Slovenia by age and by sex, June 30, 2011.

Age	Total	Males	Females
0–4	107,935	55,491	52,444
5–9	91,415	47,042	44,373
10–14	92,798	47,798	45,000
15–19	100,877	51,885	48,992
20–24	125,692	65,167	60,525
25–29	143,004	74,903	68,101
30–34	157,765	82,888	74,877
35–39	152,403	79,603	72,800
40–44	148,795	76,473	72,322
45–49	157,195	80,166	77,029
50–54	153,172	77,810	75,362
55–59	152,273	77,547	74,726
60–64	127,980	63,256	64,724
65–69	93,306	43,361	49,945
70–74	88,038	38,782	49,256
75–79	72,685	28,147	44,538
80+	87,163	25,111	62,052
Total	**2,052,496**	**1,015,430**	**1,037,066**

In the number of inhabitants by statistical regions (following table) the permanent, but not the temporary residence of the Slovenian citizens is used, contrary to the standard "statistical" definition.

Population by Slovenian statistical regions and by sex, June 30, 2011.

Statistical region	Total	Males	Females
Pomurska	119,146	58,097	61,049
Podravska	322,843	159,269	163,574
Koroška	72,521	36,433	36,088
Savinjska	260,093	129,680	130,413
Zasavska	44,106	21,619	22,487
Spodnjeposavska	70,686	35,429	35,257
JV Slovenija	141,954	71,486	70,468
Osrednjeslovenska	534,807	261,420	273,387
Gorenjska	203,703	100,637	103,066
Notranjsko-Kraška	52,419	26,443	25,976
Goriška	119,163	59,544	59,619
Obalno-Kraška	111,055	55,373	55,682
Slovenia	**2,052,496**	**1,015,430**	**1,037,066**

In 2011, 12,922 patients were diagnosed with cancer, 7,162 males and 5,760 females, and 5,864 patients died from cancer, 3,266 males and 2,598 females (*Figure 1*). From those born in 2011, one in two males and one in three females are expected to develop cancer by their age of 75 (*Table 5*).

At the end of December 2011, there were 85,504 people (37,020 males and 48,484 females) alive who were diagnosed with cancer at any time since the foundation of the CRRS (*Figure 1*). It is estimated that in 2014 there was about 14,300 Slovenian inhabitants newly diagnosed with cancer, approximately 8,000 males and 6,300 females. The estimated incidence of different cancer sites together with 5-year average values in the last 10-year period are presented in *Table 1*.

The risk of cancer is slowly increasing and is the highest in older age groups; from all cancer patients, diagnosed in 2011, 58% males and 57% females were aged 65 or more at diagnosis. Cancer among children and young adults (till the age of 20) accounts for less than 1% (*Figure 2*). As Slovenian population is ageing, it is expected that the cancer burden will increase because of longer life expectancy.

As cancer incidence depends on the age structure of a population, *Table 2* presents crude as well as age standardized rates. For better comparison with other countries and as different standard populations are used worldwide, three standard populations, World, European and Slovenian, were applied.

First five most frequent cancers (skin – except melanoma, colorectal, prostate, lung and breast) comprise 59% of all new cancer cases (*Figure 3*). Cancer of these sites is associated with unhealthy lifestyle, such as excessive sunbathing, unhealthy diet, smoking and excessive alcohol consumption; the aim of primary prevention is to lower the risk associated with these factors. In males, the most frequent cancer site in 2011 was prostate (21.5% of all new cases) (*Figure 3*). In females, breast was the most frequent cancer site with 19.8% of all new cases (*Figure 3*).

Since 1950, the crude cancer incidence rate in Slovenia increased by 589% in males and by 346% in females. In the last 10 years, the average annual increase in males was 3.3% and 1.9% in females. The increase in crude mortality rate in the last 10 years was substantially lower; on average by 1.6% per year in males and by 2.1% in females (*Figure 4*). More than half of the crude incidence rate increase is a consequence of ageing of the population. In the last 10 years, the average annual increase in cumulative incidence rate in males was 1.7% and 0.4% in females. Cumulative mortality rate is decreasing in both sexes in the last 10 years, in males on average by 1.6% and in females on average by 1.1% annually. The decreasing mortality despite increasing incidence indicates improvement in treatment of cancer patients. It is a proof that more and more are cured of or living with and not dying from cancer.

The time trends of common cancers, presented in *Figure 5*, in males show that lung cancer incidence was increasing since the beginning of the nineties, while it became stable onwards (85/100.000) and is slowly decreasing and was finally overcome by prostate and colorectal cancer. On the contrary, the female lung cancer incidence is steadily but persistently increasing. The huge increase in

prostate cancer incidence rate in the last years is not due to some new risk factor, but more frequent use of prostate specific antigen (PSA) test as an opportunistic screening method, resulting in detection of many cancers that would have never progressed or would even not have been detected during lifetime without screening. In the last 10 years the incidence rate of head and neck cancer is slowly decreasing. In females, the incidence rate of breast cancer is increasing, while the incidence of cervical cancer is slowly decreasing since 2003. In both sexes, the incidence of cancers of colon and rectum, melanoma and other skin cancer is increasing as in other countries, while the incidence of stomach cancer is decreasing. The average annual percentage changes of incidence rates are presented in *Figure 5*.

In *Figure 6*, five-year relative survival of all cancer patients (without patients with non-melanoma skin cancer) and patients with cancer of selected sites diagnosed in 2007–2011 is presented and compared to those diagnosed in 2002–2006. In males, the overall five-year relative survival increased for 7 percentage points, especially because of better detection and reporting of earlier stage prostate cancer with better prognosis, as for these patients with the most common male cancer the survival increased for 8 percentage points. As 95% confidence intervals are not overlapping, it can be concluded that the difference is statistically significant. In females, the overall survival in both time periods was nearly the same, almost 59%, mostly because the survival of the most common female cancer was not importantly changed (survival for breast cancer is around 85.5%).

At the end of November 2014, the results of CONCORD-2 study have been published. In this study, survival of 25.7 million adults (age 15–99 years) and 75.000 children (age 0–14 years) diagnosed with cancer during 1995–2009 and followed up to December 31, 2009 or later has been analysed. Data were submitted by 279 population-based cancer registries in 67 countries. In *Figure 7*, age-standardized five-year net survival from breast, cervix and colorectal cancer from all countries and regions that participated in this study is presented. In the published report on this study, in addition survival from stomach, liver, lung, breast, ovary and prostate cancer is presented together with adult and childhood leukaemia. Survival for three consecutive time periods, 1995–1999, 2000–2004 in 2005–2009 was calculated; in *Figure 7* survival in the last time-period is presented to compare participating registries. Five-year survival from colon, rectal, and breast cancers has increased steadily in most developed countries. For patients diagnosed during 2005–2009, survival for colon and rectal cancer reached 60% or more in 22 countries around the world; in Slovenia, it was 56.0% (colon) and 55.2% (rectum). For breast cancer, five-year survival rose to 85% or higher in 17 countries worldwide; in Slovenia it was 80.2%. For cervical cancer, national estimates of five-year survival range from less than 50% to more than 70%; improvements between 1995–1999 and 2005–2009 have generally been only slight. Such international comparisons are important for cancer patients, health professionals and politicians as they reveal very wide differences that are likely to be attributable to inequalities in access to early diagnosis and optimum treatment. They also stress the importance of cancer registries in monitoring the cancer burden and the quality of their data (from the published report it is evident which estimates of survival are less reliable).

The most frequent cancers vary by age. In children and adolescents till the age of 20, cancer is a very rare disease; in the last 5 years (2007–2011) it was diagnosed in 34 boys and 32 girls on average per year. In boys, the most frequent were leukaemias (26.0%), followed by tumours of central and autonomous nervous system (16.6%) and Hodgkin's lymphoma (11.8%), while in girls the most frequent were leukaemias (25.6%), followed by tumours of central and autonomous nervous system (14.4%) and Hodgkin's lymphoma in the third place (11.3%). In young adult males (aged 20–34) there were on average 126 new cases per year; the most frequent cancer sites were testis (41.3%), followed by skin cancer (melanoma 9.9% and non-melanoma 8.7%) and tumours of central and autonomous nervous system (6.0%). In younger females (146 new cases on average per year) the most common was skin melanoma (16.0%), followed by breast cancer (15.8%) and thyroid cancer (13.8%) (*Figure 8*).

In the majority of new cases, the diagnosis was confirmed microscopically. *Table 3* shows that in 2011, in 93.9 % from 12,922 newly diagnosed cancer cases**,** the diagnosis was confirmed by histology or by cytology, in 5.8% with other investigations and only 0.3% of cases were registered from death certificate only. This latter percentage has been similar for several years and represents the patients not treated in the hospital due to age or advanced disease. *Table 3* presents the number of new cases by cancer site by basis of diagnosis, while in *Table 4* their distribution by 5-year age group is presented. In *Table 5,* there are age specific incidence rates for all and specific cancer sites.

In *Table 6a*, the number of new cases of all and selected cancer sites by different statistical regions is presented. While these data are important for planning health care facilities, the age standardised rates in *Table 6b* indicate the differences in the risk of cancer, as these differences are not due to different age structure of population in these regions.

The morphology of tumours in 12,138 microscopically diagnosed cases is presented in *Table 7*. In this table, cases confirmed by histology (95%) and by cytology only (5%) are presented separately.

Table 8 shows the distribution of cancer patients by stage at diagnosis. A simplified definition of stages at diagnosis is used, which takes into account all investigation methods, including surgery or autopsy in case the patient has not been treated before death.

Age distribution of extranodal and nodal sites of non-Hodgkin's malignant lymphomas is presented in *Table 9*. Owing to a small number of extranodal sites, only the absolute numbers are given.

Table 10 shows the age distribution of malignant neoplasms of lymphoid, haematopoietic and related tissue according to 2010 version of 10th revision of the International Statistical Classification of Diseases and Related Health Problems (ICD-10).

Table 11 presents basic data on cancer patients' treatment. As in many cases combined treatment is applied, the sum of patients treated by different modalities

is bigger than the number of new cases. *Table 11a* presents the mode of treatment of all cancer patients. *Tables 11b and 11c* show the hospital where patients had surgery and/or systemic treatment as primary treatment; radiotherapy is performed at Institute of Oncology Ljubljana only (with few exceptions, irradiated abroad).

In *Table 13*, there are official data on cancer mortality in 2011. The data for this table have been prepared at the National Institute of Public Health of the RS.

Acknowledgement

Physicians, nurses, and the administrative staff from the Slovenian hospitals and other health institutions have been conscientiously providing data on new cancer cases, on the course of each individual disease as well as of its eventual outcome. If data on new cases had been incomplete, they effectively sought/willingly completed the missing information. If data necessary for the Registry had not been available in hospitals, they were kindly provided by the family and general physicians.

At least half of data presented in the current report have been contributed by Mrs. Ana Dotzauer in Mrs. Maruška Ferjančič from the Ljubljana Institute of Oncology Hospital Registry. The pathologist Dr. Gorana Gašljević helped us with proper coding of histological diagnoses.

The Report could not be published – at least with the currently assured high credibility of data – without the traditional good cooperation of the Republic of Slovenia Population Registry, National Institute of Public Health of RS, and Statistical Office of RS.

The Registry is grateful to the above mentioned as well as to all others who have contributed to the current Report.

Editors

- Ravnihar B, Gruden I. Statističen pregled in kratka analiza prijavljenih rakovnih obolenj iz področja LRS za leto 1950. Zdrav Vestn 1951; 20: 264-77.
- Epidemiological and vital statistics report. Geneva: World Health Organization, 1961-1966.
- World health statistics report. Geneva: World Health Organization, 1970-1974.
- Rak v Sloveniji (1965-77). Ljubljana: Onkološki inštitut, Register raka za Slovenijo, 1967-1980.
- Incidenca raka v Sloveniji (1978-2001). Ljubljana: Onkološki inštitut, Register raka za Slovenijo, 1981-2004.
- Doll R, Payne P, Waterhouse J, eds. Cancer incidence in five continents. Vol 1. Berlin: Springer, 1966.
- Doll R, Muir C, Waterhouse J, eds. Cancer incidence in five continents. Vol 2. Lyon: International Agency for Research on Cancer, 1970.
- Waterhouse J, Muir C, Correa C, Powell J, eds. Cancer incidence in five continents. Vol 3. Lyon: International Agency for Research on Cancer, 1976 (IARC Sci Publ 15).
- Waterhouse J, Muir C, Shanmugaratnam K, Powell J, eds. Cancer incidence in five continents. Vol 4. Lyon: International Agency for Research on Cancer, 1982 (IARC Sci Publ 42).
- Muir C, Waterhouse J, Mack T, Powell J, Whelan S, eds. Cancer incidence in five continents. Vol 5. Lyon: International Agency for Research on Cancer, 1987 (IARC Sci Publ 88).
- Parkin DM, Muir C, Whelan S, Gao Y, Ferlay J, Powell J, eds. Cancer incidence in five continents Lyon. Vol 6. International Agency for Research on Cancer, 1992 (IARC Sci Publ 120).
- Parkin DM, Whelan S, Ferlay J, Raymond L, Young J, eds. Cancer incidence in five continents. Vol 7. Lyon: International Agency for Research on Cancer, 1997 (IARC Sci Publ 143).
- Parkin DM, Whelan S, Ferlay J, Teppo L, Thomas DB, eds. Cancer incidence in five continents. Vol 8. Lyon: International Agency for Research on Cancer, 2002 (IARC Sci Publ 155).
- Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M, Boyle P, eds. Cancer incidence in five continents. Vol 9. Lyon: International Agency for Research on Cancer, 2007 (IARC Sci Publ 160).
- Forman D, Bray F, Brewster DH, Gombe Mbalawa C, Kohler B, Piñeros M, Steliarova-Foucher E, Swaminathan R and Ferlay J eds. Cancer Incidence in Five Continents, Vol. X (electronic version) Lyon, IARC, 2013. http://ci5.iarc.fr.
- Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray, F.GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. URL: http://globocan.iarc.fr
- Steliarova-Foucher E, O'Callaghan M, Ferlay J, Masuyer E, Forman D, Comber H, Bray F: European Cancer Observatory: Cancer Incidence, Mortality, Prevalence and Survival in Europe. Version 1.0 (September 2012) European Network of Cancer Registries, International Agency for Research on Cancer. URL: http://eco.iarc.fr.
- Berrino F, Capocaccia R, Esteve J et al, eds. Survival of cancer patients in Europe: the EUROCARE-2 study. Lyon: International Agency for Research on Cancer, 1999.
- Berrino F, Capocaccia R, Gatta G et al, eds. Survival of cancer patients in Europe: the EUROCARE-3 study. Ann Oncol 2003: 14 (Suppl 5).
- Berrino F, DeAngelis R, Sant M et al. Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995–1999: Results of the EUROCARE-4 study. Lancet Oncol 2007; 8: 773-83.
- De Angelis R, Sant M, Coleman MP et al. Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE-5—a population-based study. Lancet Oncol 2013; published online Dec 5.
- Gatta G, L Botta, S Rossi et al. Childhood cancer survival in Europe 1999–2007: results of EUROCARE-5–a population-based study. Lancet Oncol 2013; published online Dec 5.
- Gatta G, van der Zwan JM, Casali PG et al. Rare cancers are not so rare: the rare cancer burden in Europe. Eur J Cancer 2011: 47; 2493-511.
- Pompe-Kirn V, Primic Žakelj M, Ferligoj A, Škrk J. Zemljevidi incidence raka v Sloveniji 1978-1987 (Atlas of cancer incidence in Slovenia 1978-1987). Ljubljana: Onkološki inštitut, Register raka za Slovenijo, 1992.
- Pompe-Kirn V, Zakotnik B, Benulič T, Volk N, Škrk J. Preživetje bolnikov z rakom v Sloveniji 1963-1990 (Cancer patients' survival in Slovenia 1963-1990). Ljubljana: Onkološki inštitut, Register raka za Slovenijo, 1995.
- Pompe-Kirn V, Zakotnik B, Zadnik V. Preživetje bolnikov z rakom v Sloveniji 1983-1997 (Cancer patients' survival in Slovenia 1983-1997). Ljubljana: Onkološki inštitut, Register raka za Slovenijo, 2003.
- Primic-Žakelj M, Zadnik V, Žagar T, Zakotnik B. Preživetje bolnikov z rakom, zbolelih v letih 1991–2005 v Sloveniji (Survival of cancer patients, diagnosed in 1991–2005 in Slovenia). Ljubljana: Onkološki inštitut, 2009.

- Uredba o standardni klasifikaciji teritorialnih enot – SKTE. Ur. l. RS št. 28/2000.
- Savezni zavod za zdravstvenu zaštitu. Međunarodna klasifikacija bolesti, povreda i uzroka smrti. 8. revizija. Novi sad: Savezni zavod za zdravstvenu zaštitu, 1970.
- Inštitut za varovanje zdravja RS. Mednarodna klasifikacija bolezni in sorodnih zdravstvenih problemov za statistične namene. 10. revizija (International statistical classification of diseaseses and related health problems). Ljubljana: Inštitut za varovanje zdravja, 1995.
- World Health Organisation. International classification of diseases for Oncology. Third Edition. Geneva: World Health Organisation, 2000.
- World Health Organisation. International statistical classification of diseases and related health problems. - 10th revision, edition 2010 (4th edition). Geneva: WHO Press, 2011.
- Jensen OM, Parkin M et al, eds. Cancer registration: principles and methods. Lyon: International Agency for Research on Cancer, 1991. (IARC Sci Publ 95).
- Dos Santos Silva I. Cancer epidemiology: principles and methods. Lyon: International Agency for Research on Cancer, 1999.
- Moller B, Fekjaer H, Hakulinen T et al. Prediction of cancer incidence in the Nordic countries: empirical comparison of different approaches. Stat Med 2003; 15: 2751-66.
- SI-STAT podatkovni portal. Ljubljana, Statistični urad Republike Slovenije, 2014. URL: http://pxweb.stat.si/.
- Pohar M, Stare J. Relative survival analysis in R. Computer Methods and Programs in Biomedicine 2006; 81: 272-8.
- Žagar T. Lifetables for Slovenia 1982–2007. Rostock: Max Planck, 2008. URL: http://www.lifetable.de/cgi-bin/Country.plx?Country=Slovenia.
- Allemani C et all. Global surveillance of cancer survival 1995–2009: analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2). The Lancet. Published online November 26, 2014 http://dx.doi.org/10.1016/S0140-6736(14)62038-9.

Slika 1: Breme raka, Slovenija 2011.
Figure 1: Cancer burden, Slovenia 2011.



Slika 2: Odstotni delež vseh rakov po starostnih skupinah in spolu, Slovenija 2011.
Figure 2: Percentage distribution of all cancer sites by age group and by sex, Slovenia 2011.



Slika 3: Najpogostejše lokacije raka in njihov odstotni delež po spolu in pri obeh spolih skupaj, Slovenija 2011.
Figure 3: The leading cancer sites with percentage distribution by sex and for both sexes together, Slovenia 2011.





* Pojasnilo / Explanation:
Glava in vrat / Head and neck (C00–C14, C30–C32)
Debelo črevo in danka / Colorectum (C18–C20)
Sapnik, sapnici in pljuča / Trachea, bronchus and lung (C33–C34)
Ledvica z ledvičnim mehom / Kidney with renal pelvis (C64–C65)

Slika 4: Groba in kumulativna letna incidenčna in umrljivostna stopnja vseh rakov po spolu s povprečno letno spremembo za zadnjih 10 let, Slovenija 1950–2011.

Figure 4: Crude and cumulative annual incidence and mortality rates for all cancer sites by sex with average annual change in last 10 years, Slovenia 1950–2011.





* Povprečna letna sprememba je statistično značilna pri stopnji tveganja 0,05

* Average annual change is statistically significant at 0.05 significance level

Slika 5: Groba letna incidenčna stopnja izbranih rakov po spolu s povprečno letno spremembo za zadnjih 10 let, Slovenija 1950–2011.

Figure 5: Crude annual incidence rates of selected primary cancer sites by sex with average annual change in last 10 years, Slovenia 1950–2011.



* Povprečna letna sprememba je statistično značilna pri stopnji tveganja 0,05

* Average annual change is statistically significant at 0.05 significance level

Slika 6: Petletno relativno preživetje (s 95 % intervalom zaupanja) bolnikov, zbolelih za izbranimi raki v letih 2002–2006 in 2007–2011 po spolu.

Figure 6: Five-year relative survival (with 95% confidence interval) of patients diagnosed with selected cancers in periods 2002–2006 and 2007–2011 by sex.



Slika 6: Nadaljevanje.
Figure 6: Continued.



Slika 6: Nadaljevanje.
Figure 6: Continued.



Slika 7: Petletno starostno standardizirano čisto preživetje (s 95 % intervalom zaupanja) odraslih bolnikov (starih 15–99 let), zbolelih za izbranimi raki v letih 2005–2009, po kontinetu in državi: rezultati raziskave CONCORD-2.

Figure 7: Five-year age-standardised net survival (with 95% confidence interval) of adult patients (age 15–99 years) diagnosed with selected cancers in 2005–2009 by continent and country: results of the CONCORD-2 study.



* Podatki pokrivajo 100 % prebivalstva države
$ Ocene preživetja niso zanesljive
Druga pojasnila: C Allemani et all. Global surveillance of cancer survival 1995–2009: analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet. Dostopno od 26. novembra 2014 [Epub ahead of print].

* Data with 100% coverage of the national population
$ Survival estimate considered less reliable
Additional explanations: C Allemani et all. Global surveillance of cancer survival 1995–2009: analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet. Available online from 26 November 2014 [Epub ahead of print].

Slika 7: Nadaljevanje.
Figure 7: Continued.



* Podatki pokrivajo 100 % prebivalstva države
$ Ocene preživetja niso zanesljive
Druga pojasnila: C Allemani et all. Global surveillance of cancer survival 1995–2009: analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet. Dostopno od 26. novembra 2014 [Epub ahead of print].

* Data with 100% coverage of the national population
$ Survival estimate considered less reliable
Additional explanations: C Allemani et all. Global surveillance of cancer survival 1995–2009: analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet. Available online from 26 November 2014 [Epub ahead of print].

Slika 7: Nadaljevanje.
Figure 7: Continued.

Rak debelega črevesa in danke, moški in ženske / **Cancer of colon and rectum, males and females**



* Podatki pokrivajo 100 % prebivalstva države
$ Ocene preživetja niso zanesljive
Druga pojasnila: C Allemani et all. Global surveillance of cancer survival 1995–2009: analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet. Dostopno od 26. novembra 2014 [Epub ahead of print].

* Data with 100% coverage of the national population
$ Survival estimate considered less reliable
Additional explanations: C Allemani et all. Global surveillance of cancer survival 1995–2009: analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet. Available online from 26 November 2014 [Epub ahead of print].

Slika 8: Odstotni deleži napogostejših rakov po starostnih skupinah in spolu, Slovenija 2007–2011.
Figure 8: Percentage distribution of leading cancer sites by age group and by sex, Slovenia 2007–2011.

MOŠKI / MALES



Pojasnilo / Explanation:

Glava in vrat / Head and neck (C00–C14, C30–C32)
Želodec / Stomach (C16)
Debelo črevo in danka / Colorectum (C18–C20)
Pljuča / Lung (C33–C34)
Koža, melanom / Skin, melanoma (C43)
Koža, razen melanoma / Skin, non-melanoma (C44)
Vezivno in mehko tkivo / Connective and soft tissue (C48–C49)
Prostata / Prostate (C61)
Modo / Testis (C62)
Ledvica z ledvičnim mehom / Kidney with renal pelvis (C64–C65)
Sečni mehur / Bladder (C67)
Centralni in avtonomni živčni sistem / Central and autonomic nervous system (C70–C72)
Hodgkinova bolezen / Hodgkin's disease (C81)
NHL: ne-Hodgkinovi limfomi / NHL: non-Hodgkin's lymphoma (C82–C85)
Levkemije / Leukaemias (C91–C95)

Slika 8: Nadaljevanje.
Figure 8: Continued.

ŽENSKE / FEMALES



Pojasnilo / Explanation:

Želodec / Stomach (C16)
Debelo črevo in danka / Colorectum (C18–C20)
Trebušna slinavka / Pancreas (C25)
Pljuča / Lung (C33–C34)
Kosti / Bone (C40–C41)
Koža, melanom / Skin, melanoma (C43)
Koža, razen melanoma / Skin, non-melanoma (C44)
Vezivno in mehko tkivo / Connective and soft tissue (C48–C49)
Dojka / Breast (C50)
Maternični vrat / Cervix uteri (C53)
Maternično telo / Corpus uteri (C54)
Jajčnik / Ovary (C56)
Centralni in avtonomni živčni sistem / Central and autonomic nervous system (C70–C72)
Ščitnica / Thyroid gland (C73)
Hodgkinova bolezen / Hodgkin's disease (C81)
Levkemije / Leukaemias (C91–C95)

Tabela 1: Opazovana in ocenjena incidenca raka, Slovenija 2002–2011 in 2014.

Table 1: Observed and estimated cancer incidence, Slovenia 2002–2011 and 2014.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Povprečne letne opazovane vrednosti 2002–2006		Povprečne letne opazovane vrednosti 2007–2011		Ocena za 2014			
			Število	Incidenčna stopnja na 100.000	Število	Incidenčna stopnja na 100.000	Število (95 % napovedni interval)		Incidenčna stopnja na 100.000 (95 % napovedni interval)	
			Average annual observed values 2002–2006		Average annual observed values 2007–2011		Estimation for 2014			
			Number	Incidence rate per 100,000	Number	Incidence rate per 100,000	Number (95% prediction interval)		Incidence rate per 100,000 (95% prediction interval)	
C00–C96	Vse lokacije All sites	M+Ž	10770	538,6	12541	615,6	14311	13999–14623	694	679–709
		M	5570	568,7	6753	670,5	7990	7755–8225	782	759–805
		Ž	5200	509,5	5788	561,7	6321	6115–6526	608	588–627
C00–C14	Usta in žrelo Mouth and pharynx	M	254	25,9	271	26,9	276	232–320	27	23–31
		Ž	65	6,3	69	6,7	77	53–101	7	5–10
C15	Požiralnik Oesophagus	M	75	7,6	69	6,9	61	41–81	6	4–8
		Ž	18	1,7	17	1,6	15	5–26	1	1–2
C16	Želodec Stomach	M	291	29,7	290	28,8	284	239–328	28	23–32
		Ž	181	17,7	187	18,1	186	149–223	18	14–21
C18	Debelo črevo Colon	M	377	38,5	508	50,5	647	580–713	63	57–70
		Ž	319	31,2	394	38,2	458	403–514	44	39–49
C19–C20	Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction	M	333	34,0	407	40,4	482	423–540	47	41–53
		Ž	228	22,4	253	24,6	253	210–296	24	20–28
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	M	99	10,1	115	11,4	127	96–157	12	9–15
		Ž	45	4,4	45	4,4	48	26–69	5	2–7
C23–C24	Žolčnik in žolčevodi Gallbladder and billiary tract	M	54	5,5	65	6,5	79	55–103	8	5–10
		Ž	87	8,5	101	9,8	123	94–153	12	9–15
C25	Trebušna slinavka Pancreas	M	129	13,1	163	16,2	203	165–240	20	16–24
		Ž	140	13,7	175	17,0	212	172–252	20	17–24
C32	Grlo Larynx	M	94	9,6	98	9,8	96	69–124	9	7–12
		Ž	11	1,1	11	1,0	10	2–18	1	0–2
C33–C34	Sapnik, sapnici in pljuča Trachea, bronchus and lung	M	890	90,9	868	86,2	844	762–927	83	75–91
		Ž	291	28,5	358	34,8	426	372–479	41	36–46
C43	Maligni melanom kože Malignant melanoma of skin	M	158	16,1	223	22,1	288	245–332	28	24–32
		Ž	181	17,8	241	23,4	287	244–331	28	23–32
C44	Druge maligne neoplazme kože Skin, other malignomas	M	756	77,1	981	97,4	1259	1165–1353	123	114–132
		Ž	851	83,3	1035	100,4	1216	1124–1308	117	108–126
C48–C49	Vezivno in mehko tkivo Connective and soft tissue	M	28	2,9	27	2,7	24	11–36	2	1–4
		Ž	34	3,4	36	3,5	40	27–53	4	3–5
C50	Dojka Breast	M	10	1,0	10	1,0	10	2–18	1	0–2
		Ž	1103	108,0	1176	114,2	1236	1142–1330	119	110–128
C53	Maternični vrat Cervix uteri	M	–	–	–	–	–	–	–	–
		Ž	188	18,4	140	13,6	109	85–133	11	8–13
C54	Maternično telo Corpus uteri	M	–	–	–	–	–	–	–	–
		Ž	296	29,0	296	28,7	298	252–345	29	24–33
C56	Jajčnik Ovary	M	–	–	–	–	–	–	–	–
		Ž	178	17,5	169	16,4	159	124–193	15	12–19
C61	Prostata Prostate	M	844	86,2	1319	131,0	1824	1715–1933	179	168–189
		Ž	–	–	–	–	–	–	–	–
C62	Modo Testis	M	95	9,7	100	10,0	105	78–132	10	8–13
		Ž	–	–	–	–	–	–	–	–
C64–C65	Ledvica z ledvičnim mehom Kidney with renal pelvis	M	174	17,7	222	22,0	272	228–315	27	22–31
		Ž	97	9,5	113	10,9	137	106–169	13	10–16
C67	Sečni mehur Bladder	M	192	19,6	210	20,8	237	195–280	23	19–27
		Ž	70	6,9	78	7,5	82	58–107	8	6–10
C70–C72	Centralni in avtonomni živčni sistem Central and autonomic nervous system	M	74	7,6	82	8,2	88	68–107	9	7–10
		Ž	64	6,2	65	6,3	63	42–84	6	4–8
C73	Ščitnica Thyroid gland	M	27	2,8	36	3,6	45	28–62	4	3–6
		Ž	101	9,9	116	11,2	115	93–137	11	9–13
C81	Hodgkinova bolezen Hodgkin's disease	M	26	2,7	26	2,6	24	11–38	2	1–4
		Ž	21	2,1	25	2,4	25	15–36	2	1–3
C82–C85	Ne-Hodgkinovi limfomi Non-Hodgkin's lymphoma	M	116	11,8	146	14,5	156	130–182	15	13–18
		Ž	131	12,8	145	14,1	154	128–180	15	12–17
C90	Difuzni plazmocitom in maligne neoplazme plazmocitov Multiple myeloma and malignant plasma cell neoplasms	M	48	4,9	63	6,3	79	55–103	8	5–10
		Ž	54	5,3	57	5,5	66	44–88	6	4–8
C91–C95	Levkemije Leukaemias	M	122	12,5	146	14,5	160	134–187	16	13–18
		Ž	99	9,7	111	10,7	119	96–142	11	9–14

Tabela 2: Incidenca, groba incidenčna stopnja in po svetovni, evropski ter slovenski standardni populaciji standardizirane incidenčne stopnje raka, Slovenija 2011.

Table 2: Incidence, crude incidence rate and according to World, European and Slovenian standard population standardized cancer incidence rates, Slovenia 2011.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Število Number	Groba incidenčna stopnja na 100.000 Crude incidence rate per 100,000	SSS* – svetovni standard ASR** – World standard	SSS* – evropski standard ASR** – European standard	SSS* – slovenski standard ASR** – Slovenian standard
C00–C96	Vse lokacije All sites	M+Ž	12922	629,6	327,5	465,0	547,8
		M	7162	705,3	402,4	583,8	700,9
		Ž	5760	555,4	271,0	378,7	438,7
C00–C14	Usta in žrelo	M	242	23,8	14,7	20,3	22,4
	Mouth and pharynx	Ž	75	7,2	3,8	5,2	6,0
C15	Požiralnik	M	68	6,7	3,9	5,6	6,5
	Oesophagus	Ž	18	1,7	0,8	1,2	1,4
C16	Želodec	M	302	29,7	16,3	24,5	30,0
	Stomach	Ž	195	18,8	7,7	11,4	13,7
C18	Debelo črevo	M	556	54,8	30,4	45,0	54,5
	Colon	Ž	415	40,0	18,1	26,2	31,0
C19–C20	Rektum in rektosigmoidna zveza	M	434	42,7	24,2	35,3	42,2
	Rectum and rectosigmoid junction	Ž	227	21,9	10,1	14,6	17,4
C22	Jetra in intrahepatični vodi	M	114	11,2	6,0	9,1	11,3
	Liver and intrahepatic bile ducts	Ž	37	3,6	1,3	2,0	2,5
C23–C24	Žolčnik in žolčevodi	M	71	7,0	3,6	5,7	7,1
	Gallbladder and billiary tract	Ž	95	9,2	3,3	5,1	6,3
C25	Trebušna slinavka	M	178	17,5	9,6	14,4	17,7
	Pancreas	Ž	186	17,9	6,3	9,9	12,4
C32	Grlo	M	98	9,7	5,7	8,1	9,1
	Larynx	Ž	11	1,1	0,5	0,8	0,8
C33–C34	Sapnik, sapnici in pljuča	M	824	81,1	44,9	66,4	79,0
	Trachea, bronchus and lung	Ž	376	36,3	17,6	25,1	28,9
C43	Maligni melanom kože	M	248	24,4	15,3	20,7	24,1
	Malignant melanoma of skin	Ž	233	22,5	13,4	17,4	19,7
C44	Druge maligne neoplazme kože	M	1050	103,4	56,1	85,0	105,2
	Skin, other malignomas	Ž	1054	101,6	41,7	61,5	74,5
C48–C49	Vezivno in mehko tkivo	M	27	2,7	1,8	2,4	2,8
	Connective and soft tissue	Ž	38	3,7	1,9	2,6	3,1
C50	Dojka	M	14	1,4	0,8	1,1	1,4
	Breast	Ž	1143	110,2	60,3	82,4	92,9
C53	Maternični vrat	M	–	–	–	–	–
	Cervix uteri	Ž	142	13,7	9,0	11,4	12,6
C54	Maternično telo	M	–	–	–	–	–
	Corpus uteri	Ž	301	29,0	14,6	20,7	23,2
C56	Jajčnik	M	–	–	–	–	–
	Ovary	Ž	153	14,8	8,5	11,4	12,6
C61	Prostata	M	1539	151,6	84,6	124,1	151,3
	Prostate	Ž	–	–	–	–	–
C62	Modo	M	106	10,4	8,9	9,6	10,3
	Testis	Ž	–	–	–	–	–
C64–C65	Ledvica z ledvičnim mehom	M	225	22,2	12,8	18,3	21,5
	Kidney with renal pelvis	Ž	114	11,0	4,9	7,0	8,4
C67	Sečni mehur	M	226	22,3	11,5	18,0	22,5
	Bladder	Ž	72	6,9	2,4	3,9	4,8
C70–C72	Centralni in avtonomni živčni sistem	M	83	8,2	6,0	7,3	7,8
	Central and autonomic nervous system	Ž	61	5,9	3,9	4,9	5,2
C73	Ščitnica	M	45	4,4	3,0	3,9	4,4
	Thyroid gland	Ž	98	9,4	7,2	8,5	9,1
C81	Hodgkinova bolezen	M	14	1,4	1,2	1,3	1,4
	Hodgkin's disease	Ž	27	2,6	2,5	2,6	2,7
C82–C85	Ne-Hodgkinovi limfomi	M	174	17,1	10,2	14,4	16,9
	Non-Hodgkin's lymphoma	Ž	172	16,6	8,5	11,6	13,1
C90	Difuzni plazmocitom in maligne neoplazme plazmocitov	M	56	5,5	2,9	4,5	5,5
	Multiple myeloma and malignant plasma cell neoplasms	Ž	57	5,5	2,5	3,6	4,3
C91–C95	Levkemije	M	152	15,0	10,3	13,2	15,2
	Leukaemias	Ž	103	9,9	5,5	6,6	7,2

* SSS – starostno standardizirana incidenčna stopnja na 100.000
**ASR – age-standardised incidence rate per 100,000

Tabela 3: Incidenca raka glede na način postavitve diagnoze po lokaciji in spolu, Slovenija 2011.
Table 3: Cancer incidence according to basis of diagnosis by site and by sex, Slovenia 2011.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Število novih primerov Number of new cases	Mikroskopsko potrjeni primeri Microscopically confirmed cases		Ugotovljeni z drugimi preiskavami Confirmed by other investigations		Registrirani samo iz zdravniških poročil o vzroku smrti Registered from death certificates only	
				Število Number	%* %*	Število Number	%* %*	Število Number	%* %*
C00–C96	Vse lokacije All sites	M+Ž	12922	12138	93,9	748	5,8	36	0,3
		M	7162	6762	94,4	387	5,4	13	0,2
		Ž	5760	5376	93,3	361	6,3	23	0,4
C00	Ustnica Lip	M	20	20	100	0	0	0	0
		Ž	9	9	–	0	–	0	–
C01	Baza jezika Base of tongue	M	10	10	–	0	–	0	–
		Ž	1	1	–	0	–	0	–
C02	Jezik, drugi deli Tongue, other & unspecified parts	M	22	22	100	0	0	0	0
		Ž	3	3	–	0	–	0	–
C03	Dlesen Gum	M	2	2	–	0	–	0	–
		Ž	5	5	–	0	–	0	–
C04	Ustno dno Floor of mouth	M	22	22	100	0	0	0	0
		Ž	8	8	–	0	–	0	–
C05	Nebo Palate	M	17	17	100	0	0	0	0
		Ž	4	4	–	0	–	0	–
C06	Usta, drugi deli Mouth, other & unspecified parts	M	6	6	–	0	–	0	–
		Ž	11	11	–	0	–	0	–
C07	Parotidna žleza Parotid gland	M	6	6	–	0	–	0	–
		Ž	6	6	–	0	–	0	–
C08	Druge in neopredeljene velike žleze slinavke Other & unspecified major salivary glands	M	2	2	–	0	–	0	–
		Ž	1	1	–	0	–	0	–
C09	Tonzila Tonsil	M	50	50	100	0	0	0	0
		Ž	14	14	–	0	–	0	–
C10	Orofarinks Oropharynx	M	39	39	100	0	0	0	0
		Ž	6	5	–	1	–	0	–
C11	Nazofarinks Nasopharynx	M	9	9	–	0	–	0	–
		Ž	3	2	–	1	–	0	–
C12	Piriformni sinus Pyriform sinus	M	19	19	100	0	0	0	0
		Ž	2	2	–	0	–	0	–
C13	Hipofarinks Hypopharynx	M	18	18	100	0	0	0	0
		Ž	2	2	–	0	–	0	–
C14	Druga in slabo opredeljena mesta na ustnici, v ustni votlini in farinksu Other and ill-defined sites in the lip, oral cavity and pharynx	M	0	0	–	0	–	0	–
		Ž	0	0	–	0	–	0	–
C15	Požiralnik Oesophagus	M	68	65	95,6	3	4,4	0	0
		Ž	18	17	94,4	1	5,6	0	0
C16	Želodec Stomach	M	302	296	98,0	6	2,0	0	0
		Ž	195	184	94,4	11	5,6	0	0
C17	Tanko črevo Small intestine	M	19	19	100	0	0	0	0
		Ž	14	14	–	0	–	0	–
C18	Debelo črevo Colon	M	556	538	96,8	14	2,5	4	0,7
		Ž	415	392	94,5	21	5,1	2	0,5
C19	Rektosigmoidna zveza Rectosigmoid junction	M	85	84	98,8	1	1,2	0	0
		Ž	56	53	94,6	3	5,4	0	0
C20	Rektum Rectum	M	349	341	97,7	8	2,3	0	0
		Ž	171	164	95,9	5	2,9	2	1,2
C21	Anus in analni kanal Anus and anal canal	M	5	5	–	0	–	0	–
		Ž	11	11	–	0	–	0	–
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	M	114	64	56,1	50	43,9	0	0
		Ž	37	19	51,4	18	48,6	0	0
C23	Žolčnik Gallbladder	M	13	7	–	6	–	0	–
		Ž	39	24	61,5	15	38,5	0	0
C24	Drugi in neopredeljeni deli biliarnega trakta Billiary tract, other and unspecified parts	M	58	34	58,6	24	41,4	0	0
		Ž	56	28	50,0	28	50,0	0	0

Nadaljevanje —>
Continued —>

Tabela 3: Nadaljevanje.
Table 3: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Število novih primerov Number of new cases	Mikroskopsko potrjeni primeri Microscopically confirmed cases		Ugotovljeni z drugimi preiskavami Confirmed by other investigations		Registrirani samo iz zdravniških poročil o vzroku smrti Registered from death certificates only	
				Število Number	%* %*	Število Number	%* %*	Število Number	%* %*
C25	Trebušna slinavka	M	178	102	57,3	76	42,7	0	0
	Pancreas	Ž	186	83	44,6	100	53,8	3	1,6
C26	Druga in slabo opredeljena mesta v prebavnih organih	M	4	3	–	0	–	1	–
	Other and ill-defined digestive organs	Ž	0	0	–	0	–	0	–
C30	Nosna votlina in srednje uho	M	7	7	–	0	–	0	–
	Nasal cavity and middle ear	Ž	5	5	–	0	–	0	–
C31	Obnosni sinusi	M	5	5	–	0	–	0	–
	Accessory sinuses	Ž	5	4	–	1	–	0	–
C32	Grlo	M	98	97	99,0	1	1,0	0	0
	Larynx	Ž	11	11	–	0	–	0	–
C33	Sapnik	M	5	5	–	0	–	0	–
	Trachea	Ž	0	0	–	0	–	0	–
C34	Sapnica in pljuča	M	819	759	92,7	59	7,2	1	0,1
	Bronchus and lung	Ž	376	347	92,3	26	6,9	3	0,8
C37	Timus	M	4	4	–	0	–	0	–
	Thymus	Ž	4	4	–	0	–	0	–
C38	Srce, mediastinum, plevra	M	1	1	–	0	–	0	–
	Heart, mediastinum, pleura	Ž	0	0	–	0	–	0	–
C39	Druga in slabo opredeljena mesta v dihalih in prsnih organih	M	0	0	–	0	–	0	–
	Other and ill-defined sites in the respiratory system and intrathoracic organs	Ž	0	0	–	0	–	0	–
C40	Kosti, sklepni hrustanec udov	M	3	3	–	0	–	0	–
	Bone and articular cartilage of limbs	Ž	7	7	–	0	–	0	–
C41	Kosti, sklepni hrustanec, drugje	M	4	4	–	0	–	0	–
	Bone and articular cartilage of other and unspecified parts	Ž	0	0	–	0	–	0	–
C43	Maligni melanom kože	M	248	248	100	0	0	0	0
	Malignant melanoma of skin	Ž	233	233	100	0	0	0	0
C44	Druge maligne neoplazme kože	M	1050	1044	99,4	6	0,6	0	0
	Skin, other malignomas	Ž	1054	1041	98,8	13	1,2	0	0
C45	Mezoteliom	M	31	31	100	0	0	0	0
	Mesothelioma	Ž	7	7	–	0	–	0	–
C46	Kaposijev sarkom	M	3	3	–	0	–	0	–
	Kaposi's sarcoma	Ž	0	0	–	0	–	0	–
C47	Periferni živci in avtonomno živčevje	M	2	2	–	0	–	0	–
	Peripheral nerves and autonomic nervous system	Ž	3	3	–	0	–	0	–
C48	Peritonej in retroperitonej	M	8	8	–	0	–	0	–
	Retroperitoneum and peritoneum	Ž	19	19	100	0	0	0	0
C49	Drugo vezivno in mehko tkivo	M	19	19	100	0	0	0	0
	Other connective and soft tissue	Ž	19	19	100	0	0	0	0
C50	Dojka	M	14	12	–	2	–	0	–
	Breast	Ž	1143	1122	98,2	15	1,3	6	0,5
C51	Žensko zunanje spolovilo	M	–	–	–	–	–	–	–
	Vulva	Ž	41	41	100	0	0	0	0
C52	Nožnica	M	–	–	–	–	–	–	–
	Vagina	Ž	9	9	–	0	–	0	–
C53	Maternični vrat	M	–	–	–	–	–	–	–
	Cervix uteri	Ž	142	142	100	0	0	0	0
C54	Maternično telo	M	–	–	–	–	–	–	–
	Corpus uteri	Ž	301	301	100	0	0	0	0
C55	Maternica, neopredeljeno	M	–	–	–	–	–	–	–
	Uterus, unspecified	Ž	13	11	–	0	–	2	–
C56	Jajčnik	M	–	–	–	–	–	–	–
	Ovary	Ž	153	144	94,1	9	5,9	0	0

Nadaljevanje —>
Continued —>

Tabela 3: Nadaljevanje.
Table 3: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Število novih primerov Number of new cases	Mikroskopsko potrjeni primeri Microscopically confirmed cases		Ugotovljeni z drugimi preiskavami Confirmed by other investigations		Registrirani samo iz zdravniških poročil o vzroku smrti Registered from death certificates only	
				Število Number	%* %*	Število Number	%* %*	Število Number	%* %*
C57	Drugi in neopredeljeni ženski spolni organi	M	–	–	–	–	–	–	–
	Other and unspecified parts of female genital organs	Ž	10	8	–	2	–	0	–
C58	Posteljica	M	–	–	–	–	–	–	–
	Placenta	Ž	0	0	–	0	–	0	–
C60	Penis	M	9	9	–	0	–	0	–
	Penis	Ž	–	–	–	–	–	–	–
C61	Prostata	M	1539	1486	96,6	48	3,1	5	0,3
	Prostate	Ž	–	–	–	–	–	–	–
C62	Modo	M	106	106	100	0	0	0	0
	Testis	Ž	–	–	–	–	–	–	–
C63	Drugi in neopredeljeni moški spolni organi	M	1	1	–	0	–	0	–
	Other and unspecified male genital organs	Ž	–	–	–	–	–	–	–
C64	Ledvica razen meha	M	217	203	93,5	13	6,0	1	0,5
	Kidney, except renal pelvis	Ž	106	93	87,7	12	11,3	1	0,9
C65	Ledvični meh	M	8	8	–	0	–	0	–
	Renal pelvis	Ž	8	8	–	0	–	0	–
C66	Sečevod	M	12	11	–	1	–	0	–
	Ureter	Ž	3	3	–	0	–	0	–
C67	Sečni mehur	M	226	218	96,5	7	3,1	1	0,4
	Bladder	Ž	72	65	90,3	7	9,7	0	0
C68	Drugi in neopredeljeni sečni organi	M	1	1	–	0	–	0	–
	Other and unspecified urinary organs	Ž	1	1	–	0	–	0	–
C69	Oko in očesni adneksi	M	4	4	–	0	–	0	–
	Eye and adnexa	Ž	11	11	–	0	–	0	–
C70	Meninge	M	2	2	–	0	–	0	–
	Meninges	Ž	1	1	–	0	–	0	–
C71	Možgani	M	78	73	93,6	5	6,4	0	0
	Brain	Ž	58	50	86,2	8	13,8	0	0
C72	Hrbtni mozeg, možganski živci in drugi deli CŽS	M	3	3	–	0	–	0	–
	Spinal cord, cranial nerves and other parts of CNS	Ž	2	1	–	1	–	0	–
C73	Ščitnica	M	45	45	100	0	0	0	0
	Thyroid gland	Ž	98	98	100	0	0	0	0
C74	Nadledvična žleza	M	2	2	–	0	–	0	–
	Adrenal gland	Ž	2	2	–	0	–	0	–
C75	Druge endokrine žleze in sorodne strukture	M	0	0	–	0	–	0	–
	Other endocrine glands and related structures	Ž	0	0	–	0	–	0	–
C76	Druga in slabo opredeljena mesta	M	8	4	–	4	–	0	–
	Other and ill-defined sites	Ž	26	11	42,3	15	57,7	0	0
C77	Metastaza in neopredeljena maligna neoplazma bezgavk	M	21	20	95,2	1	4,8	0	0
	Metastasis and unspecified malignant neoplasm of lymph nodes	Ž	12	12	–	0	–	0	–
C78	Metastaze dihal in prebavil	M	45	18	40,0	27	60,0	0	0
	Metastases of respiratory and digestive organs	Ž	52	28	53,8	23	44,2	1	1,9
C79	Metastaze, drugje	M	10	5	–	5	–	0	–
	Metastases of other sites	Ž	17	6	35,3	10	58,8	1	5,9
C80	Maligna neoplazma brez opredeljenega mesta	M	57	37	64,9	20	35,1	0	0
	Malignant neoplasm without specification of site	Ž	44	27	61,4	15	34,1	2	4,5
C81	Hodgkinova bolezen	M	14	14	–	0	–	0	–
	Hodgkin's disease	Ž	27	27	100	0	0	0	0
C82	Folikularni ne-Hodgkinov limfom	M	28	28	100	0	0	0	0
	Follicular non-Hodgkin's lymphoma	Ž	57	57	100	0	0	0	0
C83	Difuzni ne-Hodgkinov limfom	M	122	122	100	0	0	0	0
	Diffuse non-Hodgkin's lymphoma	Ž	88	88	100	0	0	0	0

Nadaljevanje —>
Continued —>

Tabela 3: Nadaljevanje.
Table 3: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Število novih primerov Number of new cases	Mikroskopsko potrjeni primeri Microscopically confirmed cases		Ugotovljeni z drugimi preiskavami Confirmed by other investigations		Registrirani samo iz zdravniških poročil o vzroku smrti Registered from death certificates only	
				Število Number	%* %*	Število Number	%* %*	Število Number	%* %*
C84	Limfomi celic T in kožni limfom celic T	M	14	14	–	0	–	0	–
	Peripheral and cutaneous T-cell lymphomas	Ž	15	15	100	0	0	0	0
C85	Druge in neopredeljene vrste ne-Hodgkinovega limfoma	M	10	10	–	0	–	0	–
	Other and unspecified types of non-Hodgkin's lymphoma	Ž	12	12	–	0	–	0	–
C88	Maligne imunoproliferativne bolezni	M	0	0	–	0	–	0	–
	Malignant immunoproliferative diseases	Ž	0	0	–	0	–	0	–
C90	Difuzni plazmocitom in maligne neoplazme plazmocitov	M	56	56	100	0	0	0	0
	Multiple myeloma and malignant plasma cell neoplasms	Ž	57	57	100	0	0	0	0
C91.0	Limfatična levkemija, akutna	M	13	13	–	0	–	0	–
	Lymphoblastic leukaemia, acute	Ž	9	9	–	0	–	0	–
C91.1–C91.9	Limfatična levkemija, druga	M	63	63	100	0	0	0	0
	Lymphoid leukaemia, other	Ž	36	36	100	0	0	0	0
C92	Mieloična levkemija	M	58	58	100	0	0	0	0
	Myeloid leukaemia	Ž	43	43	100	0	0	0	0
C93	Monocitna levkemija	M	3	3	–	0	–	0	–
	Monocytic leukaemia	Ž	2	2	–	0	–	0	–
C94	Druge opredeljene levkemije	M	13	13	–	0	–	0	–
	Other leukaemias of specified cells	Ž	7	7	–	0	–	0	–
C95	Levkemija z neopredeljenim celičnim tipom	M	2	2	–	0	–	0	–
	Leukaemia, unspecified cell type	Ž	6	6	–	0	–	0	–
C96	Druge in neopredeljene maligne neoplazme limfatičnega, krvotvornega ali sorodnega tkiva	M	58	58	100	0	0	0	0
	Other and unspecified malignant neoplasms of lymphoid, haematopoietic and related tissue	Ž	60	60	100	0	0	0	0

Zgoraj neupoštevani
Not included above

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Število novih primerov Number of new cases	Mikroskopsko potrjeni primeri Microscopically confirmed cases		Ugotovljeni z drugimi preiskavami Confirmed by other investigations		Registrirani samo iz zdravniških poročil o vzroku smrti Registered from death certificates only	
				Število Number	%* %*	Število Number	%* %*	Število Number	%* %*
D03	Melanom, in situ	M	85	85	100	0	0	0	0
	Melanoma, in situ	Ž	89	89	100	0	0	0	0
D05	Dojka, in situ	M	1	1	–	0	–	0	–
	Breast, in situ	Ž	100	100	100	0	0	0	0
D06	Maternični vrat, CIN III	M	–	–	–	–	–	–	–
	Cervix uteri, in situ	Ž	886	886	100	0	0	0	0
D09.0	Sečni mehur, in situ	M	123	123	100	0	0	0	0
	Bladder, in situ	Ž	31	31	100	0	0	0	0
D32.0	Meninge, benigna neoplazma	M	24	24	100	0	0	0	0
	Benign neoplasm of meninges	Ž	52	52	100	0	0	0	0
D33.0–D33.2	Možgani, benigna neoplazma	M	0	0	–	0	–	0	–
	Benign neoplasm of brain	Ž	1	0	–	1	–	0	–
D39.1	Jajčnik, neoplazma negotovega značaja	M	–	–	–	–	–	–	–
	Ovary, neoplasm of uncertain behavior	Ž	73	73	100	0	0	0	0
D43.0–D43.2	Možgani, neopredeljeno	M	8	0	–	8	–	0	–
	CNS, uncertain or unknown	Ž	3	1	–	2	–	0	–

* Odstotki niso računani, če je število novih primerov manjše od 15
* Percentages are not calculated when number of new cases is less than 15

Tabela 4: Incidenca raka po lokaciji, spolu in starosti, Slovenija 2011.

Table 4: Cancer incidence by site, by sex and by age, Slovenia 2011.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+
C00–C96	Vse lokacije All sites	M+Ž	12922	14	12	18	25	35	75	147	192	293	542	922	1430	1750	1762	1803	1692	2210
		M	7162	6	8	10	13	17	44	62	80	128	239	486	820	1071	1112	1177	952	937
		Ž	5760	8	4	8	12	18	31	85	112	165	303	436	610	679	650	626	740	1273
C00	Ustnica Lip	M	20	0	0	0	0	0	0	0	0	0	2	2	1	2	1	4	3	5
		Ž	9	0	0	0	0	0	0	0	0	0	0	1	0	2	1	2	1	2
C01	Baza jezika Base of tongue	M	10	0	0	0	0	0	0	0	0	0	2	2	3	0	2	1	0	0
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
C02	Jezik, drugi deli Tongue, other & unspecified parts	M	22	0	0	0	0	0	1	0	1	2	2	4	3	4	5	0	0	0
		Ž	3	0	0	0	0	0	0	0	0	1	0	0	0	0	0	2	0	0
C03	Dlesen Gum	M	2	0	0	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0
		Ž	5	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1	2
C04	Ustno dno Floor of mouth	M	22	0	0	0	0	0	0	0	0	1	0	4	8	4	3	1	0	1
		Ž	8	0	0	0	0	0	0	0	0	0	2	1	2	1	1	1	0	0
C05	Nebo Palate	M	17	0	0	0	0	0	0	0	1	0	2	4	2	3	2	1	0	2
		Ž	4	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	0	2
C06	Usta, drugi deli Mouth, other & unspecified parts	M	6	0	0	0	0	0	0	0	0	0	1	2	1	0	1	0	1	0
		Ž	11	0	0	0	0	0	0	1	0	1	0	1	2	3	0	0	1	2
C07	Parotidna žleza Parotid gland	M	6	0	0	0	0	0	0	0	0	1	0	2	0	0	0	0	2	1
		Ž	6	0	0	0	1	0	0	0	0	0	0	0	0	0	1	1	1	2
C08	Druge in neopredeljene velike žleze slinavke Other & unspecified major salivary glands	M	2	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
C09	Tonzila Tonsil	M	50	0	0	0	0	0	0	0	0	2	5	12	9	10	5	5	1	1
		Ž	14	0	0	0	0	0	0	0	0	0	1	5	3	1	2	2	0	0
C10	Orofarinks Oropharynx	M	39	0	0	0	0	0	0	0	2	2	4	7	7	6	5	4	1	1
		Ž	6	0	0	0	0	0	0	0	0	0	1	1	2	1	0	0	1	0
C11	Nazofarinks Nasopharynx	M	9	0	0	0	0	0	0	0	0	0	0	2	1	2	0	2	1	1
		Ž	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	1
C12	Piriformni sinus Pyriform sinus	M	19	0	0	0	0	0	0	0	0	1	2	6	4	1	2	1	2	0
		Ž	2	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	0
C13	Hipofarinks Hypopharynx	M	18	0	0	0	0	0	0	0	0	2	3	3	4	4	1	0	0	1
		Ž	2	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	0
C14	Druga in slabo opredeljena mesta na ustnici, v ustni votlini in farinksu Other and ill-defined sites in the lip, oral cavity and pharynx	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C15	Požiralnik Oesophagus	M	68	0	0	0	0	0	0	0	1	4	4	5	11	11	10	11	5	6
		Ž	18	0	0	0	0	0	0	0	0	1	0	1	0	4	4	2	4	2
C16	Želodec Stomach	M	302	0	0	0	0	1	1	2	4	4	15	14	33	31	51	38	47	61
		Ž	195	0	0	0	0	0	0	4	2	4	10	9	17	14	21	14	39	61
C17	Tanko črevo Small intestine	M	19	0	0	0	0	0	0	0	0	2	1	1	3	3	5	0	1	3
		Ž	14	0	0	0	0	0	0	0	0	0	0	1	2	1	3	1	3	3
C18	Debelo črevo Colon	M	556	0	0	0	0	0	0	1	6	7	9	41	58	93	95	98	76	72
		Ž	415	0	0	1	1	0	0	0	3	7	13	38	38	42	60	52	62	98
C19	Rektosigmoidna zveza Rectosigmoid junction	M	85	0	0	0	0	0	0	1	0	1	2	8	11	10	12	20	12	8
		Ž	56	0	0	0	0	0	0	0	0	0	4	3	4	3	7	11	11	13
C20	Rektum Rectum	M	349	0	0	0	0	0	0	1	3	7	15	40	40	55	53	54	47	34
		Ž	171	0	0	0	0	0	0	1	3	4	12	14	18	16	22	24	26	31
C21	Anus in analni kanal Anus and anal canal	M	5	0	0	0	0	0	0	0	0	0	0	1	2	0	1	0	1	0
		Ž	11	0	0	0	0	0	0	0	0	0	0	0	1	0	2	1	1	6
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	M	114	0	0	0	0	0	0	0	0	1	0	8	11	17	17	25	20	15
		Ž	37	0	0	0	0	0	0	1	0	0	1	0	2	2	4	9	5	13
C23	Žolčnik Gallbladder	M	13	0	0	0	0	0	0	0	0	0	0	0	3	1	3	2	0	4
		Ž	39	0	0	0	0	0	0	0	0	0	0	2	2	2	6	5	6	16
C24	Drugi in neopredeljeni deli biliarnega trakta Billiary tract, other and unspecified parts	M	58	0	0	0	0	0	0	1	1	1	0	1	5	4	9	10	10	16
		Ž	56	0	0	0	0	0	0	0	0	0	1	1	5	4	7	8	8	22
C25	Trebušna slinavka Pancreas	M	178	0	0	0	0	0	1	0	2	2	5	11	17	20	30	33	26	31
		Ž	186	0	0	0	0	0	0	0	1	0	3	8	10	17	17	20	46	64
C26	Druga in slabo opredeljena mesta v prebavnih organih Other and ill-defined digestive organs	M	4	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	2
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Nadaljevanje —>
Continued —>

Tabela 4: Nadaljevanje.
Table 4: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age															
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+
C30	Nosna votlina in srednje uho	M	7	0	0	0	0	0	0	1	0	0	1	0	1	2	0	0	0	2
	Nasal cavity and middle ear	Ž	5	0	0	0	0	0	0	0	0	0	0	1	1	0	0	1	1	1
C31	Obnosni sinusi	M	5	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	2	1
	Accessory sinuses	Ž	5	0	0	0	0	0	0	0	0	0	0	1	0	0	3	1	0	0
C32	Grlo	M	98	0	0	0	0	0	0	0	0	0	9	16	22	13	14	11	5	8
	Larynx	Ž	11	0	0	0	0	0	0	0	0	0	0	3	3	0	1	1	1	2
C33	Sapnik	M	5	0	0	0	0	0	0	0	0	0	0	0	2	0	1	1	1	0
	Trachea	Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C34	Sapnica in pljuča	M	819	0	0	0	0	0	0	2	0	4	27	58	130	144	121	130	114	89
	Bronchus and lung	Ž	376	0	0	0	0	0	0	0	2	9	11	32	48	64	57	40	48	65
C37	Timus	M	4	0	0	0	0	0	0	0	0	0	1	0	2	0	1	0	0	0
	Thymus	Ž	4	0	0	0	1	0	0	0	0	0	1	0	0	0	1	0	1	0
C38	Srce, mediastinum, plevra	M	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
	Heart, mediastinum, pleura	Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C39	Druga in slabo opredeljena mesta v dihalih in prsnih organih	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Other and ill-defined sites in the respiratory system and intrathoracic organs	Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C40	Kosti, sklepni hrustanec udov	M	3	0	0	1	1	0	0	0	0	0	0	0	0	1	0	0	0	0
	Bone and articular cartilage of limbs	Ž	7	0	0	1	0	2	0	0	1	1	1	0	0	1	0	0	0	0
C41	Kosti, sklepni hrustanec, drugje	M	4	0	0	1	0	0	0	0	0	0	1	0	1	0	1	0	0	0
	Bone and articular cartilage of other and unspecified parts	Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C43	Maligni melanom kože	M	248	0	0	0	0	1	5	5	16	14	23	25	23	33	34	29	20	20
	Malignant melanoma of skin	Ž	233	0	0	0	0	3	6	14	14	15	22	22	18	29	19	18	24	29
C44	Druge maligne neoplazme kože	M	1050	0	0	0	0	2	3	10	12	22	26	55	84	115	166	186	154	215
	Skin, other malignomas	Ž	1054	0	0	1	0	1	5	9	17	20	31	56	68	99	101	145	165	336
C45	Mezoteliom	M	31	0	0	0	0	0	0	0	1	0	0	0	5	7	3	7	5	3
	Mesothelioma	Ž	7	0	0	0	0	0	0	0	0	0	0	1	0	0	1	1	2	2
C46	Kaposijev sarkom	M	3	0	0	0	0	0	0	0	1	1	0	0	1	0	0	0	0	0
	Kaposi's sarcoma	Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C47	Periferni živci in avtonomno živčevje	M	2	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0	0
	Peripheral nerves and autonomic nervous system	Ž	3	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2
C48	Peritonej in retroperitonej	M	8	0	0	0	0	0	0	0	0	0	1	2	1	0	2	0	1	1
	Retroperitoneum and peritoneum	Ž	19	0	0	0	0	0	0	0	0	1	1	0	2	3	4	5	2	1
C49	Drugo vezivno in mehko tkivo	M	19	0	1	0	1	0	0	1	0	1	2	1	1	0	3	4	3	1
	Other connective and soft tissue	Ž	19	0	0	0	0	0	0	0	0	1	2	3	3	1	1	2	2	4
C50	Dojka	M	14	0	0	0	0	0	0	0	2	0	2	0	0	2	1	5	2	0
	Breast	Ž	1143	0	0	0	0	1	1	17	31	50	98	106	155	183	149	100	103	149
C51	Žensko zunanje spolovilo	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
	Vulva	Ž	41	0	0	0	0	0	0	0	0	0	1	7	5	3	4	4	5	12
C52	Nožnica	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
	Vagina	Ž	9	0	0	0	0	0	0	1	0	0	0	0	0	2	1	1	0	4
C53	Maternični vrat	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
	Cervix uteri	Ž	142	0	0	0	0	0	7	11	17	13	12	17	13	14	7	9	10	12
C54	Maternično telo	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
	Corpus uteri	Ž	301	0	0	0	0	0	0	0	0	8	9	29	56	57	31	36	33	42
C55	Maternica, neopredeljeno	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
	Uterus, unspecified	Ž	13	0	0	0	0	0	0	0	0	1	1	1	5	1	0	1	0	3
C56	Jajčnik	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
	Ovary	Ž	153	0	0	1	1	0	1	3	1	7	14	20	19	23	21	13	5	24
C57	Drugi in neopredeljeni ženski spolni organi	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
	Other and unspecified parts of female genital organs	Ž	10	0	0	0	0	0	0	0	0	0	1	1	1	2	2	1	0	2
C58	Posteljica	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
	Placenta	Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C60	Penis	M	9	0	0	0	0	0	0	0	0	0	1	0	2	1	1	2	1	1
	Penis	Ž	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
C61	Prostata	M	1539	0	0	0	0	0	0	0	1	3	17	55	171	299	312	335	212	134
	Prostate	Ž	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–

Nadaljevanje —>
Continued —>

Tabela 4: Nadaljevanje.
Table 4: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age															
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+
C62	Modo Testis	M Ž	106 –	0 –	0 –	0 –	2 –	9 –	21 –	24 –	13 –	11 –	7 –	6 –	3 –	6 –	1 –	2 –	0 –	1 –
C63	Drugi in neopredeljeni moški spolni organi Other and unspecified male genital organs	M Ž	1 –	0 –	0 –	0 –	0 –	0 –	0 –	0 –	0 –	0 –	0 –	0 –	0 –	0 –	0 –	0 –	0 –	1 –
C64	Ledvica razen meha Kidney, except renal pelvis	M Ž	217 106	1 0	0 0	0 0	0 1	1 0	1 0	2 1	2 1	7 3	11 4	19 7	30 12	37 10	24 9	30 13	28 20	24 25
C65	Ledvični meh Renal pelvis	M Ž	8 8	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	1 0	2 0	1 1	0 2	3 1	0 2	1 2
C66	Sečevod Ureter	M Ž	12 3	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	1 0	0 0	1 0	0 0	0 0	1 0	2 0	3 1	4 2
C67	Sečni mehur Bladder	M Ž	226 72	1 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	4 1	3 0	11 2	22 6	25 4	27 9	34 8	51 17	48 25
C68	Drugi in neopredeljeni sečni organi Other and unspecified urinary organs	M Ž	1 1	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	1 0	0 0	0 1	0 0
C69	Oko in očesni adneksi Eye and adnexa	M Ž	4 11	0 1	0 0	0 0	0 0	0 0	0 0	0 0	0 1	0 0	2 1	0 1	1 3	0 1	0 0	0 1	0 0	1 2
C70	Meninge Meninges	M Ž	2 1	0 0	0 0	0 0	0 0	0 1	1 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	1 0	0 0	0 0	0 0
C71	Možgani Brain	M Ž	78 58	1 0	1 2	3 1	1 0	0 0	2 0	1 2	0 1	1 0	4 4	7 5	14 13	16 8	10 8	9 7	4 3	4 4
C72	Hrbtni mozeg, možganski živci in drugi deli CŽS Spinal cord, cranial nerves and other parts of CNS	M Ž	3 2	0 0	1 0	0 0	0 0	0 0	0 0	1 1	0 0	1 0	0 0	0 1	0 0	0 0	0 0	0 0	0 0	0 0
C73	Ščitnica Thyroid gland	M Ž	45 98	0 0	0 0	0 0	1 3	1 7	2 5	2 9	3 5	3 6	4 6	4 12	3 12	6 11	5 11	4 4	3 2	4 5
C74	Nadledvična žleza Adrenal gland	M Ž	2 2	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 1	1 0	0 0	1 0	0 0	0 0	0 0	0 0	0 0	0 1
C75	Druge endokrine žleze in sorodne strukture Other endocrine glands and related structures	M Ž	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0
C76	Druga in slabo opredeljena mesta Other and ill-defined sites	M Ž	8 26	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 2	2 1	2 0	0 3	1 6	3 14
C77	Metastaza in neopredeljena maligna neoplazma bezgavk Metastasis and unspecified malignant neoplasm of lymph nodes	M Ž	21 12	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	1 1	2 1	3 0	5 3	4 2	3 0	1 1	1 2	1 2
C78	Metastaze dihal in prebavil Metastases of respiratory and digestive organs	M Ž	45 52	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 1	0 0	0 1	4 2	3 4	7 2	7 6	6 10	18 26
C79	Metastaze, drugje Metastases of other sites	M Ž	10 17	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	1 1	1 2	3 1	0 0	1 1	2 7	2 5
C80	Maligna neoplazma brez opredeljenega mesta Malignant neoplasm without specification of site	M Ž	57 44	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 1	5 3	2 1	12 3	9 6	5 4	9 4	12 6	3 16
C81	Hodgkinova bolezen Hodgkin's disease	M Ž	14 27	0 0	0 0	0 1	2 4	0 1	1 2	1 3	2 4	0 1	1 2	2 1	1 3	0 0	2 2	2 0	0 2	0 1
C82	Folikularni ne-Hodgkinov limfom Follicular non-Hodgkin's lymphoma	M Ž	28 57	0 0	0 0	0 0	0 0	0 0	0 1	0 2	1 1	1 1	3 7	7 7	4 10	3 6	4 5	2 2	2 5	1 10
C83	Difuzni ne-Hodgkinov limfom Diffuse non-Hodgkin's lymphoma	M Ž	122 88	0 1	2 0	1 0	0 0	0 0	3 0	5 0	1 2	1 1	5 5	9 2	9 14	18 12	11 5	14 9	19 14	24 23
C84	Limfomi celic T in kožni limfom celic T Peripheral and cutaneous T-cell lymphomas	M Ž	14 15	0 0	0 0	0 0	0 0	1 0	0 2	0 2	0 0	0 1	0 1	0 1	3 1	4 1	2 3	1 2	1 0	2 1
C85	Druge in neopredeljene vrste ne-Hodgkinovega limfoma Other and unspecified types of non-Hodgkin's lymphoma	M Ž	10 12	0 0	0 0	0 0	0 0	0 0	0 0	0 1	1 0	0 1	1 1	0 1	0 2	1 0	0 1	1 1	2 1	4 3

Nadaljevanje —>
Continued —>

Tabela 4: Nadaljevanje.
Table 4: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age															
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+
C88	Maligne imunoproliferativne bolezni Malignant immunoproliferative diseases	M Ž	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0
C90	Difuzni plazmocitom in maligne neoplazme plazmocitov Multiple myeloma and malignant plasma cell neoplasms	M Ž	56 57	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	3 0	1 5	6 0	6 6	6 3	6 14	6 9	15 6	7 14
C91.0	Limfatična levkemija, akutna Lymphoblastic leukaemia, acute	M Ž	13 9	3 5	3 2	2 0	2 0	0 1	0 0	0 0	0 0	0 0	0 0	0 0	1 0	0 0	0 0	2 0	0 0	0 1
C91.1–C91.9	Limfatična levkemija, druga Lymphoid leukaemia, other	M Ž	63 36	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	1 1	1 0	6 1	4 2	7 4	14 4	8 2	8 5	14 17
C92	Mieloična levkemija Myeloid leukaemia	M Ž	58 43	0 0	0 0	2 1	1 0	1 1	1 0	0 0	2 2	2 0	2 5	3 2	7 4	6 3	4 2	7 6	6 2	14 15
C93	Monocitna levkemija Monocytic leukaemia	M Ž	3 2	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	1 0	0 0	1 0	1 0	0 2
C94	Druge opredeljene levkemije Other leukaemias of specified cells	M Ž	13 7	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	1 0	0 0	0 1	2 1	3 1	2 0	2 1	3 1	0 2
C95	Levkemija z neopredeljenim celičnim tipom Leukaemia, unspecified cell type	M Ž	2 6	0 0	0 0	0 0	1 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	1 0	0 1	0 1	0 4
C96	Druge in neopredeljene maligne neoplazme limfatičnega, krvotvornega ali sorodnega tkiva Other and unspecified malignant neoplasms of lymphoid, haematopoietic and related tissue	M Ž	58 60	0 0	0 0	0 1	1 0	0 0	1 1	1 2	0 2	2 2	1 4	4 3	2 2	8 4	5 6	9 7	8 5	16 21

Zgoraj neupoštevani
Not included above

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age															
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+
D03	Melanom, in situ Melanoma, in situ	M Ž	85 89	0 0	0 0	0 0	0 0	0 2	3 0	3 7	5 10	7 9	5 5	5 7	6 8	15 10	11 10	12 7	9 5	4 9
D05	Dojka, in situ Breast, in situ	M Ž	1 100	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 1	0 4	0 10	0 28	0 20	0 17	0 11	0 3	1 4	0 2
D06	Maternični vrat, CIN III Cervix uteri, in situ	M Ž	– 886	– 0	– 0	– 0	– 2	– 61	– 179	– 220	– 158	– 93	– 68	– 48	– 18	– 15	– 12	– 7	– 1	– 4
D09.0	Sečni mehur, in situ Bladder, in situ	M Ž	123 31	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	2 0	3 2	13 7	13 2	16 9	19 2	20 5	19 3	18 1
D32.0	Meninge, benigna neoplazma Benign neoplasm of meninges	M Ž	24 52	0 0	0 0	0 0	0 0	0 0	0 0	1 1	1 3	1 3	1 7	3 6	2 3	6 7	1 7	2 8	2 5	4 2
D33.0–D33.2	Možgani, benigna neoplazma Benign neoplasm of brain	M Ž	0 1	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 1	0 0	0 0
D39.1	Jajčnik, neoplazma negotovega značaja Ovary, neoplasm of uncertain behavior	M Ž	– 73	– 0	– 0	– 0	– 0	– 4	– 5	– 7	– 5	– 8	– 5	– 8	– 10	– 7	– 3	– 5	– 4	– 2
D43.0–D43.2	Možgani, neopredeljeno CNS, uncertain or unknown	M Ž	8 3	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	3 1	1 0	0 0	0 0	1 0	1 1	2 1

Tabela 5: Groba in starostno specifična incidenčna stopnja na 100.000 prebivalcev ter komulativna stopnja (KS) po lokaciji in spolu, Slovenija 2011.

Table 5: Crude and age specific cancer incidence rate per 100,000 and comulative rate (CR) by site and by sex, Slovenia 2011.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																KS CR
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+	0–74
C00–C96	Vse lokacije All sites	M+Ž	629,6	13,0	13,1	19,4	24,8	27,9	52,5	93,2	126,0	196,9	344,8	601,9	939,1	1367,4	1888,4	2048,0	2327,9	2535,5	38,8
		M	705,3	10,8	17,0	20,9	25,1	26,1	58,7	74,8	100,5	167,4	298,1	624,6	1057,4	1693,1	2564,5	3034,9	3382,2	3731,4	48,9
		Ž	555,4	15,3	9,0	17,8	24,5	29,7	45,5	113,5	153,8	228,1	393,4	578,5	816,3	1049,1	1301,4	1270,9	1661,5	2051,5	30,2
C00	Ustnica	M	2,0	0	0	0	0	0	0	0	0	0	2,5	2,6	1,3	3,2	2,3	10,3	10,7	19,9	0,1
	Lip	Ž	0,9	0	0	0	0	0	0	0	0	0	0	1,3	0	3,1	2,0	4,1	2,2	3,2	0,1
C01	Baza jezika	M	1,0	0	0	0	0	0	0	0	0	0	2,5	2,6	3,9	0	4,6	2,6	0	0	0,1
	Base of tongue	Ž	0,1	0	0	0	0	0	0	0	0	0	0	0	0	0	2,0	0	0	0	0,0
C02	Jezik, drugi deli	M	2,2	0	0	0	0	0	1,3	0	1,3	2,6	2,5	5,1	3,9	6,3	11,5	0	0	0	0,2
	Tongue, other & unspecified parts	Ž	0,3	0	0	0	0	0	0	0	0	1,4	0	0	0	0	0	4,1	0	0	0,0
C03	Dlesen	M	0,2	0	0	0	0	0	0	0	1,3	0	0	0	0	1,6	0	0	0	0	0,0
	Gum	Ž	0,5	0	0	0	0	0	0	0	0	0	0	0	0	1,5	0	2,0	2,2	3,2	0,0
C04	Ustno dno	M	2,2	0	0	0	0	0	0	0	0	1,3	0	5,1	10,3	6,3	6,9	2,6	0	4,0	0,2
	Floor of mouth	Ž	0,8	0	0	0	0	0	0	0	0	0	2,6	1,3	2,7	1,5	2,0	2,0	0	0	0,1
C05	Nebo	M	1,7	0	0	0	0	0	0	0	1,3	0	2,5	5,1	2,6	4,7	4,6	2,6	0	8,0	0,1
	Palate	Ž	0,4	0	0	0	0	0	0	0	0	0	1,3	0	0	0	0	2,0	0	3,2	0,0
C06	Usta, drugi deli	M	0,6	0	0	0	0	0	0	0	0	0	1,2	2,6	1,3	0	2,3	0	3,6	0	0,0
	Mouth, other & unspecified parts	Ž	1,1	0	0	0	0	0	0	1,3	0	1,4	0	1,3	2,7	4,6	0	0	2,2	3,2	0,1
C07	Parotidna žleza	M	0,6	0	0	0	0	0	0	0	0	1,3	0	2,6	0	0	0	0	7,1	4,0	0,0
	Parotid gland	Ž	0,6	0	0	0	2,0	0	0	0	0	0	0	0	0	0	2,0	2,0	2,2	3,2	0,0
C08	Druge in neopredeljene velike žleze slinavke	M	0,2	0	0	0	0	0	0	0	0	1,3	0	1,3	0	0	0	0	0	0	0,0
	Other & unspecified major salivary glands	Ž	0,1	0	0	0	0	0	0	0	0	0	0	0	0	0	2,0	0	0	0	0,0
C09	Tonzila	M	4,9	0	0	0	0	0	0	0	0	2,6	6,2	15,4	11,6	15,8	11,5	12,9	3,6	4,0	0,4
	Tonsil	Ž	1,3	0	0	0	0	0	0	0	0	0	1,3	6,6	4,0	1,5	4,0	4,1	0	0	0,1
C10	Orofarinks	M	3,8	0	0	0	0	0	0	0	2,5	2,6	5,0	9,0	9,0	9,5	11,5	10,3	3,6	4,0	0,3
	Oropharynx	Ž	0,6	0	0	0	0	0	0	0	0	0	1,3	1,3	2,7	1,5	0	0	2,2	0	0,0
C11	Nazofarinks	M	0,9	0	0	0	0	0	0	0	0	0	0	2,6	1,3	3,2	0	5,2	3,6	4,0	0,1
	Nasopharynx	Ž	0,3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2,0	2,2	1,6	0,0
C12	Piriformni sinus	M	1,9	0	0	0	0	0	0	0	0	1,3	2,5	7,7	5,2	1,6	4,6	2,6	7,1	0	0,1
	Pyriform sinus	Ž	0,2	0	0	0	0	0	0	0	0	0	0	0	1,3	0	0	0	2,2	0	0,0
C13	Hipofarinks	M	1,8	0	0	0	0	0	0	0	0	2,6	3,7	3,9	5,2	6,3	2,3	0	0	4,0	0,1
	Hypopharynx	Ž	0,2	0	0	0	0	0	0	0	0	0	0	0	1,3	0	0	0	2,2	0	0,0
C14	Druga in slabo opredeljena mesta na ustnici, v ustni votlini in farinksu	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0
	Other and ill-defined sites in the lip, oral cavity and pharynx	Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0
C15	Požiralnik	M	6,7	0	0	0	0	0	0	0	1,3	5,2	5,0	6,4	14,2	17,4	23,1	28,4	17,8	23,9	0,5
	Oesophagus	Ž	1,7	0	0	0	0	0	0	0	0	1,4	0	1,3	0	6,2	8,0	4,1	9,0	3,2	0,1
C16	Želodec	M	29,7	0	0	0	0	1,5	1,3	2,4	5,0	5,2	18,7	18,0	42,6	49,0	117,6	98,0	167,0	242,9	1,8
	Stomach	Ž	18,8	0	0	0	0	0	0	5,3	2,7	5,5	13,0	11,9	22,7	21,6	42,0	28,4	87,6	98,3	0,8
C17	Tanko črevo	M	1,9	0	0	0	0	0	0	0	0	2,6	1,2	1,3	3,9	4,7	11,5	0	3,6	11,9	0,1
	Small intestine	Ž	1,3	0	0	0	0	0	0	0	0	0	0	1,3	2,7	1,5	6,0	2,0	6,7	4,8	0,1
C18	Debelo črevo	M	54,8	0	0	0	0	0	0	1,2	7,5	9,2	11,2	52,7	74,8	147,0	219,1	252,7	270,0	286,7	3,9
	Colon	Ž	40,0	0	0	2,2	2,0	0	0	0	4,1	9,7	16,9	50,4	50,9	64,9	120,1	105,6	139,2	157,9	2,1

Nadaljevanje —>
Continued —>

Tabela 5: Nadaljevanje.
Table 5: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																KS CR
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+	0–74
C19	Rektosigmoidna zveza	M	8,4	0	0	0	0	0	0	1,2	0	1,3	2,5	10,3	14,2	15,8	27,7	51,6	42,6	31,9	0,6
	Rectosigmoid junction	Ž	5,4	0	0	0	0	0	0	0	0	0	5,2	4,0	5,4	4,6	14,0	22,3	24,7	21,0	0,3
C20	Rektum	M	34,4	0	0	0	0	0	0	1,2	3,8	9,2	18,7	51,4	51,6	86,9	122,2	139,2	167,0	135,4	2,4
	Rectum	Ž	16,5	0	0	0	0	0	0	1,3	4,1	5,5	15,6	18,6	24,1	24,7	44,0	48,7	58,4	50,0	0,9
C21	Anus in analni kanal	M	0,5	0	0	0	0	0	0	0	0	0	0	1,3	2,6	0	2,3	0	3,6	0	0,0
	Anus and anal canal	Ž	1,1	0	0	0	0	0	0	0	0	0	0	0	1,3	0	4,0	2,0	2,2	9,7	0,0
C22	Jetra in intrahepatični vodi	M	11,2	0	0	0	0	0	0	0	0	1,3	0	10,3	14,2	26,9	39,2	64,5	71,1	59,7	0,8
	Liver and intrahepatic bile ducts	Ž	3,6	0	0	0	0	0	0	1,3	0	0	1,3	0	2,7	3,1	8,0	18,3	11,2	21,0	0,2
C23	Žolčnik	M	1,3	0	0	0	0	0	0	0	0	0	0	0	3,9	1,6	6,9	5,2	0	15,9	0,1
	Gallbladder	Ž	3,8	0	0	0	0	0	0	0	0	0	0	2,7	2,7	3,1	12,0	10,2	13,5	25,8	0,2
C24	Drugi in neopredeljeni deli biliarnega trakta	M	5,7	0	0	0	0	0	0	1,2	1,3	1,3	0	1,3	6,4	6,3	20,8	25,8	35,5	63,7	0,3
	Billiary tract, other and unspecified parts	Ž	5,4	0	0	0	0	0	0	0	0	0	1,3	1,3	6,7	6,2	14,0	16,2	18,0	35,5	0,2
C25	Trebušna slinavka	M	17,5	0	0	0	0	0	1,3	0	2,5	2,6	6,2	14,1	21,9	31,6	69,2	85,1	92,4	123,5	1,2
	Pancreas	Ž	17,9	0	0	0	0	0	0	0	1,4	0	3,9	10,6	13,4	26,3	34,0	40,6	103,3	103,1	0,7
C26	Druga in slabo opredeljena mesta v prebavnih organih	M	0,4	0	0	0	0	0	0	0	0	0	0	0	1,3	1,6	0	0	0	8,0	0,0
	Other and ill-defined digestive organs	Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0
C30	Nosna votlina in srednje uho	M	0,7	0	0	0	0	0	0	1,2	0	0	1,2	0	1,3	3,2	0	0	0	8,0	0,0
	Nasal cavity and middle ear	Ž	0,5	0	0	0	0	0	0	0	0	0	0	1,3	1,3	0	0	2,0	2,2	1,6	0,0
C31	Obnosni sinusi	M	0,5	0	0	0	0	0	0	0	0	0	1,2	0	0	1,6	0	0	7,1	4,0	0,0
	Accessory sinuses	Ž	0,5	0	0	0	0	0	0	0	0	0	0	1,3	0	0	6,0	2,0	0	0	0,0
C32	Grlo	M	9,7	0	0	0	0	0	0	0	0	0	11,2	20,6	28,4	20,6	32,3	28,4	17,8	31,9	0,7
	Larynx	Ž	1,1	0	0	0	0	0	0	0	0	0	0	4,0	4,0	0	2,0	2,0	2,2	3,2	0,1
C33	Sapnik	M	0,5	0	0	0	0	0	0	0	0	0	0	0	2,6	0	2,3	2,6	3,6	0	0,0
	Trachea	Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0
C34	Sapnica in pljuča	M	80,7	0	0	0	0	0	0	2,4	0	5,2	33,7	74,5	167,6	227,6	279,1	335,2	405,0	354,4	5,6
	Bronchus and lung	Ž	36,3	0	0	0	0	0	0	0	2,7	12,4	14,3	42,5	64,2	98,9	114,1	81,2	107,8	104,8	2,2
C37	Timus	M	0,4	0	0	0	0	0	0	0	0	0	1,2	0	2,6	0	2,3	0	0	0	0,0
	Thymus	Ž	0,4	0	0	0	2,0	0	0	0	0	0	1,3	0	0	0	2,0	0	2,2	0	0,0
C38	Srce, mediastinum, plevra	M	0,1	0	0	0	0	0	0	0	0	0	0	0	0	0	2,3	0	0	0	0,0
	Heart, mediastinum, pleura	Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0
C39	Druga in slabo opredeljena mesta v dihalih in prsnih organih	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0
	Other and ill-defined sites in the respiratory system and intrathoracic organs	Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0
C40	Kosti, sklepni hrustanec udov	M	0,3	0	0	2,1	1,9	0	0	0	0	0	0	0	0	1,6	0	0	0	0	0,0
	Bone and articular cartilage of limbs	Ž	0,7	0	0	2,2	0	3,3	0	0	1,4	1,4	1,3	0	0	1,5	0	0	0	0	0,1

Nadaljevanje —>
Continued —>

Tabela 5: Nadaljevanje.
Table 5: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																KS CR
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+	0–74
C41	Kosti, sklepni hrustanec, drugje	M	0,4	0	0	2,1	0	0	0	0	0	0	1,2	0	1,3	0	2,3	0	0	0	0,0
	Bone and articular cartilage of other and unspecified parts	Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0
C43	Maligni melanom kože	M	24,4	0	0	0	0	1,5	6,7	6,0	20,1	18,3	28,7	32,1	29,7	52,2	78,4	74,8	71,1	79,6	1,7
	Malignant melanoma of skin	Ž	22,5	0	0	0	0	5,0	8,8	18,7	19,2	20,7	28,6	29,2	24,1	44,8	38,0	36,5	53,9	46,7	1,4
C44	Druge maligne neoplazme kože	M	103,4	0	0	0	0	3,1	4,0	12,1	15,1	28,8	32,4	70,7	108,3	181,8	382,8	479,6	547,1	856,2	6,6
	Skin, other malignomas	Ž	101,6	0	0	2,2	0	1,7	7,3	12,0	23,4	27,7	40,2	74,3	91,0	153,0	202,2	294,4	370,5	541,5	4,6
C45	Mezoteliom	M	3,1	0	0	0	0	0	0	0	1,3	0	0	0	6,4	11,1	6,9	18,0	17,8	11,9	0,2
	Mesothelioma	Ž	0,7	0	0	0	0	0	0	0	0	0	0	1,3	0	0	2,0	2,0	4,5	3,2	0,0
C46	Kaposijev sarkom	M	0,3	0	0	0	0	0	0	0	1,3	1,3	0	0	1,3	0	0	0	0	0	0,0
	Kaposi's sarcoma	Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0
C47	Periferni živci in avtonomno živčevje	M	0,2	0	0	0	0	0	0	0	0	1,3	0	0	0	1,6	0	0	0	0	0,0
	Peripheral nerves and autonomic nervous system	Ž	0,3	1,9	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3,2	0,0
C48	Peritonej in retroperitonej	M	0,8	0	0	0	0	0	0	0	0	0	1,2	2,6	1,3	0	4,6	0	3,6	4,0	0,0
	Retroperitoneum and peritoneum	Ž	1,8	0	0	0	0	0	0	0	0	1,4	1,3	0	2,7	4,6	8,0	10,2	4,5	1,6	0,1
C49	Drugo vezivno in mehko tkivo	M	1,9	0	2,1	0	1,9	0	0	1,2	0	1,3	2,5	1,3	1,3	0	6,9	10,3	10,7	4,0	0,1
	Other connective and soft tissue	Ž	1,8	0	0	0	0	0	0	0	0	1,4	2,6	4,0	4,0	1,5	2,0	4,1	4,5	6,4	0,1
C50	Dojka	M	1,4	0	0	0	0	0	0	0	2,5	0	2,5	0	0	3,2	2,3	12,9	7,1	0	0,1
	Breast	Ž	110,2	0	0	0	0	1,7	1,5	22,7	42,6	69,1	127,2	140,7	207,4	282,7	298,3	203,0	231,3	240,1	7,0
C51	Žensko zunanje spolovilo	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
	Vulva	Ž	4,0	0	0	0	0	0	0	0	0	0	1,3	9,3	6,7	4,6	8,0	8,1	11,2	19,3	0,2
C52	Nožnica	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
	Vagina	Ž	0,9	0	0	0	0	0	0	1,3	0	0	0	0	0	3,1	2,0	2,0	0	6,4	0,0
C53	Maternični vrat	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
	Cervix uteri	Ž	13,7	0	0	0	0	0	10,3	14,7	23,4	18,0	15,6	22,6	17,4	21,6	14,0	18,3	22,5	19,3	0,9
C54	Maternično telo	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
	Corpus uteri	Ž	29,0	0	0	0	0	0	0	0	0	11,1	11,7	38,5	74,9	88,1	62,1	73,1	74,1	67,7	1,8
C55	Maternica, neopredeljeno	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
	Uterus, unspecified	Ž	1,3	0	0	0	0	0	0	0	0	1,4	1,3	1,3	6,7	1,5	0	2,0	0	4,8	0,1
C56	Jajčnik	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
	Ovary	Ž	14,8	0	0	2,2	2,0	0	1,5	4,0	1,4	9,7	18,2	26,5	25,4	35,5	42,0	26,4	11,2	38,7	1,0
C57	Drugi in neopredeljeni ženski spolni organi	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
	Other and unspecified parts of female genital organs	Ž	1,0	0	0	0	0	0	0	0	0	0	1,3	1,3	1,3	3,1	4,0	2,0	0	3,2	0,1
C58	Posteljica	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
	Placenta	Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0
C60	Penis	M	0,9	0	0	0	0	0	0	0	0	0	1,2	0	2,6	1,6	2,3	5,2	3,6	4,0	0,1
	Penis	Ž	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–

Nadaljevanje —>
Continued —>

Tabela 5: Nadaljevanje.
Table 5: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																KS CR
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+	0–74
C61	Prostata	M	151,6	0	0	0	0	0	0	0	1,3	3,9	21,2	70,7	220,5	472,7	719,5	863,8	753,2	533,6	11,9
	Prostate	Ž	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
C62	Modo	M	10,4	0	0	0	3,9	13,8	28,0	29,0	16,3	14,4	8,7	7,7	3,9	9,5	2,3	5,2	0	4,0	0,7
	Testis	Ž	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
C63	Drugi in neopredeljeni moški spolni organi	M	0,1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4,0	0,0
	Other and unspecified male genital organs	Ž	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
C64	Ledvica razen meha	M	21,4	1,8	0	0	0	1,5	1,3	2,4	2,5	9,2	13,7	24,4	38,7	58,5	55,3	77,4	99,5	95,6	1,4
	Kidney, except renal pelvis	Ž	10,2	0	0	0	2,0	0	0	1,3	1,4	4,1	5,2	9,3	16,1	15,5	18,0	26,4	44,9	40,3	0,5
C65	Ledvični meh	M	0,8	0	0	0	0	0	0	0	0	0	0	1,3	2,6	1,6	0	7,7	0	4,0	0,1
	Renal pelvis	Ž	0,8	0	0	0	0	0	0	0	0	0	0	0	0	1,5	4,0	2,0	4,5	3,2	0,0
C66	Sečevod	M	1,2	0	0	0	0	0	0	0	0	1,3	0	1,3	0	0	2,3	5,2	10,7	15,9	0,1
	Ureter	Ž	0,3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2,2	3,2	0,0
C67	Sečni mehur	M	22,3	1,8	0	0	0	0	0	0	0	5,2	3,7	14,1	28,4	39,5	62,3	87,7	181,2	191,2	1,2
	Bladder	Ž	6,9	0	0	0	0	0	0	0	0	1,4	0	2,7	8,0	6,2	18,0	16,2	38,2	40,3	0,3
C68	Drugi in neopredeljeni sečni organi	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2,3	0	0	0	0,0
	Other and unspecified urinary organs	Ž	0,1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2,2	0	0,0
C69	Oko in očesni adneksi	M	0,4	0	0	0	0	0	0	0	0	0	2,5	0	1,3	0	0	0	0	4,0	0,0
	Eye and adnexa	Ž	1,1	1,9	0	0	0	0	0	0	1,4	0	1,3	1,3	4,0	1,5	0	2,0	0	3,2	0,1
C70	Meninge	M	0,2	0	0	0	0	0	1,3	0	0	0	0	0	0	0	2,3	0	0	0	0,0
	Meninges	Ž	0,1	0	0	0	0	1,7	0	0	0	0	0	0	0	0	0	0	0	0	0,0
C71	Možgani	M	7,7	1,8	2,1	6,3	1,9	0	2,7	1,2	0	1,3	5,0	9,0	18,1	25,3	23,1	23,2	14,2	15,9	0,6
	Brain	Ž	5,6	0	4,5	2,2	0	0	0	2,7	1,4	0	5,2	6,6	17,4	12,4	16,0	14,2	6,7	6,4	0,4
C72	Hrbtni mozeg, možganski živci in drugi deli ČZS	M	0,3	0	2,1	0	0	0	0	1,2	0	1,3	0	0	0	0	0	0	0	0	0,0
	Spinal cord, cranial nerves and other parts of CNS	Ž	0,2	0	0	0	0	0	0	1,3	0	0	0	1,3	0	0	0	0	0	0	0,0
C73	Ščitnica	M	4,4	0	0	0	1,9	1,5	2,7	2,4	3,8	3,9	5,0	5,1	3,9	9,5	11,5	10,3	10,7	15,9	0,3
	Thyroid gland	Ž	9,4	0	0	0	6,1	11,6	7,3	12,0	6,9	8,3	7,8	15,9	16,1	17,0	22,0	8,1	4,5	8,1	0,7
C74	Nadledvična žleza	M	0,2	0	0	0	0	0	0	0	0	1,3	0	1,3	0	0	0	0	0	0	0,0
	Adrenal gland	Ž	0,2	0	0	0	0	0	0	0	1,4	0	0	0	0	0	0	0	0	1,6	0,0
C75	Druge endokrine žleze in sorodne strukture	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0
	Other endocrine glands and related structures	Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0
C76	Druga in slabo opredeljena mesta	M	0,8	0	0	0	0	0	0	0	0	0	0	0	0	3,2	4,6	0	3,6	11,9	0,0
	Other and ill-defined sites	Ž	2,5	0	0	0	0	0	0	0	0	0	0	0	2,7	1,5	0	6,1	13,5	22,6	0,1
C77	Metastaza in neopredeljena maligna neoplazma bezgavk	M	2,1	0	0	0	0	0	0	0	0	1,3	2,5	3,9	6,4	6,3	6,9	2,6	3,6	4,0	0,1
	Metastasis and unspecified malignant neoplasm of lymph nodes	Ž	1,2	0	0	0	0	0	0	0	0	1,4	1,3	0	4,0	3,1	0	2,0	4,5	3,2	0,1

Nadaljevanje —>
Continued —>

Tabela 5: Nadaljevanje.
Table 5: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																KS CR
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+	0–74
C78	Metastaze dihal in prebavil Metastases of respiratory and digestive organs	M	4,4	0	0	0	0	0	0	0	0	0	0	0	5,2	4,7	16,1	18,0	21,3	71,7	0,2
		Ž	5,0	0	0	0	0	0	0	0	0	1,4	0	1,3	2,7	6,2	4,0	12,2	22,5	41,9	0,1
C79	Metastaze, drugje Metastases of other sites	M	1,0	0	0	0	0	0	0	0	0	0	0	1,3	1,3	4,7	0	2,6	7,1	8,0	0,0
		Ž	1,6	0	0	0	0	0	0	0	0	0	0	1,3	2,7	1,5	0	2,0	15,7	8,1	0,0
C80	Maligna neoplazma brez opredeljenega mesta Malignant neoplasm without specification of site	M	5,6	0	0	0	0	0	0	0	0	0	6,2	2,6	15,5	14,2	11,5	23,2	42,6	11,9	0,4
		Ž	4,2	0	0	0	0	0	0	0	0	1,4	3,9	1,3	4,0	9,3	8,0	8,1	13,5	25,8	0,2
C81	Hodgkinova bolezen Hodgkin's disease	M	1,4	0	0	0	3,9	0	1,3	1,2	2,5	0	1,2	2,6	1,3	0	4,6	5,2	0	0	0,1
		Ž	2,6	0	0	2,2	8,2	1,7	2,9	4,0	5,5	1,4	2,6	1,3	4,0	0	4,0	0	4,5	1,6	0,2
C82	Folikularni ne-Hodgkinov limfom Follicular non-Hodgkin's lymphoma	M	2,8	0	0	0	0	0	0	0	1,3	1,3	3,7	9,0	5,2	4,7	9,2	5,2	7,1	4,0	0,2
		Ž	5,5	0	0	0	0	0	1,5	2,7	1,4	1,4	9,1	9,3	13,4	9,3	10,0	4,1	11,2	16,1	0,3
C83	Difuzni ne-Hodgkinov limfom Diffuse non-Hodgkin's lymphoma	M	12,0	0	4,3	2,1	0	0	4,0	6,0	1,3	1,3	6,2	11,6	11,6	28,5	25,4	36,1	67,5	95,6	0,7
		Ž	8,5	1,9	0	0	0	0	0	0	2,7	1,4	6,5	2,7	18,7	18,5	10,0	18,3	31,4	37,1	0,4
C84	Limfomi celic T in kožni limfom celic T Peripheral and cutaneous T-cell lymphomas	M	1,4	0	0	0	0	1,5	0	0	0	0	0	0	3,9	6,3	4,6	2,6	3,6	8,0	0,1
		Ž	1,4	0	0	0	0	0	2,9	2,7	0	1,4	1,3	1,3	1,3	1,5	6,0	4,1	0	1,6	0,1
C85	Druge in neopredeljene vrste ne-Hodgkinovega limfoma Other and unspecified types of non-Hodgkin's lymphoma	M	1,0	0	0	0	0	0	0	0	1,3	0	1,2	0	0	1,6	0	2,6	7,1	15,9	0,0
		Ž	1,2	0	0	0	0	0	0	1,3	0	1,4	1,3	1,3	2,7	0	2,0	2,0	2,2	4,8	0,1
C88	Maligne imunoproliferativne bolezni Malignant immunoproliferative diseases	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0
C90	Difuzni plazmocitom in maligne neoplazme plazmocitov Multiple myeloma and malignant plasma cell neoplasms	M	5,5	0	0	0	0	0	0	0	0	3,9	1,2	7,7	7,7	9,5	13,8	15,5	53,3	27,9	0,3
		Ž	5,5	0	0	0	0	0	0	0	0	0	6,5	0	8,0	4,6	28,0	18,3	13,5	22,6	0,3
C91.0	Limfatična levkemija, akutna Lymphoblastic leukaemia, acute	M	1,3	5,4	6,4	4,2	3,9	0	0	0	0	0	0	0	1,3	0	0	5,2	0	0	0,1
		Ž	0,9	9,5	4,5	0	0	1,7	0	0	0	0	0	0	0	0	0	0	0	1,6	0,1
C91.1 – C91.9	Limfatična levkemija, druga Lymphoid leukaemia, other	M	6,2	0	0	0	0	0	0	0	0	1,3	1,2	7,7	5,2	11,1	32,3	20,6	28,4	55,8	0,4
		Ž	3,5	0	0	0	0	0	0	0	0	1,4	0	1,3	2,7	6,2	8,0	4,1	11,2	27,4	0,1
C92	Mieloična levkemija Myeloid leukaemia	M	5,7	0	0	4,2	1,9	1,5	1,3	0	2,5	2,6	2,5	3,9	9,0	9,5	9,2	18,0	21,3	55,8	0,3
		Ž	4,1	0	0	2,2	0	1,7	0	0	2,7	0	6,5	2,7	5,4	4,6	4,0	12,2	4,5	24,2	0,2

Nadaljevanje —>
Continued —>

Tabela 5: Nadaljevanje.
Table 5: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																KS CR
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+	0–74
C93	Monocitna levkemija	M	0,3	0	0	0	0	0	0	0	0	0	0	0	0	1,6	0	2,6	3,6	0	0,0
	Monocytic leukaemia	Ž	0,2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3,2	0,0
C94	Druge opredeljene levkemije	M	1,3	0	0	0	0	0	0	0	0	1,3	0	0	2,6	4,7	4,6	5,2	10,7	0	0,1
	Other leukaemias of specified cells	Ž	0,7	0	0	0	0	0	0	0	0	0	0	1,3	1,3	1,5	0	2,0	2,2	3,2	0,0
C95	Levkemija z neopredeljenim celičnim tipom	M	0,2	0	0	0	1,9	0	0	0	0	0	0	0	0	0	2,3	0	0	0	0,0
	Leukaemia, unspecified cell type	Ž	0,6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2,0	2,2	6,4	0,0
C96	Druge in neopredeljene maligne neoplazme limfatičnega, krvotvornega ali sorodnega tkiva	M	5,7	0	0	0	1,9	0	1,3	1,2	0	2,6	1,2	5,1	2,6	12,6	11,5	23,2	28,4	63,7	0,3
	Other and unspecified malignant neoplasms of lymphoid, haematopoietic and related tissue	Ž	5,8	0	0	2,2	0	0	1,5	2,7	2,7	2,8	5,2	4,0	2,7	6,2	12,0	14,2	11,2	33,8	0,3

Zgoraj neupoštevani
Not included above

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																KS CR
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+	0–74
D03	Melanom, in situ	M	8,4	0	0	0	0	0	4,0	3,6	6,3	9,2	6,2	6,4	7,7	23,7	25,4	30,9	32,0	15,9	0,6
	Melanoma, in situ	Ž	8,6	0	0	0	0	3,3	0	9,3	13,7	12,4	6,5	9,3	10,7	15,5	20,0	14,2	11,2	14,5	0,6
D05	Dojka, in situ	M	0,1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3,6	0	0,0
	Breast, in situ	Ž	9,6	0	0	0	0	0	0	0	1,4	5,5	13,0	37,2	26,8	26,3	22,0	6,1	9,0	3,2	0,7
D06	Maternični vrat, CIN III	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
	Cervix uteri, in situ	Ž	85,4	0	0	0	4,1	100,8	262,8	293,8	217,0	128,6	88,3	63,7	24,1	23,2	24,0	14,2	2,2	6,4	6,2
D09.0	Sečni mehur, in situ	M	12,1	0	0	0	0	0	0	0	0	2,6	3,7	16,7	16,8	25,3	43,8	51,6	67,5	71,7	0,8
	Bladder, in situ	Ž	3,0	0	0	0	0	0	0	0	0	0	2,6	9,3	2,7	13,9	4,0	10,2	6,7	1,6	0,2
D32.0	Meninge, benigna neoplazma	M	2,4	0	0	0	0	0	0	1,2	1,3	1,3	1,2	3,9	2,6	9,5	2,3	5,2	7,1	15,9	0,1
	Benign neoplasm of meninges	Ž	5,0	0	0	0	0	0	0	1,3	4,1	4,1	9,1	8,0	4,0	10,8	14,0	16,2	11,2	3,2	0,4
D33.0 – D33.2	Možgani, benigna neoplazma	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0
	Benign neoplasm of brain	Ž	0,1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2,0	0	0	0,0
D39.1	Jajčnik, neopl. negotovega značaja	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
	Ovary, neopl. of uncertain behavior	Ž	7,0	0	0	0	0	6,6	7,3	9,3	6,9	11,1	6,5	10,6	13,4	10,8	6,0	10,2	9,0	3,2	0,5
D43.0 – D43.2	Možgani, neopredeljeno	M	0,8	0	0	0	0	0	0	0	0	0	0	3,9	1,3	0	0	2,6	3,6	8,0	0,0
	CNS, uncertain or unknown	Ž	0,3	0	0	0	0	0	0	0	0	0	0	1,3	0	0	0	0	2,2	1,6	0,0

Tabela 6a: Incidenca najpogostejših lokacij raka po statističnih regijah in spolu, Slovenija 2011.

Table 6a: Incidence of most frequent cancer sites by statistical regions and by sex, Slovenia 2011.

Statistična regija Statistical region	Spol Sex	Skupaj All sites	Primarna lokacija (šifra MKB) Primary site (ICD code)											
		C00–C96	C16	C18	C19	C20	C34	C44	C50	C53	C54	C61	Drugo Other	D06*
Slovenija, skupaj Slovenia, total	M	7162	302	556	85	349	819	1050	14	–	–	1539	2448	–
	Ž	5760	195	415	56	171	376	1054	1143	142	301	–	1907	886
Pomurska	M	536	14	25	7	33	56	67	0	–	–	182	152	–
	Ž	293	13	18	2	6	16	57	40	13	21	–	107	38
Podravska	M	1048	66	87	14	63	114	120	3	–	–	217	364	–
	Ž	828	35	65	11	45	46	115	193	27	59	–	232	163
Koroška	M	224	12	17	3	11	35	47	0	–	–	36	63	–
	Ž	205	10	13	3	11	20	44	32	3	8	–	61	37
Savinjska	M	770	45	70	11	50	92	120	2	–	–	125	255	–
	Ž	698	31	45	5	21	40	133	124	15	41	–	243	126
Zasavska	M	158	9	10	4	8	28	17	0	–	–	17	65	–
	Ž	127	7	7	3	6	12	13	20	4	6	–	49	19
Spodnjeposavska	M	228	7	23	3	11	26	31	2	–	–	55	70	–
	Ž	194	6	11	2	2	15	36	40	10	12	–	60	25
Jugovzhodna Slovenija	M	539	16	39	6	25	68	82	0	–	–	122	181	–
	Ž	374	14	18	9	6	25	95	64	9	19	–	115	44
Osrednjeslovenska	M	2019	67	140	22	83	218	322	3	–	–	451	713	–
	Ž	1618	41	127	13	44	99	321	347	33	69	–	524	225
Gorenjska	M	718	28	64	3	37	86	93	3	–	–	159	245	–
	Ž	592	12	41	3	12	47	104	114	13	22	–	224	77
Notranjsko-kraška	M	154	3	14	2	8	15	18	1	–	–	29	64	–
	Ž	137	5	7	0	3	10	16	35	2	7	–	52	26
Goriška	M	373	14	34	6	8	37	55	0	–	–	89	130	–
	Ž	348	9	38	4	9	23	45	62	5	20	–	133	36
Obalno-kraška	M	395	21	33	4	12	44	78	0	–	–	57	146	–
	Ž	346	12	25	1	6	23	75	72	8	17	–	107	70

Opis šifer MKB/Description of the ICD code

C16 Želodec / Stomach
C18 Debelo črevo / Colon
C19 Rektosigmoidna zveza / Rectosigmoid junction
C20 Rektum / Rectum
C34 Sapnica in pljuča / Bronchus and lung
C44 Koža, razen melanoma / Skin, non-melanoma
C50 Dojka / Breast
C53 Maternični vrat / Cervix uteri
C54 Maternično telo / Corpus uteri
C61 Prostata / Prostate
D06 Maternični vrat, in situ (CIN III) / Cervix uteri, in situ (CIN III)

* Neupoštevano v skupnem številu: D06 – maternični vrat, in situ (CIN III)

* Not included in All sites: D06 – Cervix uteri, in situ (CIN III)

Tabela 6b: Starostno standardizirana* incidenčna stopnja najpogostejših lokacij raka po statističnih regijah in spolu, Slovenija 2011.

Table 6b: Age standardised* incidence rate of most frequent cancer sites by statistical regions and by sex, Slovenia 2011.

Statistična regija Statistical region	Spol Sex	Skupaj All sites	Primarna lokacija (šifra MKB) Primary site (ICD code)											
		C00–C96	C16	C18	C19	C20	C34	C44	C50	C53	C54	C61	Drugo Other	D06**
Slovenija, skupaj Slovenia, total	M	700,9	30,0	54,5	8,3	33,9	78,5	105,2	1,4	–	–	151,3	263,1	–
	Ž	438,7	13,7	31,0	4,1	13,2	28,9	74,5	92,9	12,6	23,2	–	176,0	91,8
Pomurska	M	891,8	25,0	41,5	11,6	52,3	91,1	114,2	0,0	–	–	303,8	268,6	–
	Ž	346,6	13,8	21,9	2,9	7,6	21,1	61,5	51,2	18,4	26,1	–	136,8	69,4
Podravska	M	629,6	40,6	51,4	8,0	37,7	66,8	74,2	2,0	–	–	131,2	236,5	–
	Ž	400,8	15,3	30,9	5,2	23,7	22,0	48,6	99,5	15,2	29,7	–	133,8	107,3
Koroška	M	602,1	33,3	46,8	7,2	27,6	97,6	130,5	0,0	–	–	96,9	173,9	–
	Ž	442,0	20,7	29,1	7,6	23,4	42,7	89,2	73,4	7,5	16,1	–	151,0	115,9
Savinjska	M	600,5	36,9	53,9	8,4	36,7	70,0	98,6	1,7	–	–	97,2	218,0	–
	Ž	431,3	17,7	26,7	3,2	12,9	25,7	80,7	77,7	11,5	25,7	–	165,2	103,1
Zasavska	M	682,7	39,4	42,0	18,6	36,7	122,2	77,2	0,0	–	–	78,2	301,2	–
	Ž	414,3	24,9	23,7	10,8	17,0	39,9	37,8	71,8	10,8	16,6	–	212,7	86,9
Spodnjeposavska	M	633,6	18,9	66,3	8,2	31,4	67,3	86,9	5,3	–	–	152,0	219,4	–
	Ž	423,4	9,3	26,5	3,2	4,1	35,9	69,6	92,6	24,9	25,0	–	164,4	78,7
Jugovzhodna Slovenija	M	788,2	24,2	56,1	9,2	34,3	98,5	123,4	0,0	–	–	182,2	284,1	–
	Ž	430,8	15,3	20,9	8,6	8,4	31,0	107,9	79,6	11,8	21,3	–	154,8	66,8
Osrednjeslovenska	M	801,0	26,3	56,5	9,0	33,4	83,9	128,9	1,3	–	–	180,3	313,0	–
	Ž	489,8	11,3	37,6	3,8	13,1	29,8	90,4	111,5	11,5	21,4	–	211,1	86,2
Gorenjska	M	711,5	27,9	64,9	3,2	36,6	84,0	92,1	3,0	–	–	159,1	273,4	–
	Ž	459,6	9,3	32,6	2,3	9,4	37,1	75,2	94,7	12,1	15,3	–	210,0	81,8
Notranjsko-kraška	M	554,7	10,4	48,9	8,6	29,7	54,7	65,9	3,7	–	–	104,2	270,5	–
	Ž	406,3	16,2	15,1	0,0	10,9	22,9	37,7	111,1	7,6	19,9	–	179,8	110,7
Goriška	M	580,0	20,3	52,9	9,2	13,4	56,1	89,0	0,0	–	–	136,7	223,5	–
	Ž	412,9	9,6	39,4	3,8	7,5	26,8	43,2	85,5	8,0	29,4	–	185,4	68,7
Obalno-kraška	M	669,6	33,3	53,1	8,4	19,8	73,2	142,4	0,0	–	–	93,5	273,5	–
	Ž	471,7	13,6	32,7	1,4	8,9	31,6	94,8	103,3	13,1	23,6	–	168,4	134,9

Opis šifer MKB/Description of the ICD code

C16 Želodec / Stomach
C18 Debelo črevo / Colon
C19 Rektosigmoidna zveza / Rectosigmoid junction
C20 Rektum / Rectum
C34 Sapnica in pljuča / Bronchus and lung
C44 Koža, razen melanoma / Skin, non-melanoma
C50 Dojka / Breast
C53 Maternični vrat / Cervix uteri
C54 Maternično telo / Corpus uteri
C61 Prostata / Prostate
D06 Maternični vrat, in situ (CIN III) / Cervix uteri, in situ (CIN III)

* Standard – prebivalstvo Slovenije po popisu 2002

* Standard – population of Slovenia according to census 2002

** Neupoštevano v skupnem številu: D06 – maternični vrat, in situ (CIN III)

** Not included in All sites: D06 – Cervix uteri, in situ (CIN III)

Tabela 7: Incidenca histološko (H) in citološko (C) potrjenih primerov raka po histološki vrsti in lokaciji, Slovenija 2011.

Table 7: Incidence of histologically (H) and cytologically (C) confirmed cancer cases by histological type and by site, Slovenia 2011.

Histološka vrsta Histologic type	Skupaj All sites		Primarna lokacija (šifra MKB) Primary site (ICD code)																			
	C00–C96		C00		C01		C02		C03		C04		C05		C06		C07		C08		C09	
	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C
Vse vrste/All types	11534	604	28	1	11	0	24	1	7	0	30	0	20	1	17	0	12	0	3	0	64	0
Small cell carcinoma	154	46	–	–	–	–	–	–	–	–	–	–	–	–	–	–	1	–	–	–	–	–
Non-small cell carcinoma	36	33	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Squamous cell carcinoma	1315	50	28	–	11	–	23	–	7	–	30	–	16	–	15	–	1	–	1	–	64	–
Basal cell carcinoma	1649	16	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Transitional cell carcinoma	304	3	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Adenocarcinoma	6138	176	–	–	–	–	–	–	–	–	–	–	3	–	–	–	3	–	1	–	–	–
Other specified carcinomas	118	14	–	–	–	–	1	–	–	–	–	–	–	–	2	–	5	–	1	–	–	–
Carcinoma, unspecified	80	154	–	1	–	–	–	1	–	–	–	–	1	1	–	–	–	–	–	–	–	–
Malignant thymoma	6	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant paraganglioma/pheochromocytoma	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant melanoma	515	4	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Fibrosarcoma	5	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Fibrohistiocytic sarcoma	7	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Liposarcoma	18	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Leiomyosarcoma	18	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Rhabdomyosarcoma	4	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Synovial sarcoma	5	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Angiosarcoma	3	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Kaposi sarcoma	3	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Osteosarcoma	6	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Chondrosarcoma	5	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Ewing sarcoma/PNET	4	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other specified sarcomas	6	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Sarcoma, unspecified	16	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant complex mixed and stromal tumors	55	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	2	–	–	–	–	–
Malignat fibroepithelial tumors	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant mesothelioma	35	3	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant gonadal stromal tumors	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Dysgerminoma and seminoma	67	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other malignant germ cell tumors	34	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant trophoblastic tumors	8	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant gliomas	126	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant neuroepithelial tumors	3	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant meningioma	0	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant nerve sheath tumors	6	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Non Hodgkin lymphoma	314	32	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Hodgkin lymphoma	40	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Plasma cell tumors	106	7	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Chronic lymphoid leukemia	73	23	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Leukemia except chronic lymphoid	118	22	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other lymphoreticular neoplasms	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Chronic myeloproliferative diseases	80	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Myelodysplastic syndromes	43	11	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other specified malignant tumors	0	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant tumor, unspecified	3	6	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–

Nadaljevanje —>
Continued —>

Tabela 7: Nadaljevanje.
Table 7: Continued.

Histološka vrsta Histologic type	Skupaj All sites		Primarna lokacija (šifra MKB) Primary site (ICD code)																			
	C00–C96		C10		C11		C12		C13		C14		C15		C16		C17		C18		C19	
	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C
Vse vrste/All types	11534	604	43	1	11	0	21	0	19	1	0	0	78	4	473	7	33	0	924	6	136	1
Small cell carcinoma	154	46	–	–	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Non-small cell carcinoma	36	33	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Squamous cell carcinoma	1315	50	42	–	5	–	19	–	18	–	–	–	64	–	2	–	–	–	–	–	–	–
Basal cell carcinoma	1649	16	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Transitional cell carcinoma	304	3	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Adenocarcinoma	6138	176	1	–	2	–	1	–	1	–	–	–	11	–	440	3	23	–	907	3	133	1
Other specified carcinomas	118	14	–	–	–	–	1	–	–	–	–	–	–	–	1	–	–	–	5	–	1	–
Carcinoma, unspecified	80	154	–	1	2	–	–	–	–	1	–	–	2	3	8	4	–	–	11	3	1	–
Malignant thymoma	6	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant paraganglioma/pheochromocytoma	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant melanoma	515	4	–	–	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	1	–
Fibrosarcoma	5	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Fibrohistiocytic sarcoma	7	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Liposarcoma	18	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Leiomyosarcoma	18	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	1	–	–	–	–	–
Rhabdomyosarcoma	4	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Synovial sarcoma	5	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Angiosarcoma	3	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Kaposi sarcoma	3	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Osteosarcoma	6	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Chondrosarcoma	5	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Ewing sarcoma/PNET	4	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other specified sarcomas	6	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Sarcoma, unspecified	16	1	–	–	–	–	–	–	–	–	–	–	–	–	1	–	–	–	–	–	–	–
Malignant complex mixed and stromal tumors	55	0	–	–	–	–	–	–	–	–	–	–	1	–	21	–	9	–	1	–	–	–
Malignat fibroepithelial tumors	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant mesothelioma	35	3	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant gonadal stromal tumors	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Dysgerminoma and seminoma	67	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other malignant germ cell tumors	34	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant trophoblastic tumors	8	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant gliomas	126	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant neuroepithelial tumors	3	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant meningioma	0	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant nerve sheath tumors	6	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Non Hodgkin lymphoma	314	32	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Hodgkin lymphoma	40	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Plasma cell tumors	106	7	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Chronic lymphoid leukemia	73	23	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Leukemia except chronic lymphoid	118	22	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other lymphoreticular neoplasms	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Chronic myeloproliferative diseases	80	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Myelodysplastic syndromes	43	11	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other specified malignant tumors	0	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant tumor, unspecified	3	6	–	–	–	–	–	–	–	–	–	–	–	1	–	–	–	–	–	–	–	–

Nadaljevanje —>
Continued —>

Tabela 7: Nadaljevanje.
Table 7: Continued.

Histološka vrsta Histologic type	Skupaj All sites		Primarna lokacija (šifra MKB) Primary site (ICD code)																			
	C00–C96		C20		C21		C22		C23		C24		C25		C26		C30		C31		C32	
	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C
Vse vrste/All types	11534	604	504	1	16	0	67	16	28	3	56	6	150	35	1	2	12	0	9	0	108	0
Small cell carcinoma	154	46	2	–	–	–	–	–	–	–	–	–	2	–	–	–	–	–	–	–	–	–
Non-small cell carcinoma	36	33	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Squamous cell carcinoma	1315	50	2	–	10	–	–	–	–	–	–	–	–	–	–	–	3	–	4	–	102	–
Basal cell carcinoma	1649	16	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Transitional cell carcinoma	304	3	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Adenocarcinoma	6138	176	491	1	5	–	66	14	26	2	55	4	137	23	–	1	3	–	2	–	–	–
Other specified carcinomas	118	14	1	–	–	–	1	–	2	–	1	–	3	1	–	–	2	–	2	–	1	–
Carcinoma, unspecified	80	154	7	–	–	–	–	1	–	1	–	2	8	11	–	1	–	–	1	–	3	–
Malignant thymoma	6	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant paraganglioma/pheochromocytoma	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant melanoma	515	4	1	–	1	–	–	–	–	–	–	–	–	–	–	–	2	–	–	–	–	–
Fibrosarcoma	5	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Fibrohistiocytic sarcoma	7	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Liposarcoma	18	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Leiomyosarcoma	18	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Rhabdomyosarcoma	4	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Synovial sarcoma	5	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Angiosarcoma	3	1	–	–	–	–	–	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Kaposi sarcoma	3	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Osteosarcoma	6	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Chondrosarcoma	5	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	2	–
Ewing sarcoma/PNET	4	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other specified sarcomas	6	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Sarcoma, unspecified	16	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant complex mixed and stromal tumors	55	0	–	–	–	–	–	–	–	–	–	–	–	–	1	–	–	–	–	–	–	–
Malignat fibroepithelial tumors	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant mesothelioma	35	3	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant gonadal stromal tumors	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Dysgerminoma and seminoma	67	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other malignant germ cell tumors	34	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant trophoblastic tumors	8	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant gliomas	126	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant neuroepithelial tumors	3	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	1	–	–	–	–	–
Malignant meningioma	0	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant nerve sheath tumors	6	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	1	–	–	–	–	–
Non Hodgkin lymphoma	314	32	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Hodgkin lymphoma	40	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Plasma cell tumors	106	7	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Chronic lymphoid leukemia	73	23	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Leukemia except chronic lymphoid	118	22	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other lymphoreticular neoplasms	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Chronic myeloproliferative diseases	80	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Myelodysplastic syndromes	43	11	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other specified malignant tumors	0	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant tumor, unspecified	3	6	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–

Nadaljevanje —>
Continued —>

Tabela 7: Nadaljevanje.
Table 7: Continued.

Histološka vrsta Histologic type	Skupaj All sites		Primarna lokacija (šifra MKB) Primary site (ICD code)																			
	C00–C96		C33		C34		C37		C38		C39		C40		C41		C43		C44		C45	
	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C
Vse vrste/All types	11534	604	5	0	904	202	8	0	1	0	0	0	10	0	4	0	480	1	2052	33	35	3
Small cell carcinoma	154	46	–	–	140	42	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Non-small cell carcinoma	36	33	–	–	36	31	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Squamous cell carcinoma	1315	50	4	–	295	37	1	–	–	–	–	–	–	–	–	–	–	–	369	10	–	–
Basal cell carcinoma	1649	16	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	1645	16	–	–
Transitional cell carcinoma	304	3	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Adenocarcinoma	6138	176	–	–	371	67	1	–	–	–	–	–	–	–	–	–	–	–	20	1	–	–
Other specified carcinomas	118	14	1	–	55	7	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Carcinoma, unspecified	80	154	–	–	3	16	–	–	–	–	–	–	–	–	–	–	–	–	9	6	–	–
Malignant thymoma	6	0	–	–	–	–	6	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant paraganglioma/pheochromocytoma	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant melanoma	515	4	–	–	–	–	–	–	–	–	–	–	–	–	–	–	480	1	–	–	–	–
Fibrosarcoma	5	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Fibrohistiocytic sarcoma	7	0	–	–	–	–	–	–	–	–	–	–	1	–	–	–	–	–	6	–	–	–
Liposarcoma	18	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Leiomyosarcoma	18	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	1	–	–	–
Rhabdomyosarcoma	4	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Synovial sarcoma	5	0	–	–	1	–	–	–	1	–	–	–	–	–	–	–	–	–	–	–	–	–
Angiosarcoma	3	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Kaposi sarcoma	3	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Osteosarcoma	6	0	–	–	–	–	–	–	–	–	–	–	5	–	1	–	–	–	–	–	–	–
Chondrosarcoma	5	0	–	–	–	–	–	–	–	–	–	–	2	–	1	–	–	–	–	–	–	–
Ewing sarcoma/PNET	4	0	–	–	1	–	–	–	–	–	–	–	1	–	1	–	–	–	–	–	–	–
Other specified sarcomas	6	0	–	–	–	–	–	–	–	–	–	–	1	–	–	–	–	–	–	–	–	–
Sarcoma, unspecified	16	1	–	–	–	–	–	–	–	–	–	–	–	–	1	–	–	–	1	–	–	–
Malignant complex mixed and stromal tumors	55	0	–	–	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignat fibroepithelial tumors	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant mesothelioma	35	3	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	35	3
Malignant gonadal stromal tumors	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Dysgerminoma and seminoma	67	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other malignant germ cell tumors	34	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant trophoblastic tumors	8	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant gliomas	126	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant neuroepithelial tumors	3	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant meningioma	0	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant nerve sheath tumors	6	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Non Hodgkin lymphoma	314	32	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Hodgkin lymphoma	40	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Plasma cell tumors	106	7	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Chronic lymphoid leukemia	73	23	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Leukemia except chronic lymphoid	118	22	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other lymphoreticular neoplasms	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Chronic myeloproliferative diseases	80	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Myelodysplastic syndromes	43	11	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other specified malignant tumors	0	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant tumor, unspecified	3	6	–	–	1	2	–	–	–	–	–	–	–	–	–	–	–	–	1	–	–	–

Nadaljevanje —>
Continued —>

Tabela 7: Nadaljevanje.
Table 7: Continued.

Histološka vrsta Histologic type	Skupaj All sites		Primarna lokacija (šifra MKB) Primary site (ICD code)																			
	C00–C96		C46		C47		C48		C49		C50		C51		C52		C53		C54		C55	
	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C
Vse vrste/All types	11534	604	3	0	5	0	26	1	37	1	1043	91	41	0	9	0	142	0	299	2	10	1
Small cell carcinoma	154	46	–	–	–	–	–	–	–	–	–	–	–	–	–	–	1	–	–	–	–	–
Non-small cell carcinoma	36	33	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Squamous cell carcinoma	1315	50	–	–	–	–	–	–	–	–	–	–	35	–	6	–	110	–	–	–	–	–
Basal cell carcinoma	1649	16	–	–	–	–	–	–	–	–	–	–	2	–	–	–	2	–	–	–	–	–
Transitional cell carcinoma	304	3	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Adenocarcinoma	6138	176	–	–	–	–	11	1	–	–	1034	12	1	–	1	–	26	–	276	2	–	–
Other specified carcinomas	118	14	–	–	–	–	–	–	–	–	5	–	–	–	–	–	2	–	14	–	–	–
Carcinoma, unspecified	80	154	–	–	–	–	–	–	–	–	2	79	–	–	1	–	–	–	1	–	–	–
Malignant thymoma	6	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant paraganglioma/pheochromocytoma	2	0	–	–	–	–	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant melanoma	515	4	–	–	–	–	–	–	–	–	–	–	3	–	–	–	1	–	–	–	–	–
Fibrosarcoma	5	0	–	–	–	–	–	–	4	–	–	–	–	–	–	–	–	–	–	–	–	–
Fibrohistiocytic sarcoma	7	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Liposarcoma	18	0	–	–	–	–	8	–	7	–	–	–	–	–	–	–	–	–	–	–	–	–
Leiomyosarcoma	18	0	–	–	–	–	3	–	7	–	–	–	–	–	–	–	–	–	–	–	6	–
Rhabdomyosarcoma	4	0	–	–	–	–	–	–	2	–	–	–	–	–	–	–	–	–	–	–	1	–
Synovial sarcoma	5	0	–	–	–	–	–	–	3	–	–	–	–	–	–	–	–	–	–	–	–	–
Angiosarcoma	3	1	–	–	–	–	–	–	2	–	–	–	–	–	–	–	–	–	–	–	–	–
Kaposi sarcoma	3	0	3	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Osteosarcoma	6	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Chondrosarcoma	5	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Ewing sarcoma/PNET	4	0	–	–	–	–	–	–	1	–	–	–	–	–	–	–	–	–	–	–	–	–
Other specified sarcomas	6	0	–	–	–	–	–	–	1	–	–	–	–	–	–	–	–	–	–	–	1	–
Sarcoma, unspecified	16	1	–	–	–	–	1	–	10	1	–	–	–	–	–	–	–	–	–	–	–	–
Malignant complex mixed and stromal tumors	55	0	–	–	–	–	1	–	–	–	–	–	–	–	–	–	–	–	8	–	2	–
Malignat fibroepithelial tumors	2	0	–	–	–	–	–	–	–	–	2	–	–	–	–	–	–	–	–	–	–	–
Malignant mesothelioma	35	3	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant gonadal stromal tumors	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Dysgerminoma and seminoma	67	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other malignant germ cell tumors	34	0	–	–	–	–	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant trophoblastic tumors	8	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant gliomas	126	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant neuroepithelial tumors	3	0	–	–	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant meningioma	0	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant nerve sheath tumors	6	0	–	–	4	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Non Hodgkin lymphoma	314	32	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Hodgkin lymphoma	40	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Plasma cell tumors	106	7	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Chronic lymphoid leukemia	73	23	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Leukemia except chronic lymphoid	118	22	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other lymphoreticular neoplasms	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Chronic myeloproliferative diseases	80	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Myelodysplastic syndromes	43	11	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other specified malignant tumors	0	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant tumor, unspecified	3	6	–	–	–	–	–	–	–	–	–	–	–	–	1	–	–	–	–	–	–	1

Nadaljevanje —>
Continued —>

Tabela 7: Nadaljevanje.
Table 7: Continued.

Histološka vrsta Histologic type	Skupaj All sites		Primarna lokacija (šifra MKB) Primary site (ICD code)																			
	C00–C96		C56		C57		C58		C60		C61		C62		C63		C64		C65		C66	
	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C
Vse vrste/All types	11534	604	136	8	7	1	0	0	9	0	1485	1	106	0	1	0	286	10	15	1	14	0
Small cell carcinoma	154	46	–	–	–	–	–	–	–	–	–	1	–	–	–	–	–	–	–	–	–	–
Non-small cell carcinoma	36	33	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Squamous cell carcinoma	1315	50	–	–	–	–	–	–	9	–	–	–	–	–	–	–	–	–	–	–	–	–
Basal cell carcinoma	1649	16	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Transitional cell carcinoma	304	3	1	–	–	–	–	–	–	–	3	–	–	–	–	–	–	–	15	1	14	–
Adenocarcinoma	6138	176	119	2	7	1	–	–	–	–	1479	–	–	–	–	–	279	9	–	–	–	–
Other specified carcinomas	118	14	4	–	–	–	–	–	–	–	1	–	–	–	–	–	–	–	–	–	–	–
Carcinoma, unspecified	80	154	–	5	–	–	–	–	–	–	2	–	–	–	–	–	5	1	–	–	–	–
Malignant thymoma	6	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant paraganglioma/pheochromocytoma	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant melanoma	515	4	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Fibrosarcoma	5	0	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Fibrohistiocytic sarcoma	7	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Liposarcoma	18	0	–	–	–	–	–	–	–	–	–	–	–	–	1	–	–	–	–	–	–	–
Leiomyosarcoma	18	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Rhabdomyosarcoma	4	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Synovial sarcoma	5	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Angiosarcoma	3	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Kaposi sarcoma	3	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Osteosarcoma	6	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Chondrosarcoma	5	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Ewing sarcoma/PNET	4	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other specified sarcomas	6	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Sarcoma, unspecified	16	1	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant complex mixed and stromal tumors	55	0	6	–	–	–	–	–	–	–	–	–	–	–	–	–	2	–	–	–	–	–
Malignat fibroepithelial tumors	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant mesothelioma	35	3	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant gonadal stromal tumors	2	0	2	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Dysgerminoma and seminoma	67	0	2	–	–	–	–	–	–	–	–	–	65	–	–	–	–	–	–	–	–	–
Other malignant germ cell tumors	34	0	–	–	–	–	–	–	–	–	–	–	33	–	–	–	–	–	–	–	–	–
Malignant trophoblastic tumors	8	0	–	–	–	–	–	–	–	–	–	–	8	–	–	–	–	–	–	–	–	–
Malignant gliomas	126	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant neuroepithelial tumors	3	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant meningioma	0	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant nerve sheath tumors	6	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Non Hodgkin lymphoma	314	32	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Hodgkin lymphoma	40	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Plasma cell tumors	106	7	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Chronic lymphoid leukemia	73	23	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Leukemia except chronic lymphoid	118	22	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other lymphoreticular neoplasms	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Chronic myeloproliferative diseases	80	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Myelodysplastic syndromes	43	11	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other specified malignant tumors	0	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant tumor, unspecified	3	6	–	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–

Nadaljevanje —>
Continued —>

Tabela 7: Nadaljevanje.
Table 7: Continued.

Histološka vrsta Histologic type	Skupaj All sites		Primarna lokacija (šifra MKB) Primary site (ICD code)																			
	C00–C96		C67		C68		C69		C70		C71		C72		C73		C74		C75		C76	
	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C
Vse vrste/All types	11534	604	281	2	2	0	15	0	3	0	123	0	4	0	134	9	4	0	0	0	8	7
Small cell carcinoma	154	46	4	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Non-small cell carcinoma	36	33	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Squamous cell carcinoma	1315	50	2	–	–	–	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Basal cell carcinoma	1649	16	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Transitional cell carcinoma	304	3	268	2	2	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Adenocarcinoma	6138	176	4	–	–	–	–	–	–	–	–	–	–	–	131	3	3	–	–	–	4	5
Other specified carcinomas	118	14	–	–	–	–	–	–	–	–	–	–	–	–	3	5	–	–	–	–	–	–
Carcinoma, unspecified	80	154	2	–	–	–	–	–	–	–	–	–	–	–	–	1	–	–	–	–	2	2
Malignant thymoma	6	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant paraganglioma/pheochromocytoma	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	1	–	–	–	–	–
Malignant melanoma	515	4	–	–	–	–	13	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Fibrosarcoma	5	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Fibrohistiocytic sarcoma	7	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Liposarcoma	18	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	2	–
Leiomyosarcoma	18	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Rhabdomyosarcoma	4	0	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Synovial sarcoma	5	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Angiosarcoma	3	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Kaposi sarcoma	3	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Osteosarcoma	6	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Chondrosarcoma	5	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Ewing sarcoma/PNET	4	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other specified sarcomas	6	0	–	–	–	–	–	–	3	–	–	–	–	–	–	–	–	–	–	–	–	–
Sarcoma, unspecified	16	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant complex mixed and stromal tumors	55	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignat fibroepithelial tumors	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant mesothelioma	35	3	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant gonadal stromal tumors	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Dysgerminoma and seminoma	67	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other malignant germ cell tumors	34	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant trophoblastic tumors	8	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant gliomas	126	0	–	–	–	–	–	–	–	–	123	–	3	–	–	–	–	–	–	–	–	–
Malignant neuroepithelial tumors	3	0	–	–	–	–	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant meningioma	0	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant nerve sheath tumors	6	0	–	–	–	–	–	–	–	–	–	–	1	–	–	–	–	–	–	–	–	–
Non Hodgkin lymphoma	314	32	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Hodgkin lymphoma	40	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Plasma cell tumors	106	7	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Chronic lymphoid leukemia	73	23	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Leukemia except chronic lymphoid	118	22	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other lymphoreticular neoplasms	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Chronic myeloproliferative diseases	80	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Myelodysplastic syndromes	43	11	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other specified malignant tumors	0	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant tumor, unspecified	3	6	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–

Nadaljevanje —>
Continued —>

Tabela 7: Nadaljevanje.
Table 7: Continued.

Histološka vrsta Histologic type	Skupaj All sites		Primarna lokacija (šifra MKB) Primary site (ICD code)																			
	C00–C96		C77		C78		C79		C80		C81		C82		C83		C84		C85		C88	
	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C
Vse vrste/All types	11534	604	23	9	26	20	9	2	48	16	40	1	77	8	192	18	28	1	17	5	0	0
Small cell carcinoma	154	46	–	–	2	1	–	–	1	2	–	–	–	–	–	–	–	–	–	–	–	–
Non-small cell carcinoma	36	33	–	1	–	–	–	–	–	1	–	–	–	–	–	–	–	–	–	–	–	–
Squamous cell carcinoma	1315	50	12	2	1	–	–	–	3	1	–	–	–	–	–	–	–	–	–	–	–	–
Basal cell carcinoma	1649	16	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Transitional cell carcinoma	304	3	–	–	–	–	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Adenocarcinoma	6138	176	8	4	16	9	5	–	31	8	–	–	–	–	–	–	–	–	–	–	–	–
Other specified carcinomas	118	14	1	1	–	–	–	–	2	–	–	–	–	–	–	–	–	–	–	–	–	–
Carcinoma, unspecified	80	154	2	1	4	10	–	1	3	1	–	–	–	–	–	–	–	–	–	–	–	–
Malignant thymoma	6	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant paraganglioma/pheochromocytoma	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant melanoma	515	4	–	–	3	–	3	–	6	3	–	–	–	–	–	–	–	–	–	–	–	–
Fibrosarcoma	5	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Fibrohistiocytic sarcoma	7	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Liposarcoma	18	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Leiomyosarcoma	18	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Rhabdomyosarcoma	4	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Synovial sarcoma	5	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Angiosarcoma	3	1	–	–	–	–	–	–	1	–	–	–	–	–	–	–	–	–	–	–	–	–
Kaposi sarcoma	3	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Osteosarcoma	6	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Chondrosarcoma	5	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Ewing sarcoma/PNET	4	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other specified sarcomas	6	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Sarcoma, unspecified	16	1	–	–	–	–	–	–	1	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant complex mixed and stromal tumors	55	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignat fibroepithelial tumors	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant mesothelioma	35	3	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant gonadal stromal tumors	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Dysgerminoma and seminoma	67	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other malignant germ cell tumors	34	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant trophoblastic tumors	8	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant gliomas	126	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant neuroepithelial tumors	3	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant meningioma	0	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant nerve sheath tumors	6	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Non Hodgkin lymphoma	314	32	–	–	–	–	–	–	–	–	–	–	77	8	192	18	28	1	17	5	–	–
Hodgkin lymphoma	40	1	–	–	–	–	–	–	–	–	40	1	–	–	–	–	–	–	–	–	–	–
Plasma cell tumors	106	7	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Chronic lymphoid leukemia	73	23	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Leukemia except chronic lymphoid	118	22	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other lymphoreticular neoplasms	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Chronic myeloproliferative diseases	80	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Myelodysplastic syndromes	43	11	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other specified malignant tumors	0	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant tumor, unspecified	3	6	–	–	–	–	–	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–

Nadaljevanje —>
Continued —>

Tabela 7: Nadaljevanje.
Table 7: Continued.

Histološka vrsta Histologic type	Skupaj All sites		Primarna lokacija (šifra MKB) Primary site (ICD code)													
	C00–C96		C90		C91		C92		C93		C94		C95		C96	
	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C
Vse vrste/All types	11534	604	106	7	94	27	87	14	5	0	20	0	4	4	106	12
Small cell carcinoma	154	46	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Non-small cell carcinoma	36	33	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Squamous cell carcinoma	1315	50	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Basal cell carcinoma	1649	16	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Transitional cell carcinoma	304	3	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Adenocarcinoma	6138	176	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other specified carcinomas	118	14	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Carcinoma, unspecified	80	154	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant thymoma	6	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant paraganglioma/pheochromocytoma	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant melanoma	515	4	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Fibrosarcoma	5	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Fibrohistiocytic sarcoma	7	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Liposarcoma	18	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Leiomyosarcoma	18	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Rhabdomyosarcoma	4	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Synovial sarcoma	5	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Angiosarcoma	3	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Kaposi sarcoma	3	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Osteosarcoma	6	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Chondrosarcoma	5	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Ewing sarcoma/PNET	4	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other specified sarcomas	6	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Sarcoma, unspecified	16	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant complex mixed and stromal tumors	55	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignat fibroepithelial tumors	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant mesothelioma	35	3	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant gonadal stromal tumors	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Dysgerminoma and seminoma	67	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other malignant germ cell tumors	34	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant trophoblastic tumors	8	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant gliomas	126	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant neuroepithelial tumors	3	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant meningioma	0	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant nerve sheath tumors	6	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Non Hodgkin lymphoma	314	32	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Hodgkin lymphoma	40	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Plasma cell tumors	106	7	106	7	–	–	–	–	–	–	–	–	–	–	–	–
Chronic lymphoid leukemia	73	23	–	–	73	23	–	–	–	–	–	–	–	–	–	–
Leukemia except chronic lymphoid	118	22	–	–	21	4	87	14	5	–	1	–	4	4	–	–
Other lymphoreticular neoplasms	2	0	–	–	–	–	–	–	–	–	–	–	–	–	2	–
Chronic myeloproliferative diseases	80	1	–	–	–	–	–	–	–	–	19	–	–	–	61	1
Myelodysplastic syndromes	43	11	–	–	–	–	–	–	–	–	–	–	–	–	43	11
Other specified malignant tumors	0	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant tumor, unspecified	3	6	–	–	–	–	–	–	–	–	–	–	–	–	–	–

Tabela 8: Incidenca raka (brez primerov registriranih samo iz zdravniških poročil o vzroku smrti) po stadiju, lokaciji in spolu, Slovenija 2011.

Table 8: Cancer incidence (without cases registered from death certificates only) by stage, by site and by sex, Slovenia 2011.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Število novih primerov Number of new cases	Stadij							
				Omejen		Razširjen		Razsejan		Neznan	
				Število	%*	Število	%*	Število	%*	Število	%*
				Stage							
				Localized		Regional		Distant		Unknown	
				Number	%*	Number	%*	Number	%*	Number	%*
C00 – C80	Vse lokacije All sites	M+Ž	12013	6329	52,7	3323	27,7	2205	18,4	156	1,3
		M	6695	3523	52,6	1842	27,5	1231	18,4	99	1,5
		Ž	5318	2806	52,8	1481	27,8	974	18,3	57	1,1
C00	Ustnica Lip	M	20	19	95,0	1	5,0	0	0	0	0
		Ž	9	8	–	1	–	0	–	0	–
C01	Baza jezika Base of tongue	M	10	0	–	8	–	2	–	0	–
		Ž	1	0	–	1	–	0	–	0	–
C02	Jezik, drugi deli Tongue, other & unspecified parts	M	22	13	59,1	9	40,9	0	0	0	0
		Ž	3	0	–	3	–	0	–	0	–
C03	Dlesen Gum	M	2	0	–	2	–	0	–	0	–
		Ž	5	3	–	2	–	0	–	0	–
C04	Ustno dno Floor of mouth	M	22	7	31,8	15	68,2	0	0	0	0
		Ž	8	5	–	3	–	0	–	0	–
C05	Nebo Palate	M	17	5	29,4	12	70,6	0	0	0	0
		Ž	4	2	–	1	–	1	–	0	–
C06	Usta, drugi deli Mouth, other & unspecified parts	M	6	5	–	1	–	0	–	0	–
		Ž	11	4	–	7	–	0	–	0	–
C07	Parotidna žleza Parotid gland	M	6	5	–	1	–	0	–	0	–
		Ž	6	0	–	5	–	1	–	0	–
C08	Druge in neopredeljene velike žleze slinavke Other & unspecified major salivary glands	M	2	1	–	1	–	0	–	0	–
		Ž	1	0	–	0	–	1	–	0	–
C09	Tonzila Tonsil	M	50	5	10,0	44	88,0	1	2,0	0	0
		Ž	14	3	–	11	–	0	–	0	–
C10	Orofarinks Oropharynx	M	39	3	7,7	33	84,6	3	7,7	0	0
		Ž	6	1	–	5	–	0	–	0	–
C11	Nazofarinks Nasopharynx	M	9	0	–	7	–	2	–	0	–
		Ž	3	0	–	2	–	1	–	0	–
C12	Piriformni sinus Pyriform sinus	M	19	1	5,3	17	89,5	1	5,3	0	0
		Ž	2	1	–	1	–	0	–	0	–
C13	Hipofarinks Hypopharynx	M	18	2	11,1	15	83,3	1	5,6	0	0
		Ž	2	0	–	2	–	0	–	0	–
C14	Druga in slabo opredeljena mesta na ustnici, v ustni votlini in farinksu Other and ill-defined sites in the lip, oral cavity and pharynx	M	0	0	–	0	–	0	–	0	–
		Ž	0	0	–	0	–	0	–	0	–
C15	Požiralnik Oesophagus	M	68	7	10,3	31	45,6	30	44,1	0	0
		Ž	18	2	11,1	11	61,1	4	22,2	1	5,6
C16	Želodec Stomach	M	302	67	22,2	107	35,4	121	40,1	7	2,3
		Ž	195	46	23,6	74	37,9	69	35,4	6	3,1
C17	Tanko črevo Small intestine	M	19	8	42,1	3	15,8	8	42,1	0	0
		Ž	14	5	–	5	–	4	–	0	–
C18	Debelo črevo Colon	M	552	133	24,1	302	54,7	105	19,0	12	2,2
		Ž	413	80	19,4	227	55,0	101	24,5	5	1,2
C19	Rektosigmoidna zveza Rectosigmoid junction	M	85	11	12,9	50	58,8	24	28,2	0	0
		Ž	56	9	16,1	30	53,6	14	25,0	3	5,4
C20	Rektum Rectum	M	349	84	24,1	191	54,7	67	19,2	7	2,0
		Ž	169	36	21,3	93	55,0	35	20,7	5	3,0
C21	Anus in analni kanal Anus and anal canal	M	5	1	–	3	–	1	–	0	–
		Ž	11	4	–	7	–	0	–	0	–
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	M	114	66	57,9	14	12,3	31	27,2	3	2,6
		Ž	37	14	37,8	7	18,9	15	40,5	1	2,7
C23	Žolčnik Gallbladder	M	13	4	–	3	–	6	–	0	–
		Ž	39	7	17,9	5	12,8	26	66,7	1	2,6
C24	Drugi in neopredeljeni deli biliarnega trakta Billiary tract, other and unspecified parts	M	58	12	20,7	31	53,4	11	19,0	4	6,9
		Ž	56	19	33,9	26	46,4	11	19,6	0	0
C25	Trebušna slinavka Pancreas	M	178	18	10,1	52	29,2	102	57,3	6	3,4
		Ž	183	25	13,7	64	35,0	88	48,1	6	3,3
C26	Druga in slabo opredeljena mesta v prebavnih organih Other and ill-defined digestive organs	M	3	1	–	0	–	2	–	0	–
		Ž	0	0	–	0	–	0	–	0	–

Nadaljevanje —>
Continued —>

Tabela 8: Nadaljevanje.
Table 8: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Število novih primerov Number of new cases	Stadij							
				Omejen		Razširjen		Razsejan		Neznan	
				Število	%*	Število	%*	Število	%*	Število	%*
				Stage							
				Localized		Regional		Distant		Unknown	
				Number	%*	Number	%*	Number	%*	Number	%*
C30	Nosna votlina in srednje uho	M	7	2	–	5	–	0	–	0	–
	Nasal cavity and middle ear	Ž	5	1	–	4	–	0	–	0	–
C31	Obnosni sinusi	M	5	0	–	4	–	1	–	0	–
	Accessory sinuses	Ž	5	1	–	4	–	0	–	0	–
C32	Grlo	M	98	60	61,2	38	38,8	0	0	0	0
	Larynx	Ž	11	6	–	5	–	0	–	0	–
C33	Sapnik	M	5	1	–	3	–	1	–	0	–
	Trachea	Ž	0	0	–	0	–	0	–	0	–
C34	Sapnica in pljuča	M	818	111	13,6	275	33,6	422	51,6	10	1,2
	Bronchus and lung	Ž	373	61	16,4	108	29,0	203	54,4	1	0,3
C37	Timus	M	4	4	–	0	–	0	–	0	–
	Thymus	Ž	4	2	–	1	–	1	–	0	–
C38	Srce, mediastinum, plevra	M	1	1	–	0	–	0	–	0	–
	Heart, mediastinum, pleura	Ž	0	0	–	0	–	0	–	0	–
C39	Druga in slabo opredeljena mesta v dihalih in prsnih organih	M	0	0	–	0	–	0	–	0	–
	Other and ill-defined sites in the respiratory system and intrathoracic organs	Ž	0	0	–	0	–	0	–	0	–
C40	Kosti, sklepni hrustanec udov	M	3	0	–	2	–	1	–	0	–
	Bone and articular cartilage of limbs	Ž	7	3	–	4	–	0	–	0	–
C41	Kosti, sklepni hrustanec, drugje	M	4	1	–	1	–	2	–	0	–
	Bone and articular cartilage of other and unspecified parts	Ž	0	0	–	0	–	0	–	0	–
C43	Maligni melanom kože	M	248	175	70,6	63	25,4	9	3,6	1	0,4
	Malignant melanoma of skin	Ž	233	190	81,5	40	17,2	2	0,9	1	0,4
C44	Druge maligne neoplazme kože	M	1050	1037	98,8	12	1,1	1	0,1	0	0
	Skin, other malignomas	Ž	1054	1043	99,0	7	0,7	2	0,2	2	0,2
C45	Mezoteliom	M	31	10	32,3	12	38,7	8	25,8	1	3,2
	Mesothelioma	Ž	7	3	–	3	–	1	–	0	–
C46	Kaposijev sarkom	M	3	2	–	1	–	0	–	0	–
	Kaposi's sarcoma	Ž	0	0	–	0	–	0	–	0	–
C47	Periferni živci in avtonomno živčevje	M	2	2	–	0	–	0	–	0	–
	Peripheral nerves and autonomic nervous system	Ž	3	2	–	1	–	0	–	0	–
C48	Peritonej in retroperitonej	M	8	1	–	3	–	4	–	0	–
	Retroperitoneum and peritoneum	Ž	19	2	10,5	6	31,6	11	57,9	0	0
C49	Drugo vezivno in mehko tkivo	M	19	9	47,4	8	42,1	2	10,5	0	0
	Other connective and soft tissue	Ž	19	8	42,1	6	31,6	5	26,3	0	0
C50	Dojka	M	14	6	–	7	–	1	–	0	–
	Breast	Ž	1137	582	51,2	479	42,1	75	6,6	1	0,1
C51	Žensko zunanje spolovilo	M	–	–	–	–	–	–	–	–	–
	Vulva	Ž	41	21	51,2	17	41,5	2	4,9	1	2,4
C52	Nožnica	M	–	–	–	–	–	–	–	–	–
	Vagina	Ž	9	4	–	4	–	0	–	1	–
C53	Maternični vrat	M	–	–	–	–	–	–	–	–	–
	Cervix uteri	Ž	142	78	54,9	51	35,9	12	8,5	1	0,7
C54	Maternično telo	M	–	–	–	–	–	–	–	–	–
	Corpus uteri	Ž	301	225	74,8	59	19,6	13	4,3	4	1,3
C55	Maternica, neopredeljeno	M	–	–	–	–	–	–	–	–	–
	Uterus, unspecified	Ž	11	7	–	0	–	3	–	1	–
C56	Jajčnik	M	–	–	–	–	–	–	–	–	–
	Ovary	Ž	153	24	15,7	15	9,8	112	73,2	2	1,3
C57	Drugi in neopredeljeni ženski spolni organi	M	–	–	–	–	–	–	–	–	–
	Other and unspecified parts of female genital organs	Ž	10	1	–	2	–	7	–	0	–
C58	Posteljica	M	–	–	–	–	–	–	–	–	–
	Placenta	Ž	0	0	–	0	–	0	–	0	–
C60	Penis	M	9	8	–	1	–	0	–	0	–
	Penis	Ž	–	–	–	–	–	–	–	–	–
C61	Prostata	M	1534	1098	71,6	343	22,4	69	4,5	24	1,6
	Prostate	Ž	–	–	–	–	–	–	–	–	–

Nadaljevanje —>
Continued —>

Tabela 8: Nadaljevanje.
Table 8: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Število novih primerov Number of new cases	Stadij							
				Omejen		Razširjen		Razsejan		Neznan	
				Število	%*	Število	%*	Število	%*	Število	%*
				Stage							
				Localized		Regional		Distant		Unknown	
				Number	%*	Number	%*	Number	%*	Number	%*
C62	Modo	M	106	70	66,0	30	28,3	5	4,7	1	0,9
	Testis	Ž	–	–	–	–	–	–	–	–	–
C63	Drugi in neopredeljeni moški spolni organi	M	1	0	–	0	–	1	–	0	–
	Other and unspecified male genital organs	Ž	–	–	–	–	–	–	–	–	–
C64	Ledvica razen meha	M	216	134	62,0	28	13,0	53	24,5	1	0,5
	Kidney, except renal pelvis	Ž	105	69	65,7	19	18,1	17	16,2	0	0
C65	Ledvični meh	M	8	1	–	5	–	2	–	0	–
	Renal pelvis	Ž	8	0	–	7	–	1	–	0	–
C66	Sečevod	M	12	8	–	4	–	0	–	0	–
	Ureter	Ž	3	2	–	1	–	0	–	0	–
C67	Sečni mehur	M	225	187	83,1	30	13,3	8	3,6	0	0
	Bladder	Ž	72	48	66,7	13	18,1	9	12,5	2	2,8
C68	Drugi in neopredeljeni sečni organi	M	1	1	–	0	–	0	–	0	–
	Other and unspecified urinary organs	Ž	1	0	–	1	–	0	–	0	–
C69	Oko in očesni adneksi	M	4	3	–	0	–	0	–	1	–
	Eye and adnexa	Ž	11	8	–	3	–	0	–	0	–
C70	Meninge	M	2	2	–	0	–	0	–	0	–
	Meninges	Ž	1	1	–	0	–	0	–	0	–
C71	Možgani	M	78	78	100	0	0	0	0	0	0
	Brain	Ž	58	58	100	0	0	0	0	0	0
C72	Hrbtni mozeg, možganski živci in drugi deli CŽS	M	3	3	–	0	–	0	–	0	–
	Spinal cord, cranial nerves and other parts of CNS	Ž	2	1	–	1	–	0	–	0	–
C73	Ščitnica	M	45	27	60,0	10	22,2	8	17,8	0	0
	Thyroid gland	Ž	98	80	81,6	15	15,3	3	3,1	0	0
C74	Nadledvična žleza	M	2	2	–	0	–	0	–	0	–
	Adrenal gland	Ž	2	1	–	0	–	1	–	0	–
C75	Druge endokrine žleze in sorodne strukture	M	0	0	–	0	–	0	–	0	–
	Other endocrine glands and related structures	Ž	0	0	–	0	–	0	–	0	–
C76	Druga in slabo opredeljena mesta	M	8	1	–	4	–	3	–	0	–
	Other and ill-defined sites	Ž	26	0	0	12	46,2	14	53,8	0	0
C77	Metastaza in neopredeljena maligna neoplazma bezgavk	M	21	0	0	0	0	0	0	21	100
	Metastasis and unspecified malignant neoplasm of lymph nodes	Ž	12	0	–	0	–	0	–	12	–
C78	Metastaze dihal in prebavil	M	45	0	0	0	0	45	100	0	0
	Metastases of respiratory and digestive organs	Ž	51	0	0	0	0	51	100	0	0
C79	Metastaze, drugje	M	10	0	–	0	–	10	–	0	–
	Metastases of other sites	Ž	16	0	0	0	0	16	100	0	0
C80	Maligna neoplazma brez opredeljenega mesta	M	57	0	0	0	0	57	100	0	0
	Malignant neoplasm without specification of site	Ž	42	0	0	0	0	42	100	0	0

Šifra MKB	Primarna lokacija	Spol Sex	Število primerov Number of new cases	Stadij (Ann–Arbor)							
				I		II		III+IV		Neznan	
				Število	%*	Število	%*	Število	%*	Število	%*
ICD code	Primary site			Stage (Ann–Arbor)							
				I		II		III+IV		Unknown	
				Number	%*	Number	%*	Number	%*	Number	%*
C81	Hodgkinova bolezen	M	14	2	–	3	–	6	–	3	–
	Hodgkin's disease	Ž	27	3	11,1	11	40,7	9	33,3	4	14,8
C82–C85	Ne-Hodgkinov limfom	M	174	31	17,8	23	13,2	95	54,6	25	14,4
	Non-Hodgkin's lymphoma	Ž	172	40	23,3	27	15,7	73	42,4	32	18,6

* Odstotki niso računani, če je število novih primerov manjše od 15
* Percentages are not calculated when number of new cases is less than 15

Tabela 9: Incidenca ne-Hodgkinovih limfomov* po lokaciji, spolu in starosti, Slovenija 2011.

Table 9: Incidence of non-Hodgkin´s malignant lymphomas* by site, by sex and by age, Slovenia 2011.

Šifra MKB–8 ICD–8 code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age															
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+
	Vsi NHL	M+Ž	346	1	2	1	0	1	6	10	6	6	23	27	43	45	31	32	44	68
	All NHL	M	174	0	2	1	0	1	3	5	3	2	9	16	16	26	17	18	24	31
		Ž	172	1	0	0	0	0	3	5	3	4	14	11	27	19	14	14	20	37
141	Jezik	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Tongue	Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
142	Slinavke	M	1	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
	Salivary glands	Ž	3	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	1
143	Dlesni	M	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0
	Gum	Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
145	Usta, drugo	M	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0
	Mouth, other parts	Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
146	Orofarinks	M	3	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	2
	Oropharynx	Ž	9	1	0	0	0	0	0	0	0	0	0	0	1	2	1	0	1	3
147	Epifarinks	M	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Epipharynx	Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
150	Požiralnik	M	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
	Oesophagus	Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
151	Želodec	M	17	0	0	0	0	0	0	1	0	0	2	3	0	4	3	2	0	2
	Stomach	Ž	15	0	0	0	0	0	0	0	0	0	1	1	0	1	1	2	2	7
152	Tanko črevo	M	4	0	1	0	0	0	0	0	0	0	1	0	0	0	0	1	1	0
	Small intestine	Ž	2	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0
153	Debelo črevo	M	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
	Colon	Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
160	Nos, obnosne votline, drugo	M	2	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0
	Nose, sinuses, etc.	Ž	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0
162	Sapnik, sapnica, pljuča	M	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0
	Trachea, bronchus, lung	Ž	2	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0
163	Plevra, mediastinum, drugo	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Pleura, mediastinum, etc.	Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
170	Kosti	M	2	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0
	Bone	Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
171	Mehka tkiva	M	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
	Soft tissues	Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
173	Koža, drugi malignomi	M	5	0	0	0	0	0	0	0	1	0	0	1	1	0	1	0	0	1
	Skin, other malignancies	Ž	13	0	0	0	0	0	1	2	1	1	0	1	2	0	1	1	2	1
184	Nožnica, vulva, drugo	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
	Vagina, vulva, etc.	Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
186	Modo	M	5	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	2	1
	Testis	Ž	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
189	Ledvica, sečevod, drugo	M	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
	Kidney, ureter, etc.	Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
190	Oko	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Eye	Ž	6	0	0	0	0	0	0	0	0	0	1	0	1	1	0	0	1	2
191	Možgani	M	2	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0
	Brain	Ž	3	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	1	0
193	Ščitnica	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Thyroid	Ž	2	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	1
202	Bezgavke	M	125	0	0	1	0	1	3	4	2	2	4	11	14	20	10	13	17	23
	Lymph nodes	Ž	110	0	0	0	0	0	2	3	2	3	11	7	22	11	9	10	10	20

* Vključeni so samo citološko in histološko potrjeni primeri

* All cases included have been verified citologically and histologically

Tabela 10: Incidenca malignih neoplazem limfatičnega tkiva po verziji 2010 MKB-10, po spolu in starosti, Slovenija 2011.

Table 10: Incidence of malignant neoplasms of lymphoid tissue according to version 2010 of ICD-10, by sex and by age, Slovenia 2011.

Šifra MKB–10 ICD–10 code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age															
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+
	Vse vrste All types	M+Ž	621	9	7	4	8	3	9	14	12	12	33	43	66	65	73	61	80	122
		M	320	3	5	3	4	1	4	6	5	6	12	30	28	39	39	36	47	52
		Ž	301	6	2	1	4	2	5	8	7	6	21	13	38	26	34	25	33	70
C81.1	Hodgkinova bolezen, nodularna skleroza	M	3	0	0	0	2	0	0	0	1	0	0	0	0	0	0	0	0	0
	Nodular sclerosis classical Hodgkin lymphoma	Ž	13	0	0	1	2	1	2	2	2	1	1	0	1	0	0	0	0	0
C81.2	Hodgkinova bolezen, mešanocelična oblika	M	8	0	0	0	0	0	1	1	1	0	0	2	1	0	1	1	0	0
	Mixed cellularity classical Hodgkin lymphom	Ž	12	0	0	0	2	0	0	1	2	0	1	1	1	0	2	0	2	0
C81.3	Hodgkinova bolezen, oblika z malo limfocitov	M	1	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
	Lymphocyte depleted classical Hodgkin lymphoma	Ž	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0
C81.4	Hodgkinova bolezen, oblika bogata z limfociti	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Lymphocyte-rich classical Hodgkin lymphoma	Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
C81.9	Hodgkinova bolezen, neopredeljena	M	2	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0
	Hodgkin lymphoma, unspecified	Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C82.0	Folikularni limfom, stopnja I	M	2	0	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0
	Follicular lymphoma grade I	Ž	2	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	1
C82.1	Folikularni limfom, stopnja II	M	13	0	0	0	0	0	0	0	0	0	2	3	3	2	2	0	1	0
	Follicular lymphoma grade II	Ž	14	0	0	0	0	0	0	0	0	1	4	3	3	1	1	1	0	0
C82.2	Folikularni limfom, stopnja III, neopredeljena	M	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
	Follicular lymphoma grade III, unspecified	Ž	3	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	1	0
C82.3	Folikularni limfom, stopnja IIIa	M	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
	Follicular lymphoma grade IIIa	Ž	5	0	0	0	0	0	1	1	0	0	0	1	2	0	0	0	0	0
C82.4	Folikularni limfom, stopnja IIIb	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Follicular lymphoma grade IIIb	Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
C82.9	Folikularni limfom, neopredeljen	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Follicular lymphoma, unspecified	Ž	4	0	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	2
C83.0	Drobnocelični limfom B	M	19	0	0	0	0	0	0	0	0	0	0	1	2	3	1	4	4	4
	Small cell B-cell lymphoma	Ž	10	0	0	0	0	0	0	0	1	0	0	0	2	1	0	1	2	3
C83.1	Limfom plaščnih celic	M	27	0	0	0	0	0	0	0	0	0	1	2	1	7	4	4	4	4
	Mantle cell lymphoma	Ž	4	0	0	0	0	0	0	0	0	1	1	0	0	1	0	0	0	1
C83.3	Difuzni velikocelični limfom B	M	63	0	0	0	0	0	0	0	0	1	4	6	6	7	6	6	11	16
	Diffuse large B-cell lymphoma	Ž	67	0	0	0	0	0	0	0	1	0	3	2	10	10	4	6	12	19
C83.5	Difuzni limfoblastni limfom	M	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Lymphoblastic (diffuse) lymphoma	Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C83.7	Burkittov limfom	M	7	0	2	0	0	0	1	3	1	0	0	0	0	0	0	0	0	0
	Burkitt lymphoma	Ž	3	1	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0
C84.0	Fungoidna mikoza	M	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
	Mycosis fungoides	Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Nadaljevanje —>
Continued —>

Tabela 10: Nadaljevanje.

Table 10: Continued.

Šifra MKB–10 ICD–10 code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age															
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+
C84.4	Periferni limfom T	M	4	0	0	0	0	1	0	0	0	0	0	0	0	1	0	1	1	0
	Peripheral T-cell lymphoma, not classified	Ž	4	0	0	0	0	0	1	0	0	0	0	0	0	0	1	2	0	0
C84.6	Anaplastični velikocelični limfom, ALK pozitiven	M	4	0	0	0	0	0	0	0	0	0	0	0	1	3	0	0	0	0
	Anaplastic large cell lymphoma, ALK-positive	Ž	3	0	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0	1
C84.8	Kožni limfom T, neopredeljen	M	2	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1
	Cutaneous T-cell lymphoma, unspecified	Ž	4	0	0	0	0	0	1	1	0	1	0	1	0	0	0	0	0	0
C85.1	Limfom celic B, neopredeljen	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	B-cell lymphoma, unspecified	Ž	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0
C85.2	Mediastinalni (timični) velikocelični limfom B	M	5	0	0	0	0	0	2	2	0	0	0	0	0	1	0	0	0	0
	Mediastinal (thymic) large B-cell lymphoma	Ž	3	0	0	0	0	0	0	0	0	0	1	0	1	0	0	1	0	0
C85.7	Ne-Hodgkinov limfom, druge vrste	M	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
	Other specified types of non-Hodgkin lymphoma	Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C85.9	Ne-Hodgkinov limfom, neopredeljen	M	9	0	0	0	0	0	0	0	1	0	1	0	0	1	0	1	2	3
	Non-Hodgkin lymphoma, unspecified	Ž	12	0	0	0	0	0	0	1	0	1	1	1	2	0	1	1	1	3
C86.5	Angioimunoblastni limfom T	M	3	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	1
	Angioimmunoblastic T-cell lymphoma	Ž	3	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	0	0
C86.6	Primarne kožne CD30 pozitivne limfoproliferativne bolezni	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Primary cutaneous CD30-positive T-cell proliferations	Ž	1	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0
C88.4	Ekstranodalni limfom marginalne cone (MALTom)	M	11	0	0	0	0	0	0	0	1	0	1	4	1	1	2	0	1	0
	Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue [MALT-lyphoma]	Ž	28	0	0	0	0	0	0	0	1	0	2	1	5	4	3	1	4	7
C90.0	Difuzni plazmocitom	M	47	0	0	0	0	0	0	0	0	3	1	4	4	5	6	5	12	7
	Multiple myeloma	Ž	46	0	0	0	0	0	0	0	0	0	5	0	5	2	14	5	4	11
C90.2	Plazmocitom, ekstramedularni	M	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0
	Extramedullary plasmacytoma	Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0
C90.3	Solitarni plazmocitom	M	8	0	0	0	0	0	0	0	0	0	0	1	2	1	0	1	3	0
	Solitary plasmacytoma	Ž	10	0	0	0	0	0	0	0	0	0	0	0	1	1	0	4	1	3
C91.0	Akutna limfoblastna levkemija	M	10	2	1	2	2	0	0	0	0	0	0	0	1	0	0	2	0	0
	Acute lymphoblastic leukaemia [ALL]	Ž	9	5	2	0	0	1	0	0	0	0	0	0	0	0	0	0	0	1
C91.1	Kronična limfocitna levkemija B	M	61	0	0	0	0	0	0	0	0	1	1	5	4	6	14	8	8	14
	Chronic lymphocytic leukaemia of B-cell type	Ž	35	0	0	0	0	0	0	0	0	1	0	1	2	4	4	2	5	16
C91.4	Dlakastocelična levkemija	M	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0
	Hairy-cell leukaemia	Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
C91.6	Prolimfocitna levkemija T	M	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
	Prolymphocytic leukaemia of T-cell type	Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C91.8	Burkittova levkemija zrelih B-celic	M	3	1	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Mature B-cell leukaemia Burkitt-type	Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Tabela 11a: Število in deleži bolnikov (brez primerov registriranih samo iz zdravniških poročil o vzroku smrti), v Sloveniji zbolelih leta 2011, ki so bili v okviru prvega zdravljenja operirani, zdravljeni s sistemsko terapijo ali obsevani.

Table 11a: Number of patients (without cases registered from death certificates only) diagnosed in Slovenia in 2011, that were treated by surgery, systemic therapy or radiotherapy during their first treatment.

Šifra MKB ICD code	Primarna lokacija Primary site	Število novih primerov Number of new cases	Število kakorkoli zdravljenih* Number of all treated*		Število operiranih Number of treated by surgery		Število zdravljenih s sitemskim zdravljenjem Number of treated sistemic therapy		Število obsevanih Number of treated by radiotherapy	
			Število Number	%**	Število Number	%**	Število Number	%**	Število Number	%**
C00–C96	Vse lokacije All sites	12886	10413	80,8	8081	62,7	3728	28,9	2904	22,5
C00–C14	Usta in žrelo Mouth and pharynx	317	303	95,6	187	59,0	47	14,8	222	70,0
C15	Požiralnik Oesophagus	86	49	57,0	17	19,8	21	24,4	34	39,5
C16	Želodec Stomach	497	293	59,0	254	51,1	124	24,9	79	15,9
C18	Debelo črevo Colon	965	833	86,3	819	84,9	230	23,8	10	–
C19–C20	Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction	659	569	86,3	522	79,2	233	35,4	251	38,1
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	151	41	27,2	14	–	20	13,2	6	–
C23–C24	Žolčnik in žolčevodi Gallbladder and billiary tract	166	64	38,6	61	36,7	7	–	1	–
C25	Trebušna slinavka Pancreas	361	116	32,1	61	16,9	67	18,6	8	–
C32	Grlo Larynx	109	104	95,4	52	47,7	2	–	86	78,9
C33–C34	Sapnik, sapnici in pljuča Trachea, bronchus and lung	1196	863	72,2	220	18,4	459	38,4	561	46,9
C43	Maligni melanom kože Malignant melanoma of skin	481	479	99,6	478	99,4	5	–	29	6,0
C44	Druge maligne neoplazme kože Skin, other malignomas	2104	2039	96,9	1941	92,3	21	1,0	88	4,2
C48–C49	Vezivno in mehko tkivo Connective and soft tissue	65	61	93,8	52	80,0	20	30,8	18	27,7
C50	Dojka Breast	1151	1117	97,0	981	85,2	1025	89,1	621	54,0
C53	Maternični vrat Cervix uteri	142	136	95,8	107	75,4	2	–	67	47,2
C54	Maternično telo Corpus uteri	301	287	95,3	263	87,4	24	8,0	93	30,9
C56	Jajčnik Ovary	153	133	86,9	122	79,7	100	65,4	2	–
C61	Prostata Prostate	1534	1256	81,9	806	52,5	530	34,6	191	12,5
C62	Modo Testis	106	106	100,0	106	100,0	57	53,8	1	–
C64–C65	Ledvica z ledvičnim mehom Kidney with renal pelvis	337	287	85,2	266	78,9	38	11,3	19	5,6
C67	Sečni mehur Bladder	297	274	92,3	272	91,6	39	13,1	16	5,4
C70–C72	Centralni in avtonomni živčni sistem Central and autonomic nervous system	144	123	85,4	114	79,2	59	41,0	95	66,0
C73	Ščitnica Thyroid gland	143	136	95,1	128	89,5	131	91,6	106	74,1
C81	Hodgkinova bolezen Hodgkin's disease	41	37	90,2	1	–	37	90,2	19	46,3
C82–C85	Ne-Hodgkinovi limfomi Non-Hodgkin's lymphoma	346	262	75,7	39	11,3	198	57,2	123	35,5
C90	Difuzni plazmocitom in maligne neoplazme plazmocitov Multiple myeloma and malignant plasma cell neoplasms	113	57	50,4	4	–	49	43,4	26	23,0
C91–C95	Levkemije Leukaemias	255	73	28,6	0	–	71	27,8	9	–

* Število kakorkoli zdravljenih v okviru prvega zdravljenja, ne glede na način zdravljenja (vključno z drugimi zdravljenji, ki ne spadajo pod operacijo, sistemsko zdravljenje ali obsevanje)

* Number of all treated patients regardless of the means of treatment (including other treatments not included into surgery, systemic therapy or radiotherapy)

** Odstotki niso računani, če je število zdravljenih manjše od 15

** Percentages are not calculated for less than 15 cases

Tabela 11b: Število bolnikov (brez primerov registriranih samo iz zdravniških poročil o vzroku smrti), v Sloveniji zbolelih leta 2011, ki so bili v okviru prvega zdravljenja operirani*, po lokaciji raka in bolnici posega.

Table 11b: Number of patients (without cases registered from death certificates only) diagnosed in Slovenia in 2011, that were treated by surgery during their first treatment* by primary site and treatment institution.

Šifra MKB ICD code	Primarna lokacija Primary site	Število novih primerov Number of new cases	Število operiranih Number of treated by surgery	Splošna bolnišnica Brežice	Splošna bolnišnica Celje	Splošna bolnišnica Jesenice	Splošna bolnišnica Izola	Univerzitetni klinični center Ljubljana	Onkološki inštitut Ljubljana	Univerzitetni klinični center Maribor	Splošna bolnišnica Murska Sobota	Splošna bolnišnica Nova Gorica	Splošna bolnišnica Novo mesto	Splošna bolnišnica Ptuj	Splošna bolnišnica Slovenj Gradec	Zasebne ordinacije Private clinics	Ostale ustanove** Other institutions**
C00–C96	Vse lokacije All sites	12886	8081	35	592	283	280	2827	960	1210	295	276	409	52	414	386	62
C00–C14	Usta in žrelo Mouth and pharynx	317	187	0	1	1	0	118	0	59	6	0	0	0	0	1	1
C15	Požiralnik Oesophagus	86	17	0	0	0	0	14	0	3	0	0	0	0	0	0	0
C16	Želodec Stomach	497	254	0	10	5	15	117	2	75	4	3	9	0	5	6	3
C18	Debelo črevo Colon	965	819	11	61	68	53	273	28	109	28	41	41	14	29	47	16
C19–C20	Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction	659	522	7	18	29	24	186	59	94	18	8	24	15	17	22	1
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	151	14	0	0	0	1	7	0	6	0	0	0	0	0	0	0
C23–C24	Žolčnik in žolčevodi Gallbladder and billiary tract	166	61	0	0	0	2	34	0	18	1	2	1	0	1	2	0
C25	Trebušna slinavka Pancreas	361	61	0	0	0	4	38	0	18	0	0	0	0	0	0	1
C32	Grlo Larynx	109	52	0	1	0	0	39	0	11	0	0	1	0	0	0	0
C33–C34	Sapnik, sapnici in pljuča Trachea, bronchus and lung	1196	220	0	0	3	0	130	0	54	0	0	1	0	0	30	2
C43	Maligni melanom kože Malignant melanoma of skin	481	478	6	39	30	29	154	41	45	16	0	21	2	13	78	4
C44	Druge maligne neoplazme kože Skin, other malignomas	2104	1941	7	207	129	50	680	27	174	115	68	200	1	86	193	4
C48–C49	Vezivno in mehko tkivo Connective and soft tissue	65	52	0	4	0	1	10	32	1	0	0	1	1	0	0	2
C50	Dojka Breast	1151	981	0	16	0	42	1	620	200	2	64	1	0	32	1	2
C53	Maternični vrat Cervix uteri	142	107	2	8	3	1	61	3	12	3	1	2	5	3	0	3
C54	Maternično telo Corpus uteri	301	263	0	22	7	7	91	17	53	8	14	13	8	12	0	11
C56	Jajčnik Ovary	153	122	1	15	4	2	47	19	15	0	5	3	4	3	0	4
C61	Prostata Prostate	1534	806	0	133	0	17	226	0	104	67	33	27	0	197	1	1
C62	Modo Testis	106	106	0	11	1	6	55	0	11	5	5	6	0	5	0	1
C64–C65	Ledvica z ledvičnim mehom Kidney with renal pelvis	337	266	0	19	0	7	147	1	48	7	10	21	0	6	0	0
C67	Sečni mehur Bladder	297	272	0	12	0	8	148	0	46	10	18	26	0	3	0	1
C70–C72	Centralni in avtonomni živčni sistem Central and autonomic nervous system	144	114	0	0	0	0	97	0	16	0	0	0	0	0	0	1
C73	Ščitnica Thyroid gland	143	128	0	0	0	2	27	92	4	0	0	0	0	0	3	0
C81	Hodgkinova bolezen Hodgkin's disease	41	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0
C82–C85	Ne-Hodgkinovi limfomi Non-Hodgkin's lymphoma	346	39	0	3	1	3	21	3	4	0	1	0	0	1	2	0
C90	Difuzni plazmocitom in maligne neoplazme plazmocitov Multiple myeloma and malignant plasma cell neoplasms	113	4	0	0	0	0	2	0	1	0	0	1	0	0	0	0
C91–C95	Levkemije Leukaemias	255	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

* Bolniki, ki so bili v okviru prvega zdravljenja operirani več kot enkrat, so vključeni le s prvo operacijo
* Patients that underwent multiple surgery procedures in the course of first treatment were included with the first procedure only

** V posamezni ustanovi so operirali manj kot 30 bolnikov
** Less then 30 patients were treated by surgery in individual institution

Tabela 11c: Število bolnikov (brez primerov registriranih samo iz zdravniških poročil o vzroku smrti), v Sloveniji zbolelih leta 2011, ki so v okviru prvega zdravljenja prejeli sistemsko terapijo*, po lokacijah raka in bolnici posega.

Table 11c: Number of patients (without cases registered from death certificates only) diagnosed in Slovenia in 2011, that were treated by systemic therapy during their first treatment* by primary site and treatment institution.

Šifra MKB ICD code	Primarna lokacija Primary site	Število novih primerov Number of new cases	Število zdravljenih s sistemskim zdravljenjem Number of treated sistemic therapy	Splošna bolnišnica Celje	Bolnišnica Golnik	Splošna bolnišnica Izola	Univerzitetni klinični center Ljubljana	Onkološki inštitut Ljubljana	Univerzitetni klinični center Maribor	Splošna bolnišnica Murska Sobota	Splošna bolnišnica Nova Gorica	Splošna bolnišnica Novo mesto	Splošna bolnišnica Slovenj Gradec	Zasebne ordinacije Private clinics	Ostale ustanove** Other institutions**
C00–C96	Vse lokacije All sites	12886	3728	79	129	21	292	2517	380	61	79	38	48	63	21
C00–C14	Usta in žrelo Mouth and pharynx	317	47	0	0	0	0	47	0	0	0	0	0	0	0
C15	Požiralnik Oesophagus	86	21	0	0	0	0	21	0	0	0	0	0	0	0
C16	Želodec Stomach	497	124	0	0	0	5	115	2	0	0	0	0	0	2
C18	Debelo črevo Colon	965	230	4	0	0	1	202	15	0	0	0	7	0	1
C19–C20	Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction	659	233	2	0	0	0	225	5	0	0	0	1	0	0
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	151	20	0	0	0	15	3	2	0	0	0	0	0	0
C23–C24	Žolčnik in žolčevodi Gallbladder and billiary tract	166	7	0	0	0	1	6	0	0	0	0	0	0	0
C25	Trebušna slinavka Pancreas	361	67	0	0	0	17	47	2	0	0	0	0	0	1
C32	Grlo Larynx	109	2	0	0	0	0	2	0	0	0	0	0	0	0
C33–C34	Sapnik, sapnici in pljuča Trachea, bronchus and lung	1196	459	0	124	0	0	275	57	0	0	0	0	0	3
C43	Maligni melanom kože Malignant melanoma of skin	481	5	0	0	0	0	5	0	0	0	0	0	0	0
C44	Druge maligne neoplazme kože Skin, other malignomas	2104	21	0	0	0	1	1	7	1	0	0	0	9	2
C48–C49	Vezivno in mehko tkivo Connective and soft tissue	65	20	0	0	0	1	19	0	0	0	0	0	0	0
C50	Dojka Breast	1151	1025	16	0	9	0	736	195	1	45	0	18	1	4
C53	Maternični vrat Cervix uteri	142	2	0	0	0	0	2	0	0	0	0	0	0	0
C54	Maternično telo Corpus uteri	301	24	0	0	0	0	17	7	0	0	0	0	0	0
C56	Jajčnik Ovary	153	100	0	0	0	1	89	10	0	0	0	0	0	0
C61	Prostata Prostate	1534	530	33	0	9	118	113	62	54	33	33	20	51	4
C62	Modo Testis	106	57	0	0	0	0	56	0	0	0	0	0	0	1
C64–C65	Ledvica z ledvičnim mehom Kidney with renal pelvis	337	38	0	1	0	1	36	0	0	0	0	0	0	0
C67	Sečni mehur Bladder	297	39	0	0	0	15	23	1	0	0	0	0	0	0
C70–C72	Centralni in avtonomni živčni sistem Central and autonomic nervous system	144	59	0	0	0	4	55	0	0	0	0	0	0	0
C73	Ščitnica Thyroid gland	143	131	0	0	2	13	111	3	0	0	0	0	2	0
C81	Hodgkinova bolezen Hodgkin's disease	41	37	0	0	0	7	30	0	0	0	0	0	0	0
C82–C85	Ne-Hodgkinovi limfomi Non-Hodgkin's lymphoma	346	198	2	0	1	8	185	2	0	0	0	0	0	0
C90	Difuzni plazmocitom in maligne neoplazme plazmocitov Multiple myeloma and malignant plasma cell neoplasms	113	49	11	0	0	23	1	5	4	0	2	2	0	1
C91–C95	Levkemije Leukaemias	255	71	8	0	0	49	3	4	1	1	3	0	0	2

* Bolniki, ki so v okviru prvega zdravljenja prejeli več kot eno vrsto sistemskega zdravljenja, so vključeni le enkrat

* Patients that underwent multiple systemic treatments in the course of first treatment were included with the first treatment only

** V posamezni ustanovi so zdravili manj kot 10 bolnikov

** Less then 10 patients were treated in indivdual institution

Tabela 12: Prevalenca po spolu in izbrani primarni lokaciji raka, Slovenija, 31. 12. 2011.

Table 12: Prevalence of cancer patients by sex and by selected primary cancer site, Slovenia, December 31, 2011.

Šifra MKB ICD code	Primarna lokacija* Primary site*	Spol Sex	Leta po diagnozi Years after diagnosis				Celotna prevalenca Lifetime prevalence
			<1	1–4	5–9	10+	Vsi / All
C00 – C96	Vse lokacije All sites	M+Ž	10450	28792	22185	28602	85504
		M	5709	14272	9600	9757	37020
		Ž	4741	14520	12585	18845	48484
C00–C14	Usta in žrelo Mouth and pharynx	M	216	524	323	415	1478
		Ž	68	175	157	193	593
C15	Požiralnik Oesophagus	M	39	35	20	19	113
		Ž	10	15	9	5	39
C16	Želodec Stomach	M	194	291	236	317	1038
		Ž	117	213	175	299	804
C18	Debelo črevo Colon	M	462	1138	667	654	2921
		Ž	334	903	629	766	2632
C19–C20	Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction	M	375	966	607	554	2502
		Ž	194	636	421	587	1838
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	M	47	58	17	12	134
		Ž	17	22	8	9	56
C23–C24	Žolčnik in žolčevodi Gallbladder and billiary tract	M	37	38	17	26	118
		Ž	37	58	26	25	146
C25	Trebušna slinavka Pancreas	M	73	43	10	12	138
		Ž	71	53	19	12	155
C32	Grlo Larynx	M	93	270	199	299	861
		Ž	11	35	26	49	121
C33–C34	Sapnik, sapnici in pljuča Trachea, bronchus and lung	M	474	576	314	310	1674
		Ž	250	329	135	126	840
C43	Maligni melanom kože Malignant melanoma of skin	M	238	707	491	509	1945
		Ž	231	839	641	942	2653
C44	Druge maligne neoplazme kože Skin, other malignomas	M	1031	3369	2628	2594	9622
		Ž	1041	3659	3042	3304	11046
C48–C49	Vezivno in mehko tkivo Connective and soft tissue	M	20	64	61	160	305
		Ž	32	73	76	176	357
C50	Dojka Breast	M	13	25	17	28	83
		Ž	1082	3986	3735	5226	14029
C53	Maternični vrat Cervix uteri	M	–	–	–	–	–
		Ž	130	410	656	2365	3561
C54	Maternično telo Corpus uteri	M	–	–	–	–	–
		Ž	285	941	970	1947	4143
C56	Jajčnik Ovary	M	–	–	–	–	–
		Ž	125	369	286	771	1551
C61	Prostata Prostate	M	1469	3974	2135	872	8450
		Ž	–	–	–	–	–
C62	Modo Testis	M	105	383	441	1023	1952
		Ž	–	–	–	–	–
C64–C65	Ledvica z ledvičnim mehom Kidney with renal pelvis	M	189	556	391	393	1529
		Ž	88	258	235	326	907
C67	Sečni mehur Bladder	M	196	430	315	296	1237
		Ž	59	131	105	121	416
C70–C72	Centralni in avtonomni živčni sistem Central and autonomic nervous system	M	66	105	61	161	393
		Ž	40	77	56	120	293
C73	Ščitnica Thyroid gland	M	39	111	106	150	406
		Ž	94	457	430	586	1567
C81	Hodgkinova bolezen Hodgkin's disease	M	13	100	105	282	500
		Ž	27	88	88	266	469
C82–C85	Ne-Hodgkinovi limfomi Non-Hodgkin's lymphoma	M	147	348	247	397	1139
		Ž	149	342	297	379	1167
C90	Difuzni plazmocitom in maligne neoplazme plazmocitov Multiple myeloma and malignant plasma cell neoplasms	M	46	116	53	23	238
		Ž	42	107	48	30	227
C91–C95	Levkemije Leukaemias	M	104	259	186	273	822
		Ž	55	189	160	270	674

* Pri posameznih lokacijah je pri prikazu prevalence oseba z več raki vključena pri vsaki lokaciji, pri vseh lokacijah skupaj pa se v prevalenci tudi oseba z več raki šteje le enkrat

* For persons with more than one cancer the person is included as a prevalent cancer in each cancer site, but in the all sites group each person is counted once only

Tabela 13: Umrljivost* za rakom po lokaciji, spolu in starosti, Slovenija 2011.

Table 13: Cancer mortality* by site, by sex and by age, Slovenia 2011.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age															
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+
C00 – C97	Vse lokacije All sites	M+Ž	5864	3	1	2	0	5	5	16	38	69	136	258	478	579	640	836	1017	1781
		M	3266	1	0	2	0	1	5	11	21	31	69	143	309	366	411	535	567	794
		Ž	2598	2	1	0	0	4	0	5	17	38	67	115	169	213	229	301	450	987
C00	Ustnica Lip	M	2	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
C01	Baza jezika Base of tongue	M	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
		Ž	2	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0
C02	Jezik, drugi deli Tongue, other & unspecified parts	M	11	0	0	0	0	0	0	0	0	0	0	2	1	2	1	1	1	3
		Ž	5	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	1	2
C03	Dlesen Gum	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C04	Ustno dno Floor of mouth	M	8	0	0	0	0	0	0	0	0	0	1	2	2	0	1	1	1	0
		Ž	2	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1
C05	Nebo Palate	M	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C06	Usta, drugi deli Mouth, other & unspecified parts	M	8	0	0	0	0	0	0	0	0	0	0	1	2	1	2	2	0	0
		Ž	7	0	0	0	0	0	0	0	0	0	0	0	1	0	3	2	0	1
C07	Parotidna žleza Parotid gland	M	2	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0
C08	Druge in neopredeljene velike žleze slinavke Other & unspecified major salivary glands	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C09	Tonzila Tonsil	M	2	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C10	Orofarinks Oropharynx	M	56	0	0	0	0	0	0	0	0	3	5	8	14	5	7	9	2	3
		Ž	7	0	0	0	0	0	0	0	0	1	2	0	2	0	0	1	1	0
C11	Nazofarinks Nasopharynx	M	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0
		Ž	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1
C12	Piriformni sinus Pyriform sinus	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C13	Hipofarinks Hypopharynx	M	37	0	0	0	0	0	0	0	0	0	2	3	8	6	8	6	0	4
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0
C14	Druga in slabo opredeljena mesta na ustnici, v ustni votlini in farinksu Other and ill-defined sites in the lip, oral cavity and pharynx	M	5	0	0	0	0	0	0	0	0	0	0	1	0	2	1	1	0	0
		Ž	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C15	Požiralnik Oesophagus	M	70	0	0	0	0	0	0	0	1	2	1	7	12	14	8	9	8	8
		Ž	15	0	0	0	0	0	0	0	0	0	1	0	2	1	2	2	3	4
C16	Želodec Stomach	M	226	0	0	0	0	0	0	0	2	2	5	7	21	22	34	34	37	62
		Ž	154	0	0	0	0	0	0	0	1	4	4	6	7	11	16	13	32	60
C17	Tanko črevo Small intestine	M	10	0	0	0	0	0	0	0	0	1	1	0	1	3	1	1	1	1
		Ž	11	0	0	0	0	0	0	0	0	0	0	1	2	1	1	1	2	3
C18	Debelo črevo Colon	M	261	0	0	0	0	0	0	1	2	2	4	4	16	20	30	53	61	68
		Ž	219	0	0	0	0	0	0	0	1	4	1	7	9	13	11	31	46	96
C19	Rektosigmoidna zveza Rectosigmoid junction	M	29	0	0	0	0	0	0	0	0	0	1	1	2	4	3	3	2	13
		Ž	33	0	0	0	0	0	0	0	0	1	0	2	1	2	2	6	4	15
C20	Rektum Rectum	M	139	0	0	0	0	0	0	0	4	0	2	8	14	14	19	18	27	33
		Ž	90	0	0	0	0	0	0	0	0	0	2	2	5	10	6	11	19	35
C21	Anus in analni kanal Anus and anal canal	M	3	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	1
		Ž	4	0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	1
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	M	133	0	0	0	0	0	0	0	0	2	2	7	16	17	17	24	24	24
		Ž	64	0	0	0	0	0	0	1	0	0	1	2	5	3	6	7	17	22
C23	Žolčnik Gallbladder	M	10	0	0	0	0	0	0	0	0	0	0	0	2	2	2	1	0	3
		Ž	37	0	0	0	0	0	0	0	0	0	1	1	2	1	2	5	9	16
C24	Drugi in neopredeljeni deli biliarnega trakta Billiary tract, other and unspecified parts	M	30	0	0	0	0	0	0	0	0	0	1	1	2	0	10	5	1	10
		Ž	35	0	0	0	0	0	0	0	0	0	1	1	1	1	3	5	7	16
C25	Trebušna slinavka Pancreas	M	177	0	0	0	0	0	0	0	2	2	4	13	16	15	31	33	23	38
		Ž	191	0	0	0	0	0	0	0	0	0	4	5	8	16	24	22	46	66
C26	Druga in slabo opredeljena mesta v prebavnih organih Other and ill-defined digestive organs	M	7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	5
		Ž	8	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	7
C30	Nosna votlina in srednje uho Nasal cavity and middle ear	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C31	Obnosni sinusi Accessory sinuses	M	7	0	0	0	0	0	0	0	0	0	0	0	2	1	1	0	1	2
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
C32	Grlo Larynx	M	50	0	0	0	0	0	0	0	0	0	1	7	7	9	8	4	4	10
		Ž	2	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	0	0
C33	Sapnik Trachea	M	4	0	0	0	0	0	0	0	0	0	0	0	2	0	1	1	0	0
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0

Nadaljevanje —>
Continued —>

Tabela 13: Nadaljevanje.

Table 13: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age															
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+
C34	Sapnica in pljuča	M	786	0	0	0	0	0	0	1	1	4	16	44	99	132	115	134	132	108
	Bronchus and lung	Ž	328	0	0	0	0	0	0	0	0	4	12	25	35	44	41	37	52	78
C37	Timus	M	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
	Thymus	Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C38	Srce, mediastinum, plevra	M	11	0	0	0	0	0	0	0	0	0	0	1	0	1	2	2	2	3
	Heart, mediastinum, pleura	Ž	4	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	2
C39	Druga in slabo opredeljena mesta v dihalih in prsnih organih	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Other and ill-defined sites in the respiratory system and intrathoracic organs	Ž	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1
C40	Kosti, sklepni hrustanec udov	M	4	0	0	0	0	0	0	1	0	0	1	0	0	0	1	1	0	0
	Bone and articular cartilage of limbs	Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0
C41	Kosti, sklepni hrustanec, drugje	M	6	0	0	0	0	0	0	1	0	1	1	0	0	1	0	0	1	1
	Bone and articular cartilage of other and unspecified parts	Ž	3	0	0	0	0	1	0	0	0	0	1	0	0	0	0	1	0	0
C43	Maligni melanom kože	M	73	0	0	0	0	0	1	2	2	3	4	1	5	9	13	11	13	9
	Malignant melanoma of skin	Ž	53	0	0	0	0	0	0	0	1	1	4	4	3	2	5	10	8	15
C44	Druge maligne neoplazme kože	M	14	0	0	0	0	0	0	0	0	0	0	0	0	2	0	1	3	8
	Skin, other malignomas	Ž	19	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	17
C45	Mezoteliom	M	27	0	0	0	0	0	0	0	0	0	1	0	2	3	3	8	6	4
	Mesothelioma	Ž	10	0	0	0	0	0	0	0	1	0	0	0	0	1	1	2	1	4
C46	Kaposijev sarkom	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Kaposi's sarcoma	Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C47	Periferni živci in avtonomno živčevje	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Peripheral and authonomic nervous system	Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C48	Peritonej in retroperitonej	M	6	0	0	0	0	0	0	0	0	1	0	2	0	1	0	1	1	0
	Retroperitoneum and peritoneum	Ž	13	0	0	0	0	0	0	0	0	1	1	0	0	1	0	3	1	6
C49	Drugo vezivno in mehko tkivo	M	14	0	0	0	0	0	1	2	0	1	0	1	1	2	0	2	2	2
	Other connective and soft tissue	Ž	19	0	0	0	0	0	0	0	0	1	0	2	1	1	1	3	1	9
C50	Dojka	M	3	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	1
	Breast	Ž	407	0	0	0	0	0	0	1	5	11	15	26	37	33	31	41	61	146
C51	Žensko zunanje spolovilo	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
	Vulva	Ž	21	0	0	0	0	0	0	0	0	0	0	1	1	1	1	3	2	12
C52	Nožnica	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
	Vagina	Ž	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	2	1
C53	Maternični vrat	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
	Cervix uteri	Ž	42	0	0	0	0	0	0	0	1	2	5	4	1	10	3	3	5	8
C54	Maternično telo	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
	Corpus uteri	Ž	56	0	0	0	0	0	0	0	0	0	0	0	3	3	6	7	12	25
C55	Maternica, neopredeljeno	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
	Uterus, unspecified	Ž	41	0	0	0	0	0	0	0	0	0	0	1	4	3	1	10	8	14
C56	Jajčnik	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
	Ovary	Ž	141	0	0	0	0	0	0	0	0	2	4	6	14	16	17	21	22	39
C57	Drugi in neopredeljeni ženski spolni organi	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
	Other and unspecified parts of female genital organs	Ž	5	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	4
C58	Posteljica	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
	Placenta	Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C60	Penis	M	4	0	0	0	0	0	0	0	0	0	0	0	0	2	0	1	1	0
	Penis	Ž	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
C61	Prostata	M	387	0	0	0	0	0	0	0	0	0	0	4	4	15	23	57	94	190
	Prostate	Ž	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
C62	Modo	M	6	0	0	0	0	1	0	0	1	1	1	0	1	0	0	0	1	0
	Testis	Ž	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
C63	Drugi in neopredeljeni moški spolni organi	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Other and unspecified male genital organs	Ž	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
C64	Ledvica razen meha	M	83	0	0	0	0	0	0	0	0	2	1	3	7	9	8	19	14	20
	Kidney, except renal pelvis	Ž	69	0	0	0	0	0	0	0	1	1	0	4	2	4	6	6	15	30
C65	Ledvični meh	M	2	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0
	Renal pelvis	Ž	2	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0
C66	Sečevod	M	2	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1
	Ureter	Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C67	Sečni mehur	M	112	0	0	0	0	0	0	0	0	0	1	0	2	11	13	12	34	39
	Bladder	Ž	50	0	0	0	0	0	0	0	0	2	0	0	1	2	2	4	5	34
C68	Drugi in neopredeljeni sečni organi	M	2	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0
	Other and unspecified urinary organs	Ž	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0
C69	Oko in očesni adneksi	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Eye and adnexa	Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Nadaljevanje —>
Continued —>

Tabela 13: Nadaljevanje.

Table 13: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age															
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+
C70	Meninge	M	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
	Meninges	Ž	10	0	0	0	0	0	0	0	1	0	0	0	1	1	0	2	1	4
C71	Možgani	M	63	0	0	0	0	0	0	1	2	1	2	6	11	7	9	10	6	8
	Brain	Ž	63	0	0	0	0	0	0	1	1	2	1	7	7	8	11	9	10	6
C72	Hrbtni mozeg, možganski živci in drugi deli CŽS	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Spinal cord, cranial nerves and other parts of CNS	Ž	1	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0
C73	Ščitnica	M	8	0	0	0	0	0	1	0	0	0	1	1	1	0	1	1	1	1
	Thyroid gland	Ž	10	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	1	7
C74	Nadledvična žleza	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Adrenal gland	Ž	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2
C75	Druge endokrine žleze in sorodne strukture	M	1	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
	Other endocrine glands and related structures	Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C76	Druga in slabo opredeljena mesta	M	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
	Other and ill-defined sites	Ž	7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	6
C77	Metastaza in neopredeljena maligna neoplazma bezgavk	M	5	0	0	0	0	0	0	0	1	0	1	0	1	0	0	1	0	1
	Metastasis and unspecified malignant neoplasm of lymph nodes	Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C78	Metastaze dihal in prebavil	M	25	0	0	0	0	0	0	0	0	0	0	1	2	2	3	8	2	7
	Metastases of respiratory and digestive organs	Ž	23	0	0	0	0	0	0	0	0	0	0	1	0	0	1	1	3	17
C79	Metastaze, drugje	M	3	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	1	0
	Metastases of other sites	Ž	6	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	4
C80	Maligna neoplazma brez opredeljenega mesta	M	35	0	0	0	0	0	0	0	0	0	1	1	6	4	2	4	7	10
	Malignant neoplasm without specification of site	Ž	28	0	0	0	0	0	0	0	1	0	0	0	0	2	1	1	6	17
C81	Hodgkinova bolezen	M	10	0	0	0	0	0	0	1	0	1	0	1	1	1	1	2	0	2
	Hodgkin's disease	Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
C82	Folikularni ne-Hodgkinov limfom	M	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0
	Follicular non-Hodgkin's lymphoma	Ž	3	0	0	0	0	0	0	0	0	0	0	0	0	0	2	1	0	0
C83	Difuzni ne-Hodgkinov limfom	M	11	0	0	0	0	0	0	1	0	0	0	0	2	0	1	2	4	1
	Diffuse non-Hodgkin's lymphoma	Ž	9	0	0	0	0	0	0	0	0	0	0	1	2	0	1	2	2	1
C84	Limfomi celic T in kožni limfom celic T	M	5	0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	1
	Peripheral and cutaneous T-cell lymphomas	Ž	5	0	0	0	0	1	0	0	0	1	0	0	0	0	1	0	1	1
C85	Druge in neopredeljene vrste ne-Hodgkinovega limfoma	M	37	0	0	0	0	0	0	0	1	0	1	0	1	3	3	7	6	15
	Other and unspecified types of non-Hodgkin's lymphoma	Ž	55	0	0	0	0	0	0	0	0	0	0	0	3	2	5	1	12	32
C88	Maligne imunoproliferativne bolezni	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Malignant immunoproliferative diseases	Ž	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	2
C90	Difuzni plazmocitom in maligne neoplazme plazmocitov	M	49	0	0	0	0	0	0	0	0	0	1	1	4	3	5	11	10	14
	Multiple myeloma and malignant plasma cell neoplasms	Ž	38	0	0	0	0	1	0	0	0	0	0	1	1	4	4	6	9	12
C91	Limfatična levkemija	M	38	0	0	0	0	0	0	0	0	0	2	1	3	3	5	4	4	16
	Lymphoid leukaemia	Ž	55	1	1	0	0	0	0	0	0	0	0	1	2	1	2	3	5	39
C92	Mieloična levkemija	M	49	1	0	2	0	0	2	0	2	0	2	1	5	7	4	9	6	8
	Myeloid leukaemia	Ž	41	0	0	0	0	1	0	0	1	0	4	1	1	4	3	5	3	18
C93	Monocitna levkemija	M	4	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	2	1
	Monocytic leukaemia	Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C94	Druge opredeljene levkemije	M	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
	Other leukaemias of specified cells	Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C95	Levkemija z neopredeljenim celičnim tipom	M	6	0	0	0	0	0	0	0	0	0	0	0	0	1	0	2	2	1
	Leukaemia, unspecified cell type	Ž	10	0	0	0	0	0	0	0	1	0	0	0	2	0	0	2	0	5
C96	Druge in neopredeljene maligne neoplazme limfatičnega, krvotvornega in sorodnega tkiva	M	18	0	0	0	0	0	0	0	0	0	0	1	1	1	1	2	2	10
	Other & unspecified malignant neoplasms of lymphoid, haemopoetic & related tissues	Ž	22	0	0	0	0	0	0	0	0	0	2	1	0	2	1	0	3	13
C97	Maligne neoplazme na več neodvisnih (primarnih) mestih	M	61	0	0	0	0	0	0	0	0	1	0	0	5	3	7	12	12	21
	Malignant neoplasms of independant (primary) multiple sites	Ž	21	0	0	0	0	0	0	1	0	0	0	0	0	2	3	3	4	8
	Zgoraj neupoštevani Not included above																			
D32	Meninge, benigna neoplazma	M	5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	3
	Benign neoplasm of meninges	Ž	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2
D33	CŽS, benigna neoplazma	M	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0
	Benign neoplasm of brain and other parts of CNS	Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0
D43	CŽS, neopredeljeno	M	2	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0
	CNS, uncertain or unknown	Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0

* Vir: Inštitut za varovanje zdravja RS

* Source: Institute of Public Health RS

IZBOR PUBLIKACIJ, ki so jih sodelavci Epidemiologije in Registra raka objavili v zadnjih petih letih (tudi v sodelovanju z drugimi raziskovalci)

SELECTED PUBLICATIONS, published by the members of Epidemiology and Cancer Registry in the last five years (also in cooperation with other researchers)

2008

- Baili P, Micheli A, De Angelis R, Weir HK, Primic Žakelj M, Pompe-Kirn V, et al. Life tables for world-wide comparison of relative survival for cancer (CONCORD study). Tumori 94: 658–68.
- Bešič N, Černivc B, de Greve J, Lokar K, Krajc M, Novaković S, et al. BRCA2 gene mutations in Slovenian male breast cancer patients. Genet Test 2008; 12: 203–9.
- Chuang S, Hashibe M, Scelo G, Brewster DH, Pukkala E, Pompe-Kirn V, et al. Risk of second primary cancer among esophageal cancer patients: a pooled analysis of 13 cancer registries. Cancer Epidemiol Biomarkers Prev 2008; 17: 1543–9.
- Chuang S, Scelo G, Tonita JM, Tamaro S, Jonasson JG, Pompe-Kirn V, et al. Risk of second primary cancer among patients with head and neck cancers: A pooled analysis of 13 cancer registries. Int J Cancer 2008; 123: 2390–6.
- Glumac N, Hočevar M, Zadnik V, Snoj M. Sentinel lymph node micrometastasis may predict nonsentinel involvement in cutaneous melanoma patients. J Surg Oncol 2008; 98: 46–8.
- Gondos A, Bray F, Brewster DH, Coebergh JWW, Hakulinen T, Primic Žakelj M, et al. Recent trends in cancer survival across Europe between 2000 and 2004: a model-based period analysis from 12 cancer registries. Eur J Cancer 2008; 44: 1463–75.
- Gouveia J, Coleman MP, Haward R, Zanetti R, Hakama M, Primic-Žakelj M, et al. Improving cancer control in the European Union: conclusions from the Lisbon round-table under the Portuguese EU Presidency, 2008. Eur J Cancer 2008; 44: 1457–62.
- Krajc M. Screening. In: Kovačič L, Zaletel-Kragelj L, eds. Management in health care practice: a handbook for teachers, researchers and health professionals. Lage: Hans Jacobs Publishing Company; 2008. p. 286–307.
- Krajc M, Teugels E, Žgajnar J, Goelen G, Bešič N, Novaković S, et al. Five recurrent BRCA1/2 mutations are responsible for cancer predisposition in the majority of Slovenian breast cancer families. BMCMed Genet 2008; 983–91.
- Maule M, Scelo G, Pastore G, Brennan P, Hemminki K, Pompe-Kirn V, et al. Risk of second malignant neoplasms after childhood central nervous system malignant tumours: an international study. Eur J Cancer 2008; 44: 830–9.
- Primic-Žakelj M. Cancer epidemiology. In: Schrijvers D, Zakotnik B, eds. ESMO handbook of cancer prevention. London: Informa Healthcare; 2008. p. 1–9.
- Primic-Žakelj M, Zadnik V. Rak pri starejših. In: Bilban M, ed. Zbornik prispevkov Cvahtetovih dnevov. Ljubljana: Katedra za javno zdravje; 2008.
- Primic-Žakelj M, Zadnik V, Žagar T. Karcinom debelega črevesa in danke v Sloveniji in v Evropi (Colorectal cancer in Slovenia and in Europe). In: Luzar B, Cerar A, Štabuc B, eds. Tumorji debelega črevesa in danke. Ljubljana: Inštitut za patologijo, Medicinska fakulteta; 2008.
- Primic-Žakelj M, Žagar T. Cancer control in Slovenia: achievements, shortcomings and opportunities. In: Coleman MP, ed. Responding to the challenge of cancer in Europe. Ljubljana: Institute of Public Health of the Republic of Slovenia; 2008.
- Primic-Žakelj M, Žagar T, Zadnik V. Lung cancer in Slovenia (Pljučni rak v Sloveniji). Endosk rev 2008; 13: 5–13.
- Repše-Fokter A, Primic-Žakelj M. Auditing screening laboratories in Slovenia. Cytopathology 2008; 19 Suppl 1: 20.
- Repše-Fokter A, Primic-Žakelj M. Cervical cancer screening in Slovenia. Cytopathology 2008; 19 Suppl 1: 3.

- Robins G, Crabtree JE, Bailey A, Forman D, Pompe-Kirn V, et al. International variation in Helicobacter pylori infection and rates of oesophageal cancer. Eur J Cancer. 2008; 44: 726–32.
- Rojnik K, Naveršnik K, Mateović-Rojnik T, Primic Žakelj M. Probabilistic cost-effectiveness modeling of different breast cancer screening policies in Slovenia. Value Health 11: 139–48.
- Sant M, Allemani C, De Angelis R, Carbone A, de Sanjose S, Pompe-Kirn V, et al. Influence of morphology on survival for non-Hodgkin lymphoma in Europe and the United States. Eur J Cancer 2008; 44: 579–87.
- Terčelj M, Aleš A, Rott T, Sever N, Prodnik L, Primic-Žakelj M, et al. DNA-based sputum cell image analysis for lung cancer in a clinical setting. Acta Cytol 2008; 52: 584–90.
- Virgili G, Gatta G, Ciccolallo L, Capocaccia R, Primic Žakelj M, Pompe-Kirn V, et al. Survival in patients with uveal melanoma in Europe. Arch Ophthalmol 2008; 126: 1413–8.
- Zadnik V, Ivanuš U, Florjančič M, Primic-Žakelj M. Vloga registra ZORA pri obvladovanju bremena raka materničnega vratu v Sloveniji (The role of ZORA registry in cervical cancer burden control in Slovenia). Bilt-ekon organ inform zdrav 2008; 24:179–83.
- Zadnik V, Primic-Žakelj M. Rak pri ženskah. In: Štabuc B, Primic Žakelj M, Klemenčič M, Piškur J, eds. Rak rodil. Ljubljana: Zveza slovenskih društev za boj proti raku; 2008.
- Zadnik V, Žagar T, Drobne S, Primic Žakelj M. Estimation of cancer burden in Brežice municipality, a community neighboring Krško nuclear power plant in Slovenia. Croat Med J 2008; 49: 257–66.
- Zadnik V, Žagar T, Primic-Žakelj M. Ginekološki raki v Sloveniji (Gynecological cancers in Slovenia). In: Takač I, ed. 80 let hospitalne ginekologije in porodništva v Maribor: mednarodni znanstveni simpozij. Maribor: Univerzitetni klinični center Maribor; 2008.
- Zver S, Zadnik V, Černelč P, Koželj M. Cardiac toxicity of high-dose cyclophosphamide and melphalan in patients with multiple myeloma treated with tandem autologous hematopoietic stem cell transplantation. Int J Hematol. 2008; 88: 227–36.
- Zwitter M, Primic-Žakelj M. Lung cancer in Europe. In: Parikh PM, ed. Lung cancer. Mumbai: Green Room Media & Event Management Services; 2008. p. 350–7.

2009

- Anttila A, Ronco G, Primic-Žakelj M, Pogačnik A, Uršič-Vrščaj M, Zadnik V, et al. Description of the national situation of cervical cancer screening in the member states of the European Union. Eur J Cancer 2009; 45: 2685–708.
- Berrino F, Verdecchia A, Lutz JM, Lombardo C, Micheli A, Primic-Žakelj M, et al. Comparative cancer survival information in Europe. Eur J Cancer 2009; 45: 901–8.
- Ciccolallo L, Licitra L, Cantu G, Gatta G, Pompe-Kirn V, Primic Žakelj M, et al. Survival from salivary glands adenoid cystic carcinoma in European populations. Oral Oncol 2009; 45: 669–74.
- De Angelis R, Francisci S, Baili P, Marchesi F, Roazzi P, Primic-Žakelj M, et al. The EUROCARE-4 database on cancer survival in Europe: data standardisation, quality control and methods of statistical analysis. Eur J Cancer 2009; 45: 909–30.
- Francisci S, Capocaccia R, Grande E, Santaquilani M, Simonetti A, Primic-Žakelj M, et al. The cure of cancer: a European perspective. Eur J Cancer 2009; 45: 1067–79.
- Gatta G, Zigon G, Capocaccia R, Coebergh JW, Desandes E, Primic-Žakelj M, et al. Survival of European children and young adults with cancer diagnosed 1995–2002. Eur J Cancer 2009; 45: 992–1005.
- Gondos A, Bray F, Hakulinen T, Brenner H, Usel M, Primic-Žakelj M, et al. Trends in cancer survival in 11 European populations from 1990 to 2009: a model-based analysis. Ann Oncol 2009; 20: 564–73.
- Lepage C, Ciccolallo L, De Angelis R, Bouvier AM, Pompe-Kirn V, Primic-Žakelj M, et al. European disparities in malignant digestive endocrine tumours survival. Int J Cancer 2009; available from: http: //www.ncbi.nlm.nih.gov/pubmed/19569047.
- Nicula FA, Anttila A, Neamtiu L, Primic-Žakelj M, Tachezy R, Chil A, et al. Challenges in starting organised screening programmes for cervical cancer in the new member states of the European Union. Eur J Cancer 2009; 45: 2679–84.
- Pasanisi P, Hedelin G, Berrino J, Chang-Claude J, Primic-Žakelj M, Zadnik V, et al. Oral contraceptive use and BRCA penetrance: a case-only study. Cancer Epidemiol Biomarkers Prev 2009; 18: 2107–13.
- Primic-Žakelj M, Pogačnik A, Uršič-Vrščaj M, Ivanuš U. Presejalni program ZORA po petih letih delovanja že kaže pomembne javnozdravstvene rezultate. Onkologija 2009; 13: 4–6.

- Primic-Žakelj M, Zadnik V, Žagar T. Epidemiologija kožnega raka (Epidemiology of skin cancer). In: Luzar B, Jurčić V, PižemJ, Calonje E, eds. XL. memorialni sestanek profesorja Janeza Plečnika z mednarodnim simpozijem, 3.–4. december 2009, Ljubljana. Novosti v dermatopatologiji. Ljubljana: Inštitut za patologijo, Medicinska fakulteta; 2009.
- Primic-Žakelj M, Zadnik V, Žagar T, Zakotnik B. Preživetje bolnikov z rakom, zbolelih v letih 1991–2005 v Sloveniji (Survival of cancer patients, diagnosed in 1991–2005 in Slovenia). Ljubljana: Onkološki inštitut; 2009.
- Primic-Žakelj M, Krajc M, Zadnik V. Državni presejalni programi za raka (National cancer screening programs). Farm vestn 2009; 60: 90–4.
- Primic-Žakelj M, Zadnik V. Epidemiologija raka prostate (Epidemiology of prostate cancer). In: Kramer F, ed. Rak prostate: zbornik predavanj. Slovenj Gradec: Oddelek za urologijo, Splošna bolnišnica Slovenj Gradec; 2009.
- Primic-Žakelj M, Žgajnar J. Cervical and breast cancer screening in Slovenia. Public service review, European Union. 2009; 18: 272.
- Quaglia A, Tavilla A, Shack L, Brenner H, Janssen-Heijnen M, Primic-Žakelj M, et al. The cancer survival gap between elderly and middle-aged patients in Europe is widening. Eur J Cancer 2009; 45: 1006–16.
- Repše-Fokter A, Fležar M, Pogačnik A, Snoj V. Review of negative or low grade smears in women with invasive cervical cancer in Slovenia. Virchows Arch 2009; 455 Suppl,1: S6–S7.
- Ronco G, van Ballegooijen M, Becker N, Chil A, Fender M, Primic-Žakelj M, et al. Process performance of cervical screening programmes in Europe. Eur J Cancer 2009; 45: 2659–70.
- Rosso S, De Angelis R, Ciccolallo L, Carrani E, Soerjomataram I, Primic-Žakelj M, et al. Multiple tumours in survival estimates. Eur J Cancer 2009; 45: 1080–94.
- Sant M, Allemani C, Santaquilani M, Knijn A, Marchesi F, Primic-Žakelj M, et al. EUROCARE-4. Survival of cancer patients diagnosed in 1995–1999. Results and commentary. Eur J Cancer 2009 Apr; 45(6): 931–91.
- Snoj Z, Primic-Žakelj M, Ličina M, Pregelj P. Psychosocial correlates of progesterone receptors in breast cancer. Depress Anxiety 2009; 26: 544–9.
- Trapido EJ, Primic-Žakelj M, Pogačnik A, Uršic-Vrsčaj M, Krajc M, Lešničar H, et al. Critical factors influencing the establishment, maintenance and sustainability of population-based cancer control programs. Tumori 2009; 95: 637–45.
- Verdecchia A, Guzzinati S, Francisci S, De Angelis R, Bray F, Primic-Žakelj M, et al. Survival trends in European cancer patients diagnosed from 1988 to 1999. Eur J Cancer 2009; 45: 1042–66.
- Zadnik V, Žagar T, Primic-Žakelj M. Pridobivanje in uporaba georeferenciranih podatkov v registru raka Republike Slovenije (Georeferenced data aquistion and usage in the cancer registry of Republic of Slovenia). Bilt-ekon organ inform zdrav 2009; 25 (izr. št.): 14.
- Zwitter M, Kovač V, Smrdel U, Vrankar M, Zadnik V. Gemcitabine in brief versus prolonged low-dose infusion, both combined with cisplatin, for advanced non-small cell lung cancer: a randomized phase II clinical trial. J Thorac Oncol 2009; 4: 1148–55.
- Žagar T, Zadnik V, Primic-Žakelj M. Register raka Republike Slovenije in pridobivanje informacij o bolnikih iz drugih državnih podatkovnih zbirk po elektronski poti (Cancer Registry of Slovenia obtains patient information from other state databases via electronic mediums). In: Orel M, ed. Nova vizija tehnologij prihodnosti. Ljubljana: Evropska hiša; 2009.

2010

- Bouvier A, Pompe-Kirn V. What reasons lie behind long-term survival differences for gastric cancer within Europe? Eur J Cancer 2010; 46: 1086–92.
- Chuang S, Pompe-Kirn V. Risks of second primary cancer among patients with major histological types of lung cancers in both men and women. Br J Cancer 2010; 102: 1190–5.
- EurocareWorking Group, Lepage C, Pompe-Kirn V, Primic-Žakelj M. European disparities in malignant digestive endocrine tumours survival. Int J Cancer 2010; 126: 2928–34.
- Kofol-Bric T, Zadnik V et al. Zdravje moških med 20. in 64. letom. In: Zdravje v Sloveniji. Ljubljana: Inštitut za varovanje zdravja RS; 2010, 80–6.
- Krajc M, Kadivec M, Hertl K, Primic-Žakelj M. V državnem presejalnem programu za raka dojk Dora do sedaj odkritih 86 rakov dojk. Onkologija 2010; 14: 104–10.

- Mihevc Ponikvar B, Zadnik V et al. Zdravje žensk med 20. in 64. letom. In: Zdravje v Sloveniji. Ljubljana: Inštitut za varovanje zdravja RS; 2010, 71–9.
- Primic-Žakelj M. Country-specific description: Slovenia. In: Obergainer W, Vittadello F eds. Cancer mapping in Alpine regions: Austria, Italy, Slovenia, Switzerland: 2001–2005. Innsbruck: Department of Clinical Epidemiology of TILAK; 2010, 47–9.
- Primic-Žakelj M, Ivanuš U. Državni program ZORA danes. In: Ivanuš U, Primic-Žakelj M, Florjančič M, Škulj P eds. Prvi izobraževalni dan programa ZORA z mednarodno udeležbo. Zbornik. Ljubljana: Onkološki inštitut; 2010, 9-15.
- Primic-Žakelj M, Zadnik V. Rak. In: Zdravje v Sloveniji. Ljubljana: Inštitut za varovanje zdravja RS; 2010: 96–100.
- Primic-Žakelj M, Zadnik V, Žagar T. Breme raka v Sloveniji. Naša lekarna 2010; 41: 22–8.
- Primic-Žakelj M, Zadnik V, Žagar T. Razširjenost raka v Sloveniji in Evropi. In: Rotar-Pavlič D. Obravnava bolnika z rakom v osnovnem zdravstvenem varstvu: zbornik predavanj, Bled, 24. april 2010. Ljubljana: Zavod za razvoj družinske medicine; 2010, 5–8.
- Rebolj M, Ivanuš U, Lynge E. Indicators of quality assurance in cancer screening - the case of cervical cancer = Kazalniki kakovosti presejalnih programov - primer presejalnega programa za raka na materničnem vratu. Bilt.-ekon. organ. inform. zdrav 2010; 26(2): 44-51.
- Repše-Fokter A, Pogačnik A, Snoj V, Primic-Žakelj M, Strojan Fležar M. Review of negative and lowgrade cervical smears in women with invasive cervical cancer after the first 3 years of the national cervical screening programme in Slovenia. Cytopathology 2010; 22: 1–7.
- Rosso S, Gondos A, Zanetti R, Bray F, Primic-Žakelj M , Žagar T, Smailyte G, Ponti A, Brewster DH, Voogd AC, Crocetti E, Brenner H; EUNICE SurvivalWorking Group. Up-to-date estimates of breast cancer survival for the years 2000–2004 in 11 European countries : the role of screening and a comparison with data from the United States. Eur J Cancer 2010; 46: 3351–7.
- Strojan Fležar M, Snoj V, Ivanuš U, Primic-Žakelj M. Standardizacija izvidov patologije materničnega vratu. In: Ivanuš U, Primic-Žakelj M, Florjančič M, Škulj P eds. Prvi izobraževalni dan programa ZORA z mednarodno udeležbo. Zbornik. Ljubljana: Onkološki inštitut, 2010; 21-23, 61–72.
- Šelb-Šemerl J, Mihevc Ponikvar B, Primic-Žakelj M, Rok Simon M, Tomšič S, Zadnik V. Zdravje starejših. In: Zdravje v Sloveniji. Ljubljana: Inštitut za varovanje zdravja RS; 2010: 87–91.

2011

- Anttila A, Bielska-Lasota M, Davidson T, Van Delden JJ, Von Karsa L, Primic-Žakelj M, et al. Determinants for a successful implementation of population-based cancer screening programmes. Brussels: European Science Advisory Network for Health, 2011.
- Bosetti C, Scelo G, Chuang SC, Tonita JM, Tamaro S, Pompe-Kirn V, et al. High constant incidence rates of second primary cancers of the head and neck: a pooled analysis of 13 cancer registries. Int J Cancer 2011;129(1):173–9.
- Buzeti T, Djomba JK, Tomšič S, Gabrijelčič Blenkuš M, Ivanuša M, Zadnik V, et al. Neenakosti v zdravju v Sloveniji. Health inequalities in Slovenia. Ljubljana: Inštitut za varovanje zdravja, 2011.
- Gatta G, Van der Zwan JM, Casali PG, Siesling S, Dei Tos AP, Primic-Žakelj M, et al. Rare cancers are not so rare: the rare cancer burden in Europe. Eur J Cancer 2011; 47(17): 2493–511.
- Ivanuš U, Primic-Žakelj M, Uršič-Vrščaj M. Pomen triažnega testa HPV. In: Primic-Žakelj M, ed. XIX. seminar In memoriam dr. Dušana Reje. Državni presejalni programi za raka. Ljubljana: Zveza slovenskih društev za boj proti raku, 2011: 26–39.
- Kadivec M, Krajc M. Rezultati in kazalniki uspešnosti programa DORA. In: Primic-Žakelj M, ed. XIX. seminar In memoriam dr. Dušana Reje. Državni presejalni programi za raka. Ljubljana: Zveza slovenskih društev za boj proti raku, 2011: 40–8.
- Krajc M. Prednosti in omejitve mamografskega presejanja. In: Primic-Žakelj M, ed. XIX. seminar In memoriam dr. Dušana Reje. Državni presejalni programi za raka. Ljubljana: Zveza slovenskih društev za boj proti raku, 2011: 49–58.
- Krajc M. Epidemiologija raka dojk. In: Mamografska šola, 9. in 10. junij 2011. Ljubljana: Onkološki inštitut, SZD, Združenje radiologov Slovenije, 2011: 1–6.
- Krajc M. Kazalci kakovosti presejalnega programa za raka dojk. In: Farkaš-Lainščak J, ed. Z dokazi podprto javno zdravje: zbornik prispevkov. Ljubljana: Medicinska fakulteta, Katedra za javno zdravje, 2011: str 128.

– Maule M, Scélo G, Pastore G, Brennan P, Hemminki K, Pompe-Kirn V, et al. Second malignancies after childhood noncentral nervous system solid cancer: Results from 13 cancer registries. Int J Cancer 2011;129(8):1940–52.
– Primic-Žakelj M. Presejanje za raka kot javnozdravstveni ukrep. In: Primic-Žakelj M, ed. XIX. seminar In memoriam dr. Dušana Reje. Državni presejalni programi za raka. Ljubljana: Zveza slovenskih društev za boj proti raku, 2011: 7–12.
– Primic-Žakelj M. Epidemiologija raka in stopnja preživetja v Sloveniji v populaciji do 39 let. In: Ribič-Pucelj M, ed. Ohranjanje plodne sposobnosti pri onkoloških bolnicah in bolnikih: zbornik. Ljubljana: Slovensko društvo za reproduktivno medicino, 2011: 1–4.
– Primic-Žakelj M, Ivanuš U. Presejanje za raka pri ženskah. In: Čeh A, ed. Presejalni testi pri ženskah in otrocih: zbornik predavanj z recenzijo. Ljubljana: Zbornica zdravstvene in babiške nege Slovenije - Zveza strokovnih društev medicinskih sester, babic in zdravstvenih tehnikov Slovenije, Sekcija medicinskih sester – babic, 2011: 7–15.
– Primic-Žakelj M, Ivanuš U. Rezultati in kazalniki uspešnosti programa ZORA. In: Primic-Žakelj M, ed. XIX. seminar In memoriam dr. Dušana Reje. Državni presejalni programi za raka. Ljubljana: Zveza slovenskih društev za boj proti raku, 2011: 13–7.
– Primic-Žakelj M, Ivanuš U. Državni program ZORA v letih 2005-2010. In: Ivanuš U, Primic-Žakelj M, Florjančič M, Kuster M, eds. 2. izobraževalni dan programa ZORA, Brdo pri Kranju, 8. april 2011. Zbornik. Ljubljana: Onkološki inštitut Ljubljana, 2011: 9–12.
– Primic-Žakelj M, Zadnik V. Epidemiologija raka sečnega mehurja = Epidemiology of bladder cancer. In: Zupančič M, ed. Rak sečnega mehurja: zbornik predavanj. Slovenj Gradec: Oddelek za urologijo, Splošna bolnišnica Slovenj Gradec, 2010: 7–12.
– Rotovnik Kozjek N, Kompan L, Soeters P, Oblak I, Mlakar Mastnak D, Zadnik V, et al. Oral glutamine supplementation during preoperative radiochemotherapy in patients with rectal cancer: a randomised double blinded, placebo controlled pilot study. Clin Nutr 2011; 30(5): 567–70.
– Uršič-Vrščaj M, Primic-Žakelj M, Ivanuš U. Novosti v programu ZORA. In: Primic-Žakelj M, ed. XIX. seminar In memoriam dr. Dušana Reje. Državni presejalni programi za raka. Ljubljana: Zveza slovenskih društev za boj proti raku, 2011: 18–25.
– Velenik V, Štrbac D, Maučec Zakotnik J, Zadnik V. Oral glutamine supplementation during preoperative radiochemotherapy in patients with rectal cancer: a randomised double blinded, placebo controlled pilot study. Eur J Cancer 2011; 47(Supp1): S267.
– Zadnik V, Ivanuš U, Primic-Žakelj M. Geografska analiza incidence raka v Beli krajini in okolici: ugotavljanje morebitnega presežka incidence raka zaradi izpostavljenosti PCB-jem: zaključno poročilo. Ljubljana: Onkološki inštitut, 2011.
– Zadnik V, Ivanuš U, Primic-Žakelj M. Pojavljanje raka v upravnih enotah Celje in Šentjur pri Celju: zaključno poročilo. Ljubljana: Onkološki inštitut, 2011.
– Zadnik V, Kovše K, Tomšič S, Primic-Žakelj M. Breme raka v občini Dolenjske Toplice: zaključno poročilo. Ljubljana: Onkološki inštitut, 2011.
– Zadnik V, Primic-Žakelj M. SLORA - spletna stran z epidemiološkimi podatki o raku. Onkologija 2011; 15(1): 61–3.
– Zadnik V, Primic-Žakelj M. Breme raka uroloških in reproduktivnih organov v Sloveniji. Slov 2000 in rak 2011; 8–12.
– Žagar T, Zadnik V, Primic-Žakelj M. Local standardized incidence ratio estimates and comparison with other mapping methods for small geographical areas using Slovenian breast cancer data. Journal of Applied Statistics 2011; 38(12): 2751–61.

2012

- Ćuić M, Zadnik V. Prekomerna telesna teža in debelost kot dejavnik tveganja raka = Overweight and obesity as cancer risk factor. In: Babnik K, Kocbek M, eds. Slovenski dan dietetike: prva znanstvena konferenca z mednarodno udeležbo, Izola, 25. oktober 2012. Zbornik prispevkov. Koper: Založba Univerze na Primorskem, 2012: 63–8.
- Glumac N, Hočevar M, Zadnik V, Snoj M. Inguinal or inguino-iliac/obturator lymph node dissection after positive inguinal sentinel lymph node in patients with cutaneous melanoma. Radiol Oncol 2012; 46(3): 258–64.

- Gregorič B, Zadnik V, Jezeršek Novaković B. The diffuse large B-cell lymphoma - where do we stand now in everyday clinical practice. Radiol Oncol 2012; 46(2): 153–9.
- Ivanuš U, Primic-Žakelj M. Interlaboratory variability in HPV-positive rates in ASC-US/LSIL smears in the cervical cancer screening programme ZORA = Razlike med citološkimi laboratoriji v deležu HPV-pozitivnih izvidov APC-N/PIL-NS v presejalnem programu za raka materničnega vratu ZORA. In: Strojan Fležar M, Luzar B, Gutnik H, Pižem J, Kocjan G, eds. Novosti v citopatologiji: most med kliniko in diagnostično patologijo: Bridge between clinics and diagnostic pathology. Ljubljana: Inštitut za patologijo, Medicinska fakulteta, 2012: 203–8.
- Ivanuš U, Primic-Žakelj M, Uršič-Vrščaj M. Aktivnosti DP ZORA v letu 2011. In: Ivanuš U, Primic-Žakelj M, Florjančič M, Kuster M. Zbornik. Ljubljana: Onkološki inštitut, 2012: 53–63.
- Ivanuš U, Primic-Žakelj M. Samoodvzem vaginalnega vzorca za test HPV pri neodzivnicah presejalnih programov raka materničnega vratu. Onkologija 2012; 16(2): 78–86.
- Ivanuš U, Primic-Žakelj M. Tretji izobraževalni dan programa ZORA. Onkologija 2012; 16(2): 98-100.
- Jarm K. Podrobna raziskava preživetja bolnikov z rakom danke v Sloveniji, zbolelih v letih 2003-2005: specialistična naloga s področja javnega zdravja. Ljubljana: Onkološki inštitut; 2012.
- Koivisto-Korander R, Scélo G, Ferro G, Mellemkjaer L, Hemminki K, Pompe-Kirn V, et al. Second primary malignancies among women with uterine sarcoma. Gynecol Oncol 2012; 126(1): 30–5.
- Kovač V, Zwitter M, Žagar T. Improved survival after introduction of chemotherapy for malignant pleural mesothelioma in Slovenia: Population-based survey of 444 patients. Radiol Oncol 2012; 46(2): 136–44.
- Merlo DF, Ceppi M, Filiberti R, Bocchini V, Znaor A, Primic-Žakelj M, et al. Breast cancer incidence trends in European women aged 20-39 years at diagnosis. Breast Cancer Res Treat 2012; 134(1): 363–70.
- Primic-Žakelj M, Ivanuš U. Aktivnosti DP ZORA v letu 2011. In: Ivanuš U, Primic-Žakelj M, Florjančič M, Kuster M. Zbornik. Ljubljana: Onkološki inštitut, 2012: 9–14.
- Primic-Žakelj M, Zadnik V. Rak pri starejših. In: Rak pri starostniku. Ljubljana: Onkološki inštitut, 2012: 14–25.
- Primic-Žakelj M, Žagar T. Razširjenost, preprečevanje in zgodnje odkrivanje pljučnega raka. In: Matković M, ed. Pacienti in pljučni rak - trendi in novosti. Ljubljana: Sekcija medicinskih sester in zdravstvenih tehnikov v onkologiji pri Zbornici zdravstvene in babiške nege Slovenije - Zveza strokovnih društev medicinskih sester, babic in zdravstvenih tehnikov Slovenije, 2012: 19–31.
- Primic-Žakelj M. Presejanje za raka kot javnozdravstveni ukrep. Slov 2000 Rak 2012: 6–9.
- Primic-Žakelj M. Razširjenost in pomen redkih rakavih bolezni. In: Primic-Žakelj M, ed. Redki raki. Ljubljana: Zveza slovenskih društev za boj proti raku, 2012: 7–13.
- Repše-Fokter A, Pogačnik A, Snoj V, Primic-Žakelj M, Fležar MS. Review of negative and low-grade cervical smears in women with invasive cervical cancer after the first 3 years of the national cervical screening programme in Slovenia. Cytopathol Off J Br Soc Clin Cytol 2012; 23(1): 23–9.
- Uršič-Vrščaj M, Ivanuš U. HPV testiranje. In: Smrkolj Š, ed. Obnovitveni kolposkopski tečaj, Ljubljana, marec 2012. Zbornik. Ljubljana: Združenje za ginekološko onkologijo, kolposkopijo in cervikalno patologijo SZD, 2012: 63–9.
- Zadnik V, Primic-Žakelj M. Epidemiologic data on cervical cancer. In: Takač I, ed. Recent advances in cervical cancer. Kerala: Transworld Research Network, 2012: 1–7.
- Zadnik V, Primic-Žakelj M, Krajc M. Breme raka v Sloveniji v primerjavi z drugimi evropskimi državami = Cancer burden in Slovenia in comparison with the burden in other European countries. Zdr Vestn 2012; 81(5): 407–12.
- Zadnik V, Žagar T, Primic-Žakelj M. Analiza vpliva točkovnih virov onesnaženja na zbolevanje za rakom v Zasavju = Analysis of the impact of point source pollution on cancer in Zasavje. In: Kraigher A, ed. Zbornik predstavitev. Ljubljana: Sekcija za preventivno medicino Slovenskega zdravniškega društva, 2012: 1.
- Žagar T, Primic-Žakelj M, Zadnik V. Slovenian maps of local standardized incidence ratio. In: 34th International Association of Cancer Registries Conference, 17-19 September 2012. Cork: The National Cancer Registry, 2012: 42.
- Žagar T, Zadnik V, Primic-Žakelj M. Možnosti raziskovanja vpliva bivalnega okolja na pojavljanje raka. In: Kraigher A, ed. Zbornik predstavitev. Ljubljana: Sekcija za preventivno medicino Slovenskega zdravniškega društva, 2012: 1–15.
- Žist A, Milanez T, Škrbinc B, Zadnik V, Šeruga B. Spregledana korist neoadjuvantne kemoterapije v zdravljenju mišično invazivnega raka sečnega mehurja. Onkologija 2012; 16(2): 74–7.

2013

- Allemani C, Sant M, Weir HK, Richardson LC, Baili P, Primic-Žakelj M, et al. Breast cancer survival in the US and Europe: a CONCORD high-resolution study. International journal of cancer 2013; 132: 1170–81.
- Gašljević G, Lamovec J, Contreras JA, Zadnik, V, Blas M, Gašparov S. HER2 in gastric cancer: an immunohistochemical study on tissue microarrays and the coressponding whole-tissue sections with a supplemental FISH study. Pathol Oncol Res 2013; 19: 855–65.
- Ivanuš U, Primic-Žakelj M, Žagar T, Florjančič M, Kuster M. Delovanje državnega presejalnega programa za raka maternicnega vratu ZORA v osrednjeslovenski statistični regiji. In: Letnar Žbogar N, et al. Zdravje v ljubljanski zdravstveni regiji 2012. Ljubljana: Zavod za zdravstveno varstvo, 2013: 74–94.
- Ivanuš U, Primic-Žakelj M. Klinična uporaba in pomen testa za humani papilomski virus v Državnem presejalnem programu ZORA (Clinical use and value of human papillomavirus test in national cervical cancer screening programme ZORA). Med Razgl 2013; 52(3): 123–35.
- Ivanuš U, Primic-Žakelj M. Pomen izvida testa HPV v kolposkopski ambulanti. In: Smrkolj Š, ed. Zbornik. Ljubljana: Združenje za ginekološko onkologijo, kolposkopijo in cervikalno patologijo SZD: Onkološki inštitut, 2013: 78–101.
- Ivanuš U, Primic-Žakelj M. Uporaba triažnega testa HPV v programu ZORA v letu 2012. In: Ivanuš U, Primic-Žakelj M, Repše-Fokter A, eds. Zbornik predavanj. Ljubljana: Onkološki inštitut, 2013: 27–34.
- von Karsa L, Maučec-Zakotnik J, Primic-Žakelj M et al. European guidelines for quality assurance in colorectal cancer screening and diagnosis: overview and introduction to the full supplement publication. Endoscopy 2013; 45, 51–9.
- Koželj M, Zver S, Zadnik V. Long term follow-up report of cardiac toxicity in patients with multiple myeloma treated with tandem autologous hematopoietic stem cell transplantation. Radiol Oncol 2013; 47: 161–5.
- Krajc M, Šval C, Kadivec M, Hertl K, Primic-Žakelj M. Rezultati državnega presejalnega programa Dora v ljubljanski regiji. In: Letnar Žbogar N, et al. Zdravje v ljubljanski zdravstveni regiji 2012. Ljubljana: Zavod za zdravstveno varstvo, 2013: 66–73.
- Maver Vodičar P, Seme K, Korač T, Dimitrov G, Döbrőssy L, Primic-Žakelj M, et al. Cervical cancer screening practices in central and eastern Europe in 2012. Acta Dermatovenerol APA 2013; 22: 7–19.
- Primic-Žakelj M , Ivanuš U. Deset let delovanja programa ZORA. In: Ivanuš U, Primic-Žakelj M, Repše-Fokter A, eds. Zbornik predavanj. Ljubljana: Onkološki inštitut, 2013: 7–11.
- Primic-Žakelj M, Zadnik V, Žagar T. Epidemiologija raka debelega črevesa in danke. In: Šola tumorjev prebavil, Ljubljana, 30. 11. 2012. Ljubljana: Onkološki inštitut, 2013: 17–20.
- Primic-Žakelj M, Zadnik V, Žagar T. Epidemiologija raka prostate, sečnega mehurja, ledvic in mod v Sloveniji. In: Novaković S, ed. Izzivi v multidisciplinarni obravnavi bolnikov z rakom sečnega mehurja, prostate, ledvic in mod. Zbornik. Ljubljana: Onkološki inštitut: Kancerološko združenje Slovenskega zdravniškega društva, 2013: 16–23.
- Primic-Žakelj M. Epidemiology of cancer diseases in different European regions and the importance of risk factors. In: Fourth International Medical Congress, 11-15 September 2013, Portorož, Slovenia, 2013: 49–51.
- Primic-Žakelj M , Ivanuš U, Žagar T. Neodzivnice DP DORA so bolj ogrožene z rakom maternicnega vratu (Non-responders to the National Cervical Cancer Screening Programme Zora are at an increased risk of cervical cancer). In: Kraigher A, Skaza A, eds. Javno zdravje - priložnost za spreminjajočo se družbo (Public health - opportunity for changing society). Zbornik izvlečkov. Ljubljana: Sekcija za preventivno medicino Slovenskega zdravniškega društva, 2013: 29.
- Primic-Žakelj M, Zadnik V, Žagar T. Rak dojke: zbolevnost, preživetje in dejavniki tveganja. In: Matković M, ed. Pacientke z rakom dojk - trendi in novosti. Ljubljana: Sekcija medicinskih sester in zdravstvenih tehnikov v onkologiji pri Zbornici zdravstvene in babiške nege - Zveza strokovnih društev medicinskih sester, babic in zdravstvenih tehnikov Slovenije, 2013: 5–13.
- Primic-Žakelj M, Zadnik V, Žagar T. Rak v Sloveniji. In: Novosti v diagnostiki in zdravljenju raka, Ljubljana, 13. decembra 2013: ob jubilejni, 20. obletnici delovanja združenja Fundacija doc. dr. Josip Cholewa v sodelovanju z Medicinsko fakulteto Ljubljana, Kliničnim centrom Ljubljana in Onkološkim inštitutom Ljubljana. Ljubljana: Fundacija doc. dr. Josip Cholewa, 2013: 5–6.
- Zadnik V, Žagar T, Jarm K, Primic-Žakelj M. The evaluation of the mesothelioma epidemic in Slovenia. In: 35th International Association of Cancer Registries Conference, 22-24 October 2013, Buenos Aires. Programme & abstracts. Buenos Aires: The National Cancer Institute, 2013: 109.

– Zadnik V, Ivanuš U, Žagar T, Primic-Žakelj M. Pojavljanje raka na območju upravnih enot Celje in Šentjur pri Celju (Cancer incidence in adminstrative units Celje and Šentjur pri Celju). In: Kraigher A, Skaza A, eds. Javno zdravje - priložnost za spreminjajočo se družbo (Public health - opportunity for changing society). Zbornik izvlečkov. Ljubljana: Sekcija za preventivno medicino Slovenskega zdravniškega društva, 2013: 74.
– Znaor A, van den Hurk C, Primic-Žakelj M, Agius D, Coza D, Demetriou A, et al. Cancer incidence and mortality patterns in South Eastern Europe in the last decade : gaps persist compared with the rest of Europe. Eur J Cancer 2013; 49: 1683–91.
– Žagar T, Zadnik V, Primic-Žakelj M. Local estimation of standardized incidence ratio applied to Slovenian cancer data. V: International Conference Applied Statistics 2013, September 22-25, 2013, Ribno (Bled), Slovenia. Lusa L, Stare J, eds. Abstracts and program. Ljubljana: Statistical Society of Slovenia, 2013: 55.
– Žagar T, Primic-Žakelj M, Zadnik V. Zemljevidi raka, narejeni z metodo lokalno ocenjenega standardiziranega količnika (Cancer maps created with local standardized incidence ratio method). In: Kraigher A, Skaza A, eds. Javno zdravje - priložnost za spreminjajočo se družbo (Public health - opportunity for changing society). Zbornik izvlečkov. Ljubljana: Sekcija za preventivno medicino Slovenskega zdravniškega društva, 2013: 71.

POROČILO RR št. 53
REPORT No. 53
Ljubljana 2015

ISSN 1318-5845